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Abstract 
Introduction 
Recent years have seen an increase in reports of poor quality antimalarials with estimates that 
up to 30% have failed chemical analysis, even though robust empirical evidence for their 
prevalence remains scarce. Several internal (associated with national systems) and external 
(not under the direct control of national authorities) risk factors may contribute to the 
circulation of poor quality medicines. This thesis will explore these factors with an overall aim 
of providing evidence to strengthen medicines quality surveillance systems (MQSS) in low-
middle income countries (LMICs).  
Methods 
Data collection was conducted in two phases in Senegal between March 2013 and April 2014. 
The first phase involved interviews with key stakeholders of the MQSS such as authority 
representatives as well as treatment providers and explored the system’s vulnerability to risk 
factors for poor quality medicines and their perceptions of the quality of medicines available in 
Senegal. The second phase comprised a series of laboratory-based studies with technicians at 
the national medicine quality control laboratory (MQCL) including an assessment of the 
practical utility, usefulness and acceptability of a specific test, to check the quality of 
artemisinin based medicines, namely the artemisinin derivative test (ADT). Finally, a systematic 
literature review assessing the study design and reporting of antimalarial medicine quality 
studies and surveys was conducted with the included studies assessed for quality against our 
newly proposed list of criteria.  
Findings 
Overall, interviewees expressed confidence in the quality of medicines available in the public 
and regulated private sectors which was attributed to effective national medicines regulation 
and adequate technical capacity at the MQCL. In contrast, poor quality medicines were 
thought to be available in the unregulated (informal) sector as they were not subjected to 
national regulatory processes or stored appropriately, resulting in exposure to direct sunlight 
and high temperatures. Generic medicines were also perceived to be of inferior quality when 
compared to their brand versions as they were lower in cost and thought to be less effective in 
alleviating symptoms. The ADT demonstrated a promising level of accuracy to detect fake or 
grossly substandard artemisinin based medicines and laboratory technicians favoured its 
simplicity of use without the need for specific training. The literature review found that there 
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is much heterogeneity in study design and inconsistency in reporting which has impacted on 
the generalisability of findings for antimalarial medicine quality studies. 
Conclusion 
A major shift is required in the framing of medicine quality from a technical/legal to a clinical 
paradigm with evidence required to demonstrate the impact of poor quality medicines on 
public health. National governments need to invest in regulatory and technical capacity to 
strengthen MQSS to minimise the likelihood of poor quality medicines circulating in a country. 
Utilising simple, and portable (preferably handheld) tests like the ADT, in non-laboratory 
settings may enhance post-marketing surveillance, especially in resource constrained contexts. 
Nonetheless, comparative evaluation of all currently available screening technologies for their 
capability to distinguish poor quality antimalarials for confirmatory pharmacopeia testing and 
public health action is required. Suggestions that reduce the risk of bias and error have been 
proposed for conducting medicine quality studies to enable standardisation of study design 
and reporting, thereby increasing the reliability of findings and allowing comparison between 
studies. 
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Chapter 1: An introduction to monitoring the quality of antimalarial 
medicines and current strategies  
 
1.1 Background 
In 2015 the World Health Organization published 17 Sustainable Development Goals for 2030 
comprising a range of issues including improving health and education. [1] Sustainable 
Development Goal 3; ‘Ensure healthy lives and promote well-being for all at all ages’ has 
several targets. Target 3.8 stipulates ‘’achieving universal health coverage, including financial 
risk protection, access to quality essential health-care services and access to safe, effective, 
quality and affordable essential medicines and vaccines for all.’’ [2] Hence, access to quality 
medicines is of great importance if this particular goal is to be achieved. However, studies of 
medicine quality conducted in low-middle income countries (LMICs) indicate that there are 
poor quality medicines in circulation. [3] WHO estimates from 2006 suggested that as many as 
10-30% of medicines on sale in parts of Africa, Asia and Latin America were counterfeit. [4] 
More recent figures for counterfeit medicine in circulation are not available for these regions 
amid concerns of the lack of robust evidence to substantiate such estimates. [5] 
The consequences of consuming medicines with the incorrect stated active pharmaceutical 
ingredient (SAPI) or occasionally, even toxic ingredients, can be debilitating or even fatal, as 
exemplified by around 500 cases of renal failure that led to the death of children in India, 
Bangladesh and Haiti after ingesting paracetamol and cough syrups containing a renal toxin.[6-
8] The existence of poor quality medicines is of particular concern in LMICs, where the absence 
of robust medicines regulation and adequate technical capacity in the form of well-equipped 
laboratories and human resources to test the quality of medicines limits the ability of the 
health system to assure that the medicines available to the public are safe and effective.  
1.1.1 What is a poor quality medicine? 
Poor quality medicines result from a multitude of contributory factors. They may arise as a 
result of intentionally produced falsified medicines with fake packaging or the wrong active 
ingredient or low levels of the active ingredient. Inadequate manufacturing processes leading 
to non-compliance with international standards for a medicine set out in a drug monograph 
may render a medicine substandard, with not enough or too much of the active ingredient. 
Furthermore, inadequate storage of medicines during transport or storage may cause 
degradation of otherwise acceptable pharmacopeial quality medicines. These contributory or 
risk factors are discussed further in section 1.1.3 of this chapter. 
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Just as the reasons for poor quality medicines arising are varied and complex, there is also 
much variation of the description and definition of medicine quality which is dependent upon 
the field of study, the context, and the perceptions of individuals including policy-makers, 
health professionals, medicine sellers and consumers. In May 2017, the World Health 
Assembly agreed to use the term substandard and falsified medicinal products. The definition 
of both components of this new term is outlined in table 1.1 below, although there is no 
reference to degraded products. In addition, a new category, seldom used in the relevant 
academic and policy literature associated with medicines quality has also been agreed, 
‘unlicensed and unregistered medicines’ defined as ‘’Medical products that have not 
undergone evaluation and/or approval by the National Medicines Regulatory Authority 
(NMRA) for the market in which they are marketed/distributed or used, subject to permitted 
conditions under national or regional regulation and legislation.’’ It is not clear in the latest 
working document if this group is a distinct category or encompassed by the term substandard 
and falsified products. [9] The consensus on the definitions for medicine quality were 
preceded by several years of debate and negotiation by WHO Member States during which 
time the WHO used a ‘catch all’ acronym namely, SSFFC (substandard, spurious, falsely-
labelled, falsified and counterfeit). [5] This definition was criticised for its ambiguity as it 
encompassed all poor quality medicines suggesting their deficiencies are the same, whereas, 
they are in fact quite different, in terms of their causes and the solutions required to address 
them. [10, 11]   
To some extent the new, simplified definitions for substandard and falsified medicines attempt 
to homogenise medicines quality. Yet, as mentioned above, the definitions for medicines 
quality vary greatly and have been the centre of much discourse with academics, lawyers, 
pharmaceutical manufacturers, health professionals, politicians and even the WHO using 
varying nomenclature. [12] The next section of this chapter provides a synthesis of the 
evidence for definitions for poor quality medicines with an overview of the most commonly 
ascribed terms (table 1.1) whilst identifying three paradigms within which medicines quality is 
perceived and defined; legal, technical and clinical.  
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Table 1.1: Commonly used definitions for medicines quality 
Medicine 
quality 
Definition(s) (or description where no official definition exists) Defined by Paradigm 
Falsified ‘Medical products that deliberately/fraudulently misrepresent 
their identity, composition or source.’ 
WHO, 
2017 [9] 
Legal 
Substandard ‘Also called “out of specification”, these are authorized medical 
products that fail to meet either their quality standards or 
specifications, or both.’ 
WHO, 
2017 [9] 
Technical 
Unregistered/ 
unlicensed 
’Medical products that have not undergone evaluation and/or 
approval by the National Medicines Regulatory Authority 
(NMRA) for the market in which they are marketed/distributed 
or used, subject to permitted conditions under national or 
regional regulation and legislation.’ 
WHO, 
2017 [9] 
Legal 
Acceptable 
pharmacopeial 
quality  
‘…have the acceptable amount of active pharmaceutical 
ingredients as specified by the pharmacopeia’s and meet other 
quality attributes (uniformity of dosage units, purity, 
bioavailability etc.).’  
Kaur et al, 
2016 [13] 
Technical 
Counterfeit ‘…deliberately and fraudulently mislabelled with respect to 
identity and/or source. Counterfeiting can apply to both 
branded and generic products and may include products with 
the correct ingredients or with the wrong ingredients, without 
active ingredients, with insufficient (inadequate quantities of 
ingredient(s) or with fake packaging’ 
 
‘Medicines that do not comply with intellectual-property rights 
or that infringe trademark law’ 
WHO, 
1992 [5] 
 
 
 
 
 
European 
Medicines 
Agency, 
2016 [14]  
Legal/ 
technical 
 
 
 
 
 
Legal 
Degraded ‘Degraded formulations may result from exposure of good-
quality medicines to light, heat and humidity. It can be difficult 
to distinguish degraded medicines from those that left the 
factory as substandard.’ 
Hall et al, 
2016 [15] 
Technical 
 
The most frequently used definitions for medicines quality presented in the table above are 
appropriate to either the legal or technical paradigm. The definitions do not encompass the 
potential clinical consequences of poor quality medicines which may comprise the perceptions 
of health professionals or the public. The three paradigms are discussed further below. 
Legal paradigm 
The discourse alluded to previously was largely centred on the legal status of poor quality 
medicines which is best illustrated by the debate on the precise definition of counterfeit 
medicines. Generic medicine manufacturers and those involved with intellectual property law 
were concerned that misuse of the term counterfeit may lead to misclassification of some 
legitimately manufactured generic medicines. [10] From a legal standpoint, any judicial process 
against a producer would be based on providing evidence that there was intent to produce a 
poor quality medicine. [10] Intent to produce poor quality medicines is often a specific 
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problem with falsified medicines that closely mimic authentic products with deliberately fake, 
but convincing packaging which may be fraudulently mislabelled with respect to their identity 
or source. They may often contain ingredients of low quality or in the wrong dose, the wrong 
ingredients, or low levels of the active ingredient. [14, 16] New definitions for poor quality 
medicines under which counterfeit medicines are classified as ‘falsified’ do not reference 
intellectual property rights, with counterfeits categorised as “trademark counterfeit goods” 
and ‘’pirated copyright’’ as defined under the Agreement on Trade-Related Aspects of 
Intellectual Property Rights. [9] 
Substandard medicines differ from falsified and counterfeit medicines in that they are genuine 
medicines that have been manufactured poorly and hence, do not meet quality specifications 
set for them by national standards. [5] They may contain low SAPI or too much SAPI and thus, 
do not comply with pharmacopeia tolerance limits for a medicine as stated in the authorised 
drug monograph. [17] In legal terms the difference in definitions is centred on intent, whereby 
falsified and counterfeit medicines are deliberately produced as opposed to a non-deliberate 
or accidental manufacturing error resulting in a substandard medicine. [10] 
Technical Paradigm 
The technical paradigm focusses on the chemical content and pharmaceutical properties of a 
medicine. From a technical perspective, an acceptable pharmacopeial quality medicine meets 
the specifications stated in its drug monograph detailed in an international pharmacopeia. [13, 
18, 19] International pharmacopeia’s such as the British, European or United States 
Pharmacopeia contain monographs for drugs which are written documents, or standards, that 
describe a drug, providing the name of a substance; its definition; packaging, storage, and 
labelling requirements; and information on tests needed to assess the drug for its strength, 
quality, purity and bioavailability. This thesis will predominantly refer to the United States 
Pharmacopeia (USP) which also refers to an agency that provides substantial financial, 
technical and logistical support to many LMICs in building capacity for medicines quality 
assurance.  
Definitions are often centred on the results of content analysis to measure the amount of SAPI 
and calculating its percentage of the SAPI stated on the label or packaging of a medicine. 
Falsified medicines may contain zero SAPI, low SAPI or the wrong SAPI leading to treatment 
failure, severe disease and even death. [14, 16] Substandard medicines with some SAPI or too 
much SAPI or reduced bioavailability may result in treatment failure, recrudescence of 
infection (for anti-infectives such as antimicrobials and anti-parasitic medicines) and 
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potentially severe infection. [20, 21] In fact, the consequences of consuming substandard 
medicines are not only detrimental at the individual level but also at the population level 
through a theoretically posited association with drug resistance for antimalarials and 
antibiotics as sub-therapeutic doses are thought to be conducive to the selection and spread of 
drug-resistant pathogens. [22, 23] Finally, degraded medicines result from the exposure of 
acceptable pharmacopeial quality medicines to various environmental conditions such as high 
humidity and temperature, and direct sunlight. Distinguishing substandard medicines resulting 
from poor manufacturing practices from those that were degraded through improper storage 
is challenging. Currently, there is only one study which has described how degraded medicines 
should be classified, not just by their appearance but by measuring the products of 
degradation of one or both SAPIs in the formulation. [15] 
The discourse on definitions detracts from the more serious issue of the public health 
consequences (treatment failure leading to severe disease, recrudescence, drug resistance or 
death) of the consumption of medicines that deviate from the chemical content or possesses 
pharmaceutical properties that do not meet the standards stated in the monograph for that 
drug.  Moreover, poor quality medicines may increase the burden on already limited resources 
at the provider level as a result of treatment failure and/or recrudescence of infection which 
may result in patients requiring additional clinical consultation, repeat prescribing and 
additional purchase of medicines. In some cases, when treatment has failed and there has 
been progression to severe clinical disease, admission to health facilities maybe required with 
lengthy patient stay. The existence of poor quality medicines may also undermine confidence 
in health professionals, medicines quality assurance systems and the pharmaceutical 
industry.[24] 
Clinical paradigm  
The technical paradigm while including the specific public health consequences of poor quality 
medicines does not consider the perceptions of health professionals, medicine sellers and 
consumers. At the point of care, perceptions of medicine quality are more likely to be framed 
in a clinical paradigm, focussing on efficacy and safety of medicines. Treatment providers 
generally need information on the safety (side-effects) and effectiveness (how quickly and well 
the medicine works) of their medicine to enable them to make an informed decision on 
treatment selection. This information may also have an implication on patient adherence to 
the treatment regimen. [25] From the perspective of the treatment provider, medicine 
selection is sometimes a consideration of the benefits and risks of the treatment influenced by 
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numerous factors including, but not restricted to, local policy and clinical guidelines, cost and 
clinical knowledge (adverse effects) and experience (previous success with the treatment). [26]  
However, there is a paucity of information on the consideration of medicine quality as a factor 
in clinical decision-making by health professionals or whether perceptions of the public about 
medicines quality, are considered by patients when purchasing or electing to consume a 
medicine. Studies in high income settings have found that a small proportion of doctors 
viewed generic medicines as being manufactured to a poorer quality, which they believed may 
have implications for patient safety. [27] Additionally, generic medicines were perceived as 
inferior in quality to their brand versions as they were lower in cost and manufactured by 
lesser known companies. [28] Similarly, studies of patient’s perceptions of medicines quality in 
Lao and South Africa found that a medicine was considered to be of good quality, if it 
alleviated symptoms with minimal side effects (efficacy and safety), if it was a brand name 
medicine (made by a reputable company) and if it had a higher cost. [29, 30] The perceptions 
of health professionals and the public as consumers or patients demonstrate a divergent view 
of medicine quality to that presented as the technical paradigm above. 
1.1.2 Implications of poor quality medicines for public health with a focus on malaria 
Malaria remains a major public health concern in LMICs and is an affliction of the most 
vulnerable and impoverished in many countries in sub-Saharan Africa, Asia and Latin America. 
In 2016, globally there were around 216 million cases of malaria and an estimated 445,000 
deaths, 91% of which were in Africa. [31] However, in recent years there has been an overall 
decline in both malaria incidence and prevalence due to application of improved strategies for 
prevention, control and treatment. [32] Successful control strategies have included the 
widespread distribution and use of insecticide treat nets (ITNs). In sub-Saharan Africa there 
was a 23% increase (to 53%) of the total population at risk of malaria sleeping under an ITN 
between 2010 and 2015. [33] Furthermore, the replacement of chloroquine, initially by 
sulphadoxine-pyrimethamine and then by artemisinin based treatment has significantly 
contributed to the reduction in transmission and burden of the disease, with 81 out of 88 
malaria endemic countries having adopted Artemisinin Combination Treatment (ACTs) as the 
first line therapy for treatment of uncomplicated P.falciparum malaria by 2015. [34] 
Artemisinin based medicines are capable of rapidly reducing parasite levels, have minimal 
adverse effects, are less prone to the development of resistance and their gametocidal activity 
contributes to the reduction of transmission of malaria infection making them an effective 
treatment against P.falciparum malaria. [35] The advent of artemisinin based treatment was 
particularly important in the context of emerging drug resistance and subsequent 
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ineffectiveness of initially chloroquine and then sulphadoxine-pyrimethamine in malaria 
endemic countries. [36]  
The primacy of ACTs for malaria treatment demonstrates the necessity for assuring their 
quality as well as that of the other antimalarials to ensure that the success of malaria control 
and treatment strategies is maintained. A recent WHO study used impact models to estimate 
the public health and socioeconomic impact of poor quality medicines including 
antimalarials.[24] The study reported that incremental deaths in sub-Saharan Africa due to 
substandard and falsified antimalarials comprised approximately 2.1% to 4.9% of total malaria 
deaths, or approximately 3.8% to 8.9% of malaria deaths relating to patients seeking 
treatment. The study authors suggested that given the limitations of the available data 
(aggregating data from just 10 studies in 17 countries between 2007-2016) it was likely that 
the results of the model underrepresented the full health and economic impact of substandard 
and falsified antimalarial medicines.  Such findings illustrated that failing to assure the quality 
of antimalarials may have significant clinical and public health implications. Aside from 
potentially increasing the risk of mortality, clinical implications of the consumption of a 
falsified antimalarial medicine include treatment failure and progression to a severe 
manifestation of the disease as highlighted by the case of a patient who consumed purported 
artesunate monotherapy for uncomplicated malaria in Equatorial Guinea. The medicine, when 
tested did not contain the SAPI. [21] There are also public health implications from consuming 
substandard antimalarials. At the patient level, sub-therapeutic doses may lead to prolonged 
or severe illness and even death whilst also increasing the risk of recrudescence of malaria 
infection. [20] At the provider level this increases burden on already limited resources and may 
undermine confidence in health professionals. [37]  
From a broader public health perspective sub-optimal medicine concentrations may select for 
drug resistant parasites. [20] The inability of a medicine to effectively kill all parasites may 
result in surviving parasite strains multiplying, a mechanism that is a precursor for 
recrudescence of infection. However, amongst these remaining parasites there may also exist 
drug resistant mutates that are less susceptible to a medicine and have hence survived, 
promulgating resistance. [38] Chloroquine resistance emerged in the 1950s initially in 
Southeast Asia, before eventually spreading to sub-Saharan Africa. Chloroquine became a 
victim of its own success, due to overuse and misuse (inappropriate prescription, 
administration and non-compliance) for decades and by the mid 1990’s, studies in sub-Saharan 
Africa had shown a temporal association between chloroquine resistance and notable 
increases in malaria attributable mortality. [39] Whilst resistance to chloroquine developed 
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over many decades, pyrimethamine resistance emerged much faster and despite replacing 
chloroquine initially as the first line medicine for P.falciparum, within a decade, many malaria 
endemic countries had started to implement artemisinin based treatment as the first line 
therapy against uncomplicated P.falciparum malaria. [40] Sulphadoxine-pyrimethamine 
treatment in sub-Saharan Africa is now limited to seasonal chemoprevention in combination 
with amodiaquine in parts of West Africa [41] and as intermittent preventative treatment in 
pregnancy. [42]  
As with its predecessors, drug resistance has been documented with artemisinin based 
antimalarials with multi-resistant parasites detected in Southeast Asia along the Cambodia-
Thailand border. [43] Initial reports were of longer parasites clearance times, interpreted as an 
early indication of the emergence of drug resistance. [44, 45] An association between poor 
quality artemisinin based medicines and drug resistance has been postulated but not as yet 
proven. [23] This theoretical association is similar to that for other antimalarials that have 
conferred resistance. Drug pressure selects for resistant parasites especially when parasites 
are exposed to monotherapy or to sub-therapeutic concentrations. Therefore, substandard 
artemisinin based medicines theoretically increase the risk of the development of drug 
resistance as they may contain low SAPI or may have poor bioavailability. [46] The WHO 
recommended the use of combination treatments whilst mandating the removal from the 
market of artemisinin based monotherapy (artesunate, artemether and dihydroartemisinin) in 
tablet form, acknowledging that without a partner drug there was a greater likelihood for the 
development of drug resistance to artemisinin. [47]  
1.1.3 Risk factors for poor quality medicines 
Several factors may increase the risk of the circulation of poor quality medicines in LMICs. 
These factors can be categorised as internal (reflecting limitations in national health systems to 
control the medicines supply) and external (aspects over which countries may have less 
control). [48] Internal factors include inadequate medicine regulation, insufficient technical 
capacity for testing the quality of medicines and an inability to apprehend and prosecute 
manufacturers and distributors of poor quality medicines. [49] These factors are shaped by 
local systems for governance, law enforcement, and financing.  
Additionally, external factors such as medicine shortages and high cost of a medicine to the 
consumer reduce access to affordable medicines and may lead patients to seek products from 
less regulated sources, increasing their potential risk of exposure to low-quality medicines. 
Moreover, medicine shortages create a gap in the market in which counterfeiters may operate. 
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Longstanding medicines shortages in parts of North America and Europe have been shown to 
provide an opportunity for illegal sellers to introduce potentially counterfeit medicines on to 
the market, a problem accentuated by the proliferation of internet pharmacies. [50, 51] Yet, 
the availability and cost of medicines is often determined by external agents, including 
pharmaceutical manufacturers and distributors, rather than by national governments.  
Unfortunately, many of these internal and external factors are applicable to LMICs and maybe 
compounded by a lack of awareness amongst regulators, health professionals and the public 
and low political will to acknowledge and tackle the problem of poor quality medicines. [52] 
The factors that increase the risk of the presence of poor quality medicines in a country, and 
current strategies to control this risk, are discussed further in the introduction to Section 1 
(Monitoring the quality of medicines in Senegal: a stakeholder perspective). 
1.1.4 Scale of the problem of poor quality antimalarials 
Since the beginning of this century, there have been several reports of the discovery of poor 
quality antimalarials, particularly artemisinin based medicines. [53, 54] A recent review (2014) 
found that 30% (2,813) of a total of 9,348 antimalarial medicine samples from parts of Asia, 
central and South America, and sub-Saharan Africa had failed chemical content/packaging 
analysis. [3] Furthermore, an earlier review from 2012 had claimed that around a third of 1649 
antimalarials available in Southeast Asia and sub-Saharan Africa were falsified, although the 
authors did not provide separate estimates for substandard medicines. [55] ACTs are currently 
the first line medicines for uncomplicated P .falciparum malaria and in 2016 around 409 
million ACTs courses were procured by malaria endemic countries. [31] The majority of studies 
assessing antimalarial medicine quality have focussed on the quality of artemisinin based 
medicines. Recently studies have employed larger sample sizes and robust sampling and 
analytical approaches, providing estimates of the prevalence of poor quality artemisinin based 
medicines and highlighting a greater problem of substandard as opposed to falsified 
versions.[56-58] There have also been several concerning reports of artemisinin resistance in 
parts of Southeast Asia. [59-61] Together these aspects may warrant the preference for 
assessment of ACT quality in antimalarial medicine quality studies in comparison to other 
antimalarials.  
The first documented case of fake artemisinin based medicine was reported in 1999 in 
Cambodia where a nationwide survey found that 71% of 133 drug outlets stocked the 
artemisinin based monotherapy, artesunate, without the SAPI. [62] This initial discovery was 
the precursor for what has been subsequently described as a ‘’growing epidemic of fake 
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antimalarials’’ in Southeast Asia. Indeed, of 1437 samples of antimalarial drugs collected and 
analysed in Southeast Asia from 2001-2011, 36% were found to be ‘falsified’. [63] This is 
particularly worrying in the context of Southeast Asia which has been described as an 
‘epicentre of multi-drug resistant malaria.’ [45]  
The situation regarding the prevalence of poor quality antimalarials in sub-Saharan Africa is 
less clear, although, evidence suggests substandard medicines maybe of greatest concern. [56, 
58] The 2009 and 2011 the ‘Survey of the Quality of Selected Antimalarial Medicines in 
circulation in Sub-Saharan Africa’ studies by the WHO and USP found that overall 30% (n=139) 
of 464 antimalarial drug samples did not meet USP compendia quality standards. According to 
the definitions used in the report, the failing drugs were substandard. [54, 64] Furthermore, a 
study in 2012 - 2013, from Enugu, Nigeria collected and analysed 3,024 ACTs and found that 
6.6%  were substandard, 1.3% were degraded and 1.2% were falsified. [56] The latter study 
also demonstrated that a representative sampling approach is essential to accurately quantify 
the scale of the problem of poor quality medicines. Several other studies suggest that West 
Africa in particular is prone to the problem of poor quality antimalarials, especially Nigeria and 
Ghana. [57, 65-69] Research focus appears to be directed toward Nigeria and Ghana in 
comparison to neighbouring countries which is reflected in the greater volume of studies and 
surveys published. The possible reasons for this include: a) medicines quality being higher on 
the political agenda in these two countries with national authorities making a concerted effort 
to tackle poor quality antimalarials; b) both countries producing medicines nationally and 
reportedly, manufacturing facilities not always complying with Good Manufacturing Practice 
requirements [54] which increases the possibility of substandard medicines entering the 
supply chain and may in turn heighten awareness, encouraging the NMRAs to conduct 
inspections of facilities, and undertake medicine quality surveys, c) the problem of antimalarial 
medicine quality is magnified, because less research is being conducted in other countries or d) 
it may simply reflect additional research effort in the two countries. 
The exact scale of the global problem of poor quality antimalarials is not known, due to a 
relatively small number of studies, geographical disparities in research efforts and a lack of 
standardisation in study design and reporting. These geographical differences in medicines 
quality research efforts are shown in figure 1.1. Overall, research has focussed on two regions 
with highest global malaria burden, West Africa and Southeast Asia. However, there are 
relatively fewer studies from other high malaria transmission areas such as east and Central 
Africa and within West Africa the majority of studies are from Nigeria and Ghana.  
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Figure 1.1: Geographical distribution of antimalarials medicine quality surveys and studies  
Source: The Worldwide Antimalarial Resistance Network (WWARN) antimalarial drug quality surveyor is a 
database of antimalarial quality surveys and studies including academic publications, multi-country surveys 
conducted by international agencies, and where available, national surveys published by NMRAs. [70] The 
symbols show the locations in which antimalarial studies and surveys have been conducted between 1985 – 2018. 
 
The lack of standardisation of antimalarial studies exemplified by the heterogeneity in the 
methods used and in the reporting of findings, also limits the assessment of the scale of the 
problem of poor quality antimalarials. There is variation in the strategies for sampling 
medicines, the analytical techniques employed to determine medicines quality, and definitions 
used to classify poor quality medicines. [13] Moreover, this heterogeneity may limit the 
reliability and generalisability of findings and the extent to which medicine quality studies and 
surveys can be compared and contrasted. The variation in how medicine quality studies and 
surveys are conducted and reported, and the need for greater standardisation, is discussed in 
more detail in chapter 4 of this thesis.  
1.1.5 Global and national systems for preventing the circulation of poor quality 
medicines  
The previous section presents the scale of the problem of antimalarial medicine quality, yet 
there are systems and mechanisms currently in place at the global and in some cases, national 
level to control medicines quality. In 2013, the WHO created a Surveillance and Rapid Alert 
System for SSFFC Medical Products which operates on a global scale. In 2017, this system 
became known as the Global Surveillance and Monitoring System for substandard and falsified 
medical products (GSMS) to reflect the recently agreed definitions for substandard and 
falsified medicines. The primary aim of the system is to improve the quantity, quality and 
analysis of data on the incidence of substandard and falsified products. The system provides 
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stakeholders with a basis to develop strategies for reducing the incidence of substandard and 
falsified products by identifying vulnerabilities in supply chains, measuring the harm caused 
and facilitating efficient exchange of information between countries to reduce the public 
health impact.  
The WHO have trained NMRAs to report incidents involving substandard and falsified 
medicines to the system through the use of a WHO Rapid Alert Form. [71] When a report is 
received it is compared to existing reports on a database with any matches identified and 
details shared with the reporting Member State. If required the WHO will also provide 
technical support to the Member State such as facilitating urgent laboratory analysis or in 
complex cases, deploying experts to the country to provide assistance. The global alert system 
provides Member States with important information, allowing a country to tackle the problem 
swiftly, mitigating against the potential distribution and consumption of a poor quality 
medicine. In addition, technical support where required from the WHO provides reassurance 
to the Member State that the issue will be addressed by ‘experts’ as well as an opportunity for 
a national agency to learn and improve their post-marketing surveillance systems.  
The effectiveness of this global alert system is dependent on the volume and accuracy of data 
collected by national medicines quality surveillance systems (MQSS), where they exist. 
Between 2013-2017 the GSMS received 1500 reports of substandard and falsified medicines of 
which 286 were for antimalarials from 26 Member States which account for just 29% of the 91 
countries globally in which there is ongoing malaria transmission. [33, 72] Furthermore, there 
is no information currently on the number of countries with a MQSS. A 2010 report published 
by the WHO that assessed regulatory systems in 26 sub-Saharan African countries found that 
17 had a national medicines quality control laboratory (MQCL) (of which just seven were part 
of the NMRA, with unknown status in terms of ownership of the remaining 10). Moreover, just 
five countries had all five of the main functions of a regulatory system (marketing 
authorisation, licensing, inspection, quality control and pharmacovigilance) and overall, 
regulatory systems were quite fragmented. [73] 
At country level, the Unites States Agency of International Development (USAID) through their 
technical partner, USP have implemented the Promoting the Quality of Medicines programme 
which provides funding, training and logistical support for national medicines quality 
monitoring systems in LMICs including countries in central, south and Southeast Asia, Latin 
America and sub-Saharan Africa. [19] Since 1992, the Poor Quality of medicines programme 
has been active in 16 (30%) of a total of 54 countries in sub-Saharan Africa. The programme 
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aims to ‘’develop and implement systems-level interventions to combat poor quality 
medicines’’ and enable country level partners to overcome system weaknesses, in particular, 
inadequate technical capacity for analysing medicine quality so as to strengthen monitoring 
systems, minimising their vulnerability to poor quality medicines. The programme builds 
technical capacity by providing guidance and training for the sampling and analysis of 
medicines as well as the provision of medicine quality screening techniques and training on 
their use. [74, 75]   
The ability of a national MQSS to detect poor quality medicines is dependent upon the 
sampling strategies employed, the technical capacity to analyse these samples, the mechanism 
to share information between key agencies in a timely manner and the capability of regulatory 
systems to act based on findings. At the country level, an MQSS should be a component of a 
broader medicines quality assurance system which includes; effective regulatory mechanisms 
to control medicines quality at the point of entry; to authorise and register medicines and 
manufacturers and distributors; to monitor internal distribution and the appropriateness of 
medicines storage; advocate adherence to national medicines policies and to enact or support 
enforcement of action against regulatory contraventions.  
Detecting poor quality medicines  
Two of the key components of a MQSS are regular sampling of medicines and analysis of 
medicines quality. Where capacity exists, a MQSS should sample medicines at the point of 
entry into a country, (prior to distribution) on large batches of medicines received through 
official channels from manufacturers or international and/or regional wholesalers. However, 
due to limited resources, the majority of MQSS will sample medicines after they have been 
distributed, through post-marketing surveillance, at the point of care from health facilities, 
pharmacies and other medicine outlets. [76] Sampling through post-marketing surveillance 
may be instigated in response to a documented case of a poor quality medicine leading to an 
NMRA investigation, which may subsequently result in a batch recall. MQSS may also carry out 
periodic medicines quality surveys with more comprehensive sampling and analysis of 
medicines. Once sampled, medicines will be first tested using screening devices and where 
samples are suspected to be of poor quality they will be sent to a national MQCL (where they 
exist) for further testing using confirmatory analysis following pharmacopeia authorised 
methods.  
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1. Sampling strategies for collecting medicines  
There are a few sampling strategies that have been employed in medicines quality surveys and 
studies. USP guidelines indicate that a convenience sampling method can be used to collect 
medicines. [75] The majority of antimalarial medicine quality studies have utilised convenience 
sampling which is a type of non-random sampling that involves medicine collection without 
specific guidance as to which outlets to sample. It is simple, inexpensive and does not require 
comprehensive lists of outlets in defined locations, which is difficult to acquire, especially for 
unregistered drug sellers. However, the technique is prone to selection bias as the results 
depend upon on the collector’s choice of outlets. Even though convenience sampling can be 
useful to identify whether a problem of poor quality medicines exists in the selected location, 
indicating the need for further investigation [77], this sampling technique cannot be used to 
estimate the prevalence of poor quality medicines in a country. It may lead to an 
overestimation of poor quality medicines and results may be difficult to replicate. 
In contrast, a randomised sampling approach with large sample sizes and a comprehensive 
sampling frame to provide representative data is the only technique that can accurately 
quantify the scale of the problem. Random sampling can provide a sound estimate of the 
prevalence of poor quality medicines in a defined geographical area, provided that the 
sampling frame of medicine sellers and suppliers in that area is accurate and up to date. [13] 
Additional resources may be required to update pre-existing sampling frames before sampling 
can begin. Selecting an appropriate sampling strategy thus requires consideration of the 
objectives of the survey, the context, resources and a time frame. 
Another sampling technique utilised in health surveys to measure public health indicators such 
as immunisation coverage is Lot Quality Assurance Sampling (LQAS). [78] LQAS involves testing 
a sample of medicines from the same batch number to assess whether a batch of goods has 
met desired specifications, and is an approach which is particularly useful for assessing the 
quality of medicines at the point of entry into the supply chain (import or local 
manufacture).[77] If a poor quality batch is detected it can be withdrawn from the supply 
chain, without having to assess the whole lot, saving time and costs of sampling. LQAS is often 
employed to overcome issues associated with small sample sizes and convenience 
sampling.[79] LQAS does still require random sampling and its main drawback is that it does 
not estimate an exact prevalence. [77] LQAS cannot be used to determine the quality of 
medicines available to the patients from retail outlets i.e. it is more appropriate for point of 
entry sampling than point of care (post-marketing surveillance). 
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2. Analysis of medicine quality 
A well-equipped MQCL is an integral component of a national MQSS with access to 
international pharmacopeia’s that outline the methods to assess laboratory based procedures. 
Laboratories need essential equipment such as high performance liquid chromatography 
(HPLC) coupled with an appropriate detector i.e. photodiode array (PDA), as well as quality 
assured drug reference standards to measure the exact amount of SAPI, both of which have 
high capital and maintenance costs, limiting the number of medicines samples that can be 
analysed on a regular basis. Additionally, a MQCL requires staff with extensive technical 
expertise and experience in the use of analytical methods such as HPLC-PDA. [80] LMICs 
seldom have the requisite resource to operate a MQCL and hence rely on medicines quality 
screening techniques which are less expensive, simple to operate, portable (preferably 
handheld) and can be used for rapidly testing a larger volume of medicines. Screening 
technologies provide a cost-effective means to medicines quality testing, through bulk 
screening to identify medicines that may need further investigation and assessment using 
more expensive confirmatory tests such as HPLC. Advantages and disadvantages of 
confirmatory and screening medicine quality tests are listed in table 1.2. 
Table 1.2: Comparisons of confirmatory and screening medicine quality tests 
Analytical 
Method 
Advantages  Disadvantages  
Confirmatory 
tests e.g. 
HPLC  
High specificity 
High sensitivity 
Quantification of SAPI  
Objective results with exact amounts measured 
Expensive (capital and 
maintenance costs) 
Requires expertise for operation 
 
Screening 
tests e.g. 
GPHF 
MiniLab® 
Rapid 
Inexpensive 
Simple to operate  
Battery operated 
Portable (preferably handheld) 
Large number of samples analysed quickly 
Minimal training and skills required for operation 
Poor accuracy  
Not quantitative  
Subjective interpretation of 
results 
 
Screening technologies include a range of approaches and can be categorised based on 
whether they detect false labelling (product recognition and counterfeit identification), the 
presence or absence of an SAPI (detection of the SAPI) and an attempt to quantify the content 
of a medicine (determining composition). [81-83] The most widely used screening technology 
for detecting medicines quality is the Global Pharma Health Fund (GPHF) MiniLab®, which is 
reported to be available in over 95 countries worldwide, is capable of testing around 85 WHO 
essential medicines (including antimalarials) and is often used in LMICs as an integral 
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component of a MQSS. [84] Chapter 5 assesses the utility of a new screening test specifically 
developed for detecting the quality of artemisinin based formulations (the artemisinin 
derivative test, ADT) and compares its performance to the MiniLab® for detecting the quality 
of artemisinin based medicines. Screening technologies have an important role in monitoring 
medicines quality as they are the first step in the process of detecting the quality of medicines. 
Even so, as they only provide an indication of medicines quality in terms of the SAPI they 
detect, confirmatory testing methods such as HPLC must be used for accurate assessment 
through the quantification of the chemical content of a medicine (its SAPI). Screening tests 
cannot accurately quantify the amount of SAPI in a sample. HPLC is currently regarded as the 
‘gold standard’ technique for medicine quality analysis. [80] 
Monitoring medicine quality in LMICs 
Using Senegal as a case study this thesis will explore the context of a MQSS in a LMIC in sub-
Saharan Africa, assessing its strengths and weaknesses whilst exploring components of the 
medicines quality assurance system that if compromised, could increase the risk of the 
existence of poor quality medicines. This thesis will also specifically focus on a key element of a 
MQSS, the analytical techniques and methods used in evaluating the quality of medicines in 
field surveys at the point of care, highlighting the merits and drawbacks of screening 
technologies from the perspective of those that use them to undertake national medicines 
quality surveys in a LMIC. It will also evaluate the practical utility and perceptions of 
acceptability of a new screening test for assessing the quality of artemisinin based medicines, 
the ADT with a view to the feasibility of including this new screening test into a MQSS.  
 
1.2 Aims and Objectives 
1.2.1 Aim 
The aim of this thesis is to generate evidence on strategies for strengthening medicines quality 
surveillance systems in low-middle income countries including an appraisal of screening tests 
used to detect the quality of medicines as well as providing suggestions for improving the 
quality of evidence generated by future studies and surveys of medicine quality.  
1.2.2 Objectives 
1. To generate evidence on strategies for strengthening medicines quality surveillance in 
Senegal by exploring stakeholder perceptions relating to the strengths and weaknesses 
of the system and its ability to control the quality of medicines nationally. 
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2. To explore the perceptions of a range of stakeholders involved in monitoring of 
medicine quality and provision of antimalarial treatment in Senegal regarding their 
understanding of the term ‘medicine quality.’ 
 
3. To review the screening technologies and survey methods that have been used to 
assess medicine quality in low-middle income countries, as well as how findings have 
been reported and to provide a reporting template for future studies.  
 
4. To evaluate the practical utility of the artemisinin derivative test (ADT) and 
perceptions of its usefulness and acceptability in a malaria endemic country context. 
 
1.3 Research Justification  
1.3.1 Surveillance of medicine quality 
Empirical evidence has thus far not satisfied the gaps in knowledge relating specifically to 
MQSS at a national level. There is a scarcity of literature that relates specifically to medicines 
quality surveillance. However, useful insights can still be gained from the literature on disease 
surveillance systems used for public health, which frequently highlight the need for 
cooperation between a national healthcare system and its associated public health authorities 
to enable a rapid response to newly developing health threats. [85] Specifically, studies 
evaluating surveillance for infectious diseases have identified that more effective systems 
generally benefit from an adequate infrastructure and much willingness to participate in 
surveillance activities amongst stakeholders. Nonetheless, there are concerns about numerous 
challenges including; focus on reacting to disease outbreaks as opposed to prevention, a lack 
of appropriate technical capacity, obligations of national governments to contribute to 
financing the system (when funding is generally limited, especially in LMICs) and weak 
governance (poor administrative and managerial provisioning). [86, 87]   
The issues described above are also relevant to MQSS which may affect their efficiency of 
operation and their effectiveness in controlling the quality of medicines nationally. Many 
MQSS are operated by several different authorities both national and external including 
Ministries of Health (MoH), National Malaria/HIV/Tuberculosis etc. Control Programmes, 
NMRAs and USP. With several stakeholders involved, there is undoubtedly the potential for 
inefficiency through duplication of work, confusion of roles and responsibilities and debate 
over funding allocation; all of which detracts from the main goal of operating a MQSS 
effectively. In addition to considerations of resourcing and the technical capacity of a MQSS to 
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conduct surveys and analyse medicines, there is a need to understand how a medicines quality 
assurance system operates, in particular, its capacity for the regulation of medicines. A focus 
on the perspectives of different stakeholders within a local context, including effects of policy, 
process and power is also required. 
Furthermore, there are relatively few publications which focus on the awareness and 
perception of poor quality medicines amongst operators of a MQSS, treatment providers or 
drug shop operators in LMICs. Treatment providers and drug shop operators have a key role in 
a MQSS as they work at the end of the supply chain, at the point of care. Treatment providers, 
drug sellers and consumers in low, middle and high-income settings have associated quality 
with a medicine’s cost, country of manufacture, perceived efficacy and whether it is an original 
brand version or a generic. [27, 29, 88] These perceptions maybe important in influencing the 
procurement, supply and consumption of medicines and provide challenges for a MQAS 
especially for policy makers and regulators in educating treatment providers and consumers 
about the realities of medicine quality. For example, consumers may choose to purchase 
medicines from unregulated sectors if a brand name medicine they are familiar with is not 
available or out of stock in the regulated sector. Indeed, in sub-Saharan Africa, those with 
fever often self-medicate with antimalarial drugs obtained from informal sector outlets or 
iterant drug sellers. [37] Medicines in these less regulated sectors are more likely to have 
bypassed regulatory processes and hence, their quality cannot be verified. [89] The 
perceptions of medicine quality of policy makers and senior (national agency) stakeholders of a 
MQSS may also be important in shaping the policy for medicines quality assurance and 
surveillance. 
Using Senegal as a case study, the first section of this thesis explores the perceived strengths 
and weaknesses of the MQSS and perspectives of the understanding of medicine quality 
through qualitative interviews with the MQSS stakeholders. It is hoped that by establishing 
these perceptions and their impact on the operation of the MQSS this study can provide 
evidence that can be adopted to MQSS in other countries in sub-Saharan Africa as well as 
gaining a deeper understanding of the perceptions of medicines quality in LMICs. 
1.3.2 Analytical methods for medicine quality surveys 
Existing information on the scale of the problem of poor quality antimalarials in LMICs, is 
neither reliable nor robust. In part, this is because of the heterogeneity of study methodology 
for sampling antimalarials and assessing their quality. A recent systematic review found that 
there was a lack of standardisation in reporting from antimalarial quality surveys and studies 
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with data not being categorised by medicine or country. [3] Indeed, the review found that 
several studies employed screening technologies to assess antimalarial quality and in some 
cases, confirmatory analysis following pharmacopeia methods had not been conducted to 
verify the findings. Another review of counterfeit and substandard medicines also highlighted 
the lack of robust methodology to distinguish between these two categories as well as the use 
of convenience sampling and small sample sizes. [90] Guidance for conducting medicine 
quality studies includes just two sources including the aforementioned USP guidelines (for 
sampling and analysing medicines quality) and the Medicine Quality Assessment Reporting 
Guidelines (MEDQUARG) which is a proposed checklist ‘’to facilitate transparent, consistent, 
and accurate reporting.’’ [77] However, since the publication of the MEDQUARG guidelines 
(2009), by 2014, only 15.4% of antimalarial medicine quality studies and surveys had 
mentioned using the checklist. [3]  
Recent developments in the availability of data from antimalarial medicines quality studies and 
surveys include the aforementioned WWARN Antimalarial Quality Surveyor which has been 
created using data from more than 200 antimalarial medicine quality publications and 
reports.[70] In Chapter 4, I provide a systematic review that addresses some of the gaps in 
knowledge regarding appropriate guidelines for designing studies and surveys of antimalarial 
medicine quality, as well as the reporting of findings. The review in chapter 4 considers the 
extent of variation between study design and reporting as well an appraisal of the accuracy of 
the screening technologies used. It provides a new comprehensive checklist for reporting in 
antimalarial medicine quality surveys which we have developed from existing sources such as 
the MEDQUARG and USP sampling guidelines as well as following consideration of the GRADE 
guidelines (grading quality of evidence and strength of recommendations for diagnostic tests 
and strategies). [75, 77, 91] 
The second section of this thesis focusses on screening technologies which are currently 
available for use in medicines quality surveys, and includes (i) an overview of the practical 
merits and drawbacks as well as the accuracy of the existing technologies used for screening 
antimalarial quality; (ii) a systematic review of the design and reporting of medicines quality 
studies (described above); and (iii) evaluation of a new screening test, the ADT which has been 
developed to detect artemisinin derivatives only, although, this colorimetric test comprising of 
two distinct assays has not been formatted into a kit and commercialised. 
There are several medicine quality screening technologies at varying stages of development 
that can assess the quality of antimalarials. Research findings have suggested that these 
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devices need to be simple to operate, portable (preferably handheld), battery operated and 
low cost. [82, 83, 92, 93] Nevertheless, their accuracy for antimalarials in most cases, has thus 
far only been established in the laboratory and there is minimal literature on the sensitivity 
and specificity of these technologies under routine operational conditions in field surveys in 
the hands of laboratory technicians in LMICs. Just two studies have examined the sensitivity 
and specificity of the MiniLab® (the most widely used test) and both demonstrated that it had 
a propensity to overestimate the quality of a medicine, thereby potentially increasing the risk 
of antimalarials circulating in a country in which it is employed. [54, 82] One such screening 
test, the aforementioned ADT has previously shown a high level of specificity in the laboratory 
for artemisinin based derivatives. [93] Chapter 5 of this thesis aims to evaluate the practical 
utility of this test and perceptions of its usefulness and acceptability following ‘field’ evaluation 
in Senegal. Its performance in the hands of laboratory technicians was compared with that of 
the MiniLab®, and key considerations of employing screening tests outside the traditional 
laboratory setting were also explored. 
 
1.4 Study Setting 
Senegal is located at the western most point of the continent of Africa. The World Bank 
describes Senegal as one of West Africa's key political and economic hubs and considers it one 
of the most politically stable countries in Africa. [94] Senegal has a population of about 15.4 
million (2016) with at least 23% concentrated around the coastal capital city of Dakar, and 40% 
in other urban areas. [94] Senegal has a GDP per capita of 958 USD and is ranked at 162 (out of 
188) on the Human Development Index (2016). [95] Average life expectancy in Senegal is 67 
years (2015) and in 2012 the three leading causes of death were lower respiratory infections 
(16.1%), malaria (8%) and diarrhoeal diseases (6.3%,). However, the rate of mortality of all 
three causes has gradually decreased in the last decade. [96]  
Malaria has been a serious public health issue in Senegal for decades. In 2005 around 2 million 
cases of malaria were recorded and 2000 deaths attributable to malaria were reported and in 
2008 malaria accounted for 32% [97] of all outpatient consultations and 19% of deaths in 
children under 5. [98] However, by 2009, there was a reduction in the overall malaria burden 
with cases falling by 41% within a year and there has been a continued downward trend in 
malaria associated mortality for all age groups to under 5% in 2015.[97] This decline can be 
credited to a number of intervention strategies implemented at the national level by the 
Programme National de Lutte Contre le Paludisme (the National Malaria Control Programme) 
through funding provided by the Global Fund, the President’s Malaria Initiative and 
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UNICEF.[96] A key prevention intervention has been an increase in access and utilisation of 
insecticide treated nets (utilisation has increased from 10% of population in 2007 to around 
50% in 2015). [96] In terms of diagnosis and treatment, the introduction of ACTs In line with 
WHO policy in 2006 as the first line treatment of uncomplicated P.falciparum malaria was seen 
as a significant intervention strategy. As of 2008, ACTs in the form of artemether-lumefantrine 
were available free of charge in public health facilities for treating malaria diagnosed by rapid 
diagnostic test (RDT). [99] Indeed, malaria cases being tested by an RDT gradually increased, 
since their introduction in the public sector in 2007 to a reported 100% in 2015. Likewise in the 
public sector, malaria cases treated with an ACT rose from around 50% in 2008 to 100% [96] in 
2011, although this has somewhat decreased in recent years, perhaps reflecting the increase in 
utilisation of RDTs for accurate diagnosis as opposed to previous reliance upon presumptive 
treatment. 
Senegal was selected as the country of study for this thesis as it has established its own 
national MQSS. It also has several laboratories and a network of sentinel sites for monitoring 
and checking the quality of certain classes of pharmaceuticals in use in the country. Available 
literature on the extent of the quality of antimalarials in Senegal is limited to a USP report from 
2009 that published findings of a study that indicated the existence of poor quality 
antimalarials. [64] A total of 141 samples of sulphadoxine-pyrimethamine and ACTs from both 
wholesale and retail outlets in the regulated public and private sectors and from the 
unregulated informal market across seven regions were collected. Analysis of samples was 
carried out using a two-stage approach with initial screening using the GPHF MiniLab® and a 
smaller sample (n=62) sent for analysis following the medicines quality analysis methods listed 
in international pharmacopeia (confirmatory analysis). Overall 44% of the 62 samples sent for 
quality control failed (40% of ACTs failed the tests). Sample failure was most notable in the 
regulated private and unregulated informal sectors regardless of geographical location. 
Examination of the survey report revealed some important limitations. Firstly, the sample size 
of 62 for confirmatory testing is small; 35 were ACTs (n=14, failed) and 27 sulphadoxine-
pyrimethamine (n=13, failed). Detailed scrutiny of the results showed that only five of the 35 
ACT samples failed dissolution analysis and just one sample failed medicine content analysis 
with HPLC with the remainder having adequate SAPI but failing impurity testing. Medicine 
content analysis using HPLC is the most frequently used method of analysis in determining the 
quality of antimalarial medicines [100] and at the time of the study publication as well as 
currently, there are no authorised methods in international pharmacopeia to determine the 
bioavailability of ACTs using dissolution testing. 
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1.5 Thesis structure 
This thesis comprises an overall introduction (chapter 1) followed by two sections containing 
section 1 (chapters 2 and 3) and section 2 (chapters 4 and 5), as well as a final concluding 
chapter (chapter 6). Section 1 is centred on medicine quality surveillance systems, using 
Senegal as a case study and includes two chapters which examine, firstly, perceptions of 
stakeholders of the operation and function of the MQSS (chapter 2) and secondly, perceptions 
of medicine quality available in Senegal (chapter 3). Section 2 focusses on medicine quality 
screening tests and includes two chapters. The first is a review of screening technologies and 
reporting of findings in antimalarial medicine quality studies and surveys (chapter 4) and the 
second presents an evaluation of the ADT (chapter 5).   
A summary of content of each chapter is provided below. 
Section 1: Monitoring the quality of medicines in Senegal: a stakeholder perspective 
This section includes a short introduction to surveillance systems for medicines quality and 
provides a description of the current perceptions of medicines quality. A section outlining the 
methods and results which incorporates a description of participant characteristics and 
participation of MQSS stakeholders is also included. Section 1 is followed by chapters 2 and 3 
which discusses the findings of qualitative interviews with stakeholders of the MQSS in 
Senegal. 
Chapter 2: Assuring the quality of medicines in low to middle Income countries; a health systems 
perspective from Senegal 
This chapter provides an overview of the operation and function of the MQSS in Senegal 
including its strengths and weaknesses. The data was obtained from qualitative interviews 
with various stakeholders of the MQSS including representatives of several national and 
external authorities, treatment providers (doctors and nurses) and pharmacists. The data was 
analysed and presented using a framework based on the WHO six building blocks of health 
systems. [101] Suggestions for improving the MQSS and the wider health system are made, 
both specific to Senegal and relevant to other LMICs.  
Chapter 3: The quality of medicines available in Senegal; perspectives of health system 
stakeholders 
This chapter uses the same data presented in chapter 2 but provides a different interpretation 
with a focus on the perceptions of stakeholders of the term ‘medicine quality’ and their 
confidence in the quality of medicines available in Senegal. 
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Section 2: Screening Technologies for assessing antimalarial medicines quality: appraising the 
reliability of the information they provide. 
This section focusses on the specific technical aspects of the MQSS and includes a short 
introduction to screening tests outlining the current technologies available on the market and 
results from studies on their accuracy.  
Chapter 4: Antimalarial medicine quality field studies and surveys: a systematic review of 
screening technologies used and reporting of findings 
This chapter is a systematic review that assesses current screening technologies for detecting 
antimalarial quality and appraises the reporting of these studies. The chapter presents a 
proposed checklist as a template for future antimalarial medicine quality studies. This study 
was published in the Malaria Journal in May 2017. [102]  
Chapter 5: The practical utility of medicine quality screening tests: an evaluation of a new test 
for assessing the quality of artemisinin based medicines 
This chapter describes a laboratory study that evaluated the practical utility of the ADT test 
and perceptions of its usefulness and acceptability following ‘field’ testing in an LMIC. The 
study took place in Senegal at the Laboratoire Nationale de Controle de Medicaments and 
involved laboratory technicians undertaking a series of laboratory based exercises to evaluate 
the practical utility of the new test. The study also evaluated the performance of the ADT 
alongside the MiniLab®. The technicians participated in focus group discussions to provide 
opinions on the advantages and disadvantages of the new screening test as well as their 
experiences of using the MiniLab®. 
Chapter 6: Reflections, implications and conclusions 
This chapter provides a summary of the thesis and reflects on the findings from the various 
chapters. The chapter also considers the evidence gaps in medicines quality and provides 
suggestions on how medicines quality research could be focussed. It also outlines some 
priorities for LMICs with regard to monitoring and assuring the quality of medicines, providing 
broad considerations for countries with minimal resources who desire to create or develop an 
MQSS. 
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Section 1: Monitoring the quality of medicines in Senegal: a 
stakeholder perspective 
 
A1. Introduction 
This section examines the national medicines quality assurance system (MQAS) in Senegal 
presenting two chapters which explore the functioning of the MQAS, its perceived strengths, 
and points of weakness from the perspective of stakeholders. Perspectives include those of 
treatment providers and pharmacists responsible for patient care, as well as the 
representatives from authorities responsible for the regulation, monitoring and supply of 
medicines.  
The findings presented in this section are based upon the data generated from qualitative 
interviews with the various stakeholders of the MQAS which focussed on the processes 
involved in assuring the quality of medicines, the roles and responsibilities of different 
stakeholders relevant to the MQAS and the relationship between agencies, and functionality of 
the system. Scrutiny of the data also revealed a prominent emerging theme of confidence, in 
the quality of medicines available in Senegal and in the national system to monitor medicines 
quality. These data were then subjected to further analysis to explore potential emerging sub 
themes which form the basis of chapter 3, which focuses on perceptions of medicine quality. 
Thus, chapter 2 includes; 1) an examination of the national system which has been established 
to monitor medicine quality, by investigating stakeholder perceptions relating to the strengths 
and weaknesses of the MQAS and its components and associated parts, 2) an assessment of 
the system’s capability to control the quality of medicines in Senegal and 3) consideration of 
the risk factors for poor quality medicines nationally. Chapter 3 explores the perceptions of the 
same stakeholders but with a focus on their understanding of the term ‘medicine quality’ and 
perceptions of the quality of medicines in circulation in Senegal. 
 
A2. Evidence summary 
A2.1 Risk factors for poor quality medicines 
A multitude of factors can contribute to the circulation of poor quality medicines in a 
country.[1] They can be compartmentalised into internal and external factors. Internal factors 
relate to systems in place nationally (e.g. health, judicial, political etc.) whereas external 
factors consider systems not under the direct control or influence of national authorities (e.g. 
medicine manufacturers and distributors) (see figure A1 below).  
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Figure A1: Risk factors for poor quality medicines 
 
A2.1.1 External factors 
a) Sub-standard manufacturing practices and trade in fraudulent products   
As discussed in chapter 1 the distinction between substandard and falsified medicines is 
centred on intent, whereby the former arises as a result of non-deliberate poor manufacturing 
practices (such as a lack of quality control), whereas the latter are deliberately produced to be 
fraudulent. International regulatory mechanisms that encompass scientific, technical and legal 
aspects into their frameworks are designed to reduce the risk of poor manufacturing practice 
and the trade in fraudulent products. Scientific standards for medicines listed in drug 
monographs in international pharmacopeia such as the United States Pharmacopeia (USP) 
recommend procedures for assessing quality and specifications for the determination of 
pharmaceutical substances and dosage forms. [2] 
Technical aspects include manufacturer compliance with Good Manufacturing Practice (GMP), 
a system for ensuring that pharmaceutical products are produced according to quality 
standards on a consistent basis. [3] The World Health Organization (WHO) have established 
guidelines for GMP that some countries have adapted. Furthermore, they have created a 
prequalification programme for medicines, medicines quality control laboratories (MQCLs) and 
active pharmaceutical ingredients that aims to increase the availability of quality assured 
medicines. [4] The prequalification programme assesses the quality, efficacy and safety of 
medicines through the inspection of the relevant manufacturing sites to ensure compliance 
with WHO guidelines for GMP. MQCLs that comply with WHO GMP guidelines can apply to 
External factors
•High cost of medicine to the consumer
•Medicine shortages
•Substandard manufacturing practices 
and trade in fraudulent products
Internal factors
•Weak medicines regulatory system
•Inadequate technical capacity
•Inability to apprehend and act against 
manufacturers of poor quality medicines
•Inadeqaute medicines storage
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become a WHO prequalified laboratory. This accreditation should provide confidence to users 
of the services the laboratory provides. [5] WHO prequalification status of medicines and 
MQCLs should reduce the likelihood of the circulation of poor quality medicines. 
Furthermore, from a law enforcement and legal perspective INTERPOL have been working 
alongside the WHO to investigate and apprehend manufacturers of counterfeit medicines. 
Well known initiatives such as Operation Mamba (East Africa 2008-11) and Storm (south-east 
Asia 2008-15) have seized millions of counterfeit and illicit medicines. These initiatives may act 
as a deterrent, discouraging the production and illicit trade of counterfeit medicines. [6]  
b) High cost of the medicine to consumer  
Medicines with a high market price or high-volume sales may be a particularly attractive 
prospect to the producers and distributors of counterfeit medicines. Artemisinin based 
medicines for the treatment of malaria, which, until quite recently, were deemed relatively 
expensive (up to 20 times more than conventional antimalarials) to the local population in 
malaria endemic countries, [7-11] satisfy both these criteria, with over 409 million courses of 
artemisinin combination treatments (ACTs) being procured by malaria endemic countries in 
2016. [12] Indeed, within the last two decades, several reports have emerged of counterfeit 
antimalarials available on the market in parts of Southeast Asia, where artemisinin based 
treatments were first introduced. [9, 10, 13-15] Additionally, the high cost of medicines may 
dissuade a consumer from purchasing medicines from authorised treatment providers and 
instead access medicines from less regulated sectors such as market stalls and other informal 
retailers (unauthorised treatment providers such as itinerant sellers or mobile vendors) where 
their quality is not assured. [16]  
Between 2010 and 2011, the high cost of ACTs was addressed in part by the Affordable 
Medicines Facility-malaria (AMFm) which was established by the Global Fund and aimed to 
improve access to affordable and quality assured antimalarial medicines in malaria endemic 
countries. [17] AMFm was initially piloted in nine sites (one in Southeast Asia and eight in sub-
Saharan Africa) and overall, was deemed to be successful especially in terms of: reducing the 
cost of ACTs to a price comparable to that of other antimalarials; increasing the availability of 
ACTs in public and private outlets and increasing the market share of ACTs among antimalarials 
so as to ‘crowd’ out medicines like chloroquine which were no longer effective at treating 
falciparum malaria in sub-Saharan Africa. [18] Furthermore, AMFm logos on medicines 
packaging raised treatment provider, health professional and consumer awareness, providing 
reassurance that such medicines had been subject to appropriate quality assurance 
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procedures. [17] Following this large scale pilot, AMFm was subsumed into the private sector 
co-payment mechanism which provided continuation of private sector subsidies for quality-
assured ACTs, especially in countries where the private retail sector was a major provider of 
health provision for malaria. [19] 
c) Medicines shortages 
There have been several recent reports of shortages of essential medicines in low, middle and 
high income countries. [20-23] Shortages can arise from inefficiencies in the procurement and 
distribution of medicines in the public supply chain and/or budgetary constraints, resulting in 
stock outs at the point-of-care. Periodic medicine stock outs in government-funded public 
health facilities are a well-recognised problem in many low-middle income countries (LMICs). 
Medicine supply problems can also result from disagreement over pricing of medicines 
between manufacturers and governments, shortages of raw material and the failure of 
medicines batches undergoing quality control processes at a national level. [20] In the United 
States, there have been widely publicised [24] concerns that illicit sellers may fill gaps in the 
market exposed by medicines shortages. Low availability of medicines may encourage health 
facilities and providers to access alternative sources for medicines such as internet 
pharmacies, which may be more difficult to regulate and thus provide an opportunity for 
exploitation by counterfeiters. [25] Shortages may also increase the cost of a medicine 
providing further opportunities to illegal traders who sell counterfeited medicines at lower 
prices than the authentic version. 
 
A2.1.2 Internal factors 
d) Weak medicine regulatory system  
The World Health Organization (WHO) has previously estimated that 30% of countries had 
either ‘no medicine regulation or a capacity that hardly functions’ mentioning lack of 
sustainable funding and a shortage of qualified staff as prominent challenges. [26] Studies 
have suggested that weak medicine regulation may lead to the public not being adequately 
protected from access to poor quality antimalarials citing the need for wholesalers and 
medicines to be registered and authorised for use in a country. [27, 28] Furthermore, in most 
countries a NMRA has a key role in post marketing surveillance activities and is required to 
recall batches of poor quality medicines, but the WHO estimate that only 12% of NMRAs are 
able to enact an effective pharmaceutical recall. [29] National investment in medicines 
regulation, through the provision of better qualified staff such as drug inspectors and 
improved administrative processes to scrutinise wholesalers and manufacturers, and the 
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medicines they supply and distribute, would contribute to minimising the possibility of poor 
quality medicines circulating. 
e) Inadequate technical capacity 
The capacity of a country to test medicines is crucial in ensuring that poor quality medicines 
are detected. This requires the use of both screening technologies and confirmatory testing to 
work in tandem to reduce the risk of poor quality medicines. A fully equipped and accredited 
MQCL is integral to a medicine quality surveillance system (MQSS), although these seldom 
exist in LMICs due to resource constraints (particularly financial) as well as a lack of expertise 
to operate specialist equipment. [30, 31] As of July 2017, there were only eight WHO 
prequalified MQCLs in five countries ((Zimbabwe, Kenya, Tanzania, Uganda and South Africa) 
in sub-Saharan Africa and none in West Africa. [32] Enhanced technical capacity would 
increase the capability of pre and post-marketing surveillance mechanisms, thereby increasing 
the sensitivity of the MQSS to detect poor quality medicines. 
f) Inability to apprehend and act against manufacturers of poor quality medicines  
Without adequate traceability in a MQAS, counterfeiters may fail to be apprehended. 
Additionally, individuals who unknowingly consume counterfeit medicines may reside in a 
different country to the site of production and in the absence of an appropriate international 
legal framework, counterfeiters are able to evade authorities. [33] If caught, the punishment 
for counterfeiting varies and is greatly dependent on the judicial process in the country with 
India having previously considered introducing the death penalty for counterfeiters. [34] 
Nigeria has introduced a 5-15 year sentence for the distributors of counterfeit medicines, 
recognising that that the manufacturers themselves cannot always be identified and 
caught.[35] In China, the national government have exacted the most severe possible 
sentence, executing its former head of the food and drug regulator after it was found that he 
was taking bribes to approve untested medicines. [36] A recognised international treaty 
against counterfeiters may provide the basis for countries to enact legislative powers. Cross 
boarder agreements for extradition and greater penal sanctions for counterfeiters and 
distributors may act as a deterrent. 
g) Inadequate medicines storage 
Medicines storage (in the tropics and hence, malaria endemic countries) is also a challenging 
risk factor to address in LMICs. Environmental factors such as temperature and humidity which 
often exceed those recommended by manufacturers of many essential medicines may 
contribute or even accelerate degradation processes [37, 38], although to date there is no 
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information on the prevalence of degraded medicines from any global region. Maintaining 
adequate storage conditions would reduce the risk of poor quality medicines. However, it is 
acknowledged that controlling humidity and temperature is extremely challenging in malaria 
endemic countries due to lack of refrigeration and air conditioning equipment. The financial 
investment in cooling technologies may be affordable to some national medicines distributors 
but are too costly for individual health facilities and smaller businesses such as pharmacies, 
and drug stores. With many locations in the Sahel region of Africa often reaching in excess of 
40°C, even cooling technologies may struggle to adequately control temperature.  
Many malaria endemic countries are predisposed to most, if not all of the risk factors 
described above. Resource constraints such as a lack of sustainable funding and minimal 
numbers of staff with requisite expertise, exacerbate several of the internal risk factors. 
Nevertheless, establishing a functional and effective MQSS designed to detect poor quality 
medicines and a robust wider quality assurance system with stringent medicines regulation 
and supply chains supported by judicial powers for illegal drug manufacturing and distribution, 
will minimise the vulnerability of a country to the circulation of poor quality medicines. The 
external factors require much broader consideration and are dictated by global market forces 
over which national authorities have limited control.  
 
A2.2 Medicine quality assurance systems at national level 
This section outlines the importance of monitoring the quality of medicines, and the value of a 
national MQSS. Chapter 1 described two key components of a MQSS, namely the sampling and 
laboratory analysis of medicines. However, two further components can be identified that are 
integral to a wider MQAS in order for national authorities to have effective control of the 
quality of medicines available within a country: medicine regulation and medicine supply 
chains (see figure A2). These four components are described in detail below with a focus on 
minimising the risk of poor quality medicines in a country. 
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  Figure A2: Essential components of a medicines quality assurance system 
 
1. Medicines Regulation 
The regulation of health sector goods and services should be a core government function and 
requires good governance to contribute to the effective performance of the wider health 
sector. [39, 40] The WHO believes that effective medicines regulation is important to 
protecting public health and suggests that national regulatory systems are primarily 
responsible for assuring medicines quality, safety and efficacy as well as ensuring that 
medicines are appropriately manufactured, stored and distributed and that illegal 
manufacturing and trade are detected and sanctioned within their borders. [41] Between 2002 
and 2008 the WHO carried out an assessment of regulatory systems in 26 countries in sub-
Saharan Africa. [29] In this report, the WHO identified five key functions of medicines 
regulation; marketing authorisation, licensing, inspection, quality control and 
pharmacovigilance. Overall, of the 26 countries that were assessed, only five had all these 
functions in place. The report concluded that whilst the structures for medicines regulation 
existed and the main functions were considered in these structures, in practice the measures 
were often inadequate, with several important gaps that resulted in a fragmented system in 
many cases. Major weaknesses that were identified included; poor governance structures and 
management processes, a dearth of personnel and financial resources, with concerns that 
overall, most countries lacked the capacity to control the quality, safety and efficacy of 
medicines available on the market nationally. The report also concluded that additional 
support for Member States in the form of training, information and guidelines was required. 
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An effective NMRA can play a key role in assuring the quality of medicines that both enter the 
national supply chain and that are circulating in a country. Relevant to medicines quality, 
NMRAs are responsible nationally for marketing authorisation and registration of medicines, 
monitoring of medicines safety and quality before authorisation, and licensing of 
manufacturers and wholesalers. [42] This role should also include regulation at point of care, 
through licensing of retail premises and acting on evidence provided by the MQSS of suspected 
poor quality medicines detected through post-marketing surveillance and recalling batches of 
medicines, where appropriate. According to WHO recommendations, NMRAs should also 
share relevant information about medicines with health professionals and the public, including 
information on poor quality medicines. [29] Finally, NRMAs should also be involved in 
establishing a relevant national legal framework that permits the apprehension and 
prosecution of producers and distributors of poor quality medicines.  
One of the greatest challenges for medicines regulation and public health more generally in 
sub-Saharan Africa, is the presence of an unregulated (informal) health sector. People with 
malaria fever often self-medicate with antimalarial medicines obtained from both the 
regulated and unregulated private sector, in particular, informal sector outlets or iterant drug 
sellers. [43] However, it is the large-scale presence of the latter that poses the greatest 
challenge for NMRAs. A study of treatment seeking behaviour for malaria of primary caregivers 
for children under 5 in Accra, Ghana found that 47% preferred to visit drug shops or market 
vendors as opposed to government owned health facilities. [44] A survey of 11,505 adults in 
three districts in Kenya found that 47% would in the first instance seek over the counter 
treatment from private sector outlets for fever symptoms. [45] A further study in Northern 
Nigeria of primary caregivers (n=814) showed that there was a preference to access the 
informal sector (54%) (primarily loosely regulated proprietary and patent medicine vendors) as 
opposed to formal health facilities (46%). [46] A systematic review of the role of informal 
health care providers in developing countries found great variation in utilisation from as high 
as 60-77% of study participants in Bangladesh first seeking treatment for any illness from the 
less regulated providers, compared to just 9 % from a study in Kenya. [47] This extensive 
reliance of large swathes of the population upon the informal sector for the treatment of 
malaria poses a risk to public health as antimalarials in this sector may have bypassed the 
normal regulatory processes and hence, their quality cannot be assured. [16, 48] 
2. Medicines supply chains 
Medicines supply chains are channels by which medicines enter the country and are 
distributed by wholesalers which in turn provide medicines to health facilities such as 
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hospitals, health centres, pharmacies and drug shops. Broadly speaking, in many LMICs there 
are two types of medicines distributors. The first, national medical stores, supply public 
(government owned) facilities such as hospitals and health clinics via smaller regional and 
district distribution warehouses. Donations from external agencies may be an additional 
source of medicines that are supplied to the public sector through the national medical 
stores.[49] The second type of distributor is private wholesalers, which acquire medicines 
directly from manufacturers and supply the private regulated sector such as individual 
pharmacies or private health clinics. In some LMICs an additional distribution channel is 
operated by not for profit agencies such as charities, non-governmental organisations and 
social enterprises. These agencies may supply medicines to public or non-governmental 
organisation run health facilities on a long term basis, for short term public health programmes 
or during humanitarian crises. [50] Medicines may also infiltrate supply chains by illegal means 
or be diverted from the official distribution channels, from the public to the regulated private 
sector as well as to the informal (less regulated) sector. [43] 
A secure supply chain is essential for reducing the likelihood of poor quality medicines 
circulating in a country. Supply chains are intrinsically linked to medicines regulation and the 
oversight of their governance is often the responsibility of the NMRA. Where regulation is 
effective, medicines entering the supply chain should have been authorised, registered, safe 
and quality assured. To ensure a robust supply chain, medicines quality needs to be assessed 
(through sampling) at the point of entry into a country as well as at the level of distribution to 
health facilities (national and regional medical stores and wholesalers) and at the point of care 
(hospitals, health centres, pharmacies etc.). Where unofficial supply chains exist, as is the case 
with the informal sector, the risk of poor quality medicines reaching the public is higher due to 
a lack of regulatory oversight and hence, no assessment of medicine quality at the point of 
entry and distribution or minimal sampling and analysis at the point of care. [51]  
As discussed in the previous section, medicine quality in the supply chain maybe compromised 
by the environmental conditions during the storage of medicines in warehouses, during transit 
and in health facilities. A study investigating the impact of light, moisture and temperature on 
antibiotics and anti-fungal medicines demonstrated that degradation was accelerated by high 
temperature and humidity. [52] In LMICs storage conditions are most likely to be compromised 
at the point of care as most health facilities and retail outlets are unlikely to contain air 
conditioning units or cold rooms due to the financial investment required and potential 
intermittent electrical supply, which is especially pertinent in more remote areas. 
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3. Medicines sampling to check the quality of medicines 
Regulation alone is not sufficient to assure the quality of medicines, and often in LMICs it is 
also the responsibility of the NMRA to check the quality of medicines entering the supply chain 
through the sampling of medicines and analysis of their chemical content. Medicine sampling 
in the context of a MQSS involves the collection of medicines from wholesalers and a range of 
drug outlets through post-marketing surveillance. Sampling through post-marketing 
surveillance, usually at the point of care enables a MQSS to assess the quality of medicines 
available to the public in a given geographical area. Robust sampling strategies and a large 
sample size will provide a prevalence estimate for the area from which the medicines were 
sampled. [31] In LMICs in which the USP is present, its Promoting the Quality of Medicines 
programme recommends the sampling of antimalarials, antiretrovirals (ARVs), tuberculosis 
and oral contraceptive drugs on an annual or bi-annual basis using convenience sampling. [53]  
There is a dearth of information available on the extent of point of entry medicines quality 
sampling and analysis in LMICs. However, as mentioned previously, this is a key responsibility 
of a NMRA. Post-marketing surveillance in LMICs faces additional challenges in terms of the 
cost of sample collection from more remote geographical areas, as well as limited laboratory 
capacity to analyse medicines at the peripheral level (away from the national MQCL). The use 
of lower cost screening technologies in field surveys and post-marketing surveillance in LMICs 
is thus key and constitutes the focus of the second section of this thesis.   
4. Medicine quality analysis 
USP guidelines suggest that in a national program, collected samples can be initially screened 
in peripheral laboratories for quality using the Global Pharma Health Fund MiniLab®, to 
facilitate wide geographical coverage and timely results. Samples providing unsatisfactory or 
dubious results should then be subject to repeat testing by the MiniLab® and further analysis 
using USP compendia methods, primarily High Performance Liquid Chromatography (HPLC), at 
the national reference laboratory, for more confirmatory results. [54] Medicine quality analysis 
in LMICs supported by USP thus typically involves a two stage process; 1) medicine quality 
screening by the MiniLab® followed by 2) confirmatory testing using USP compendia 
methods.[55]  
 
To operate effectively, a medicines quality assurance system needs (i) effective regulations and 
guidelines, (ii) knowledge of the supply chain(s) and means to sample at different points along 
the supply chain, (iii) the technical means to sample in a comprehensive and representative 
manner and to analyse drugs with a high degree of accuracy, and (iv) a clear action plan on the 
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steps to take when poor quality medicines are detected. Enactment of these processes 
requires the financial means and political will, as well as the organisational capacity, to do so in 
an effective and timely manner.   
To further exemplify the roles of a MQAS in assuring and controlling medicine quality, figure 
A3 summarises the process through which a medicine progresses through a national MQAS. 
Stringent national medicines regulation has been proposed as an integral part of an effective 
MQAS and contributes to reducing the likelihood of poor quality medicines entering the 
country. [30] The figure illustrates the importance of medicines regulation as an overarching 
and integral component encompassing; authorisation and marketing of a medicine, 
implementing strategies for sampling for medicines quality assessment, acting upon findings 
from medicine quality surveys and where possible, enforcing laws set out in national medicines 
regulatory and statutory frameworks.  
  
Figure A3: Typical process of a medicine as it passes through a medicines quality assurance system.  
Each stage of this process has been assigned a component of the MQAS. PMS refers to post-marketing 
surveillance. 
 
There is limited publicly accessible documentation on MQSS or how well they function 
especially in sub-Saharan Africa. The country case study of Rwanda’s medicines regulatory 
system which includes medicine quality monitoring and pharmacovigilance is a rare 
exception.[56] Strengths of the Rwandan system include, the systematic testing of medicines 
shipments prior to distribution, the sampling and analysing of ACTs as part of post-marketing 
surveillance on a quarterly basis, and training of over 2000 health care workers on national 
guidelines for medicine quality monitoring and pharmacovigilance. In addition, the Rwandan 
52 
 
government’s interest in medicines quality has harmonised a successful working relationship 
with the Bureau of Standards, Customs Services and the MoH ensuring the assurance of 
medicines quality is a collaborative effort. The authors of the study that evaluated this system 
did not identify any areas of improvement but suggested a need for better collaboration with 
neighbouring countries to reduce the possibility of poor quality medicines entering Rwanda 
whilst also working toward a regional medicines quality assurance and surveillance 
strategy.[56] Nevertheless, this is an example of a relatively sophisticated system in a small 
country with a limited and highly-controlled private sector, which may not be generalisable to 
other settings. 
The lack of academic or policy literature and documentation on MQSS demonstrates the need 
to explore such systems where they do exist, although it remains unclear how many LMICs 
have a system for monitoring medicines quality or whether sampling and analysis activities 
alone are conducted on an ad hoc basis within a fragmented MQAS. Where a MQSS exists, 
there is minimal information on how they operate, their infrastructure for regulation, 
governance arrangements, roles and responsibilities of agencies, and resource capacity. 
Hence, there is a need to explore how MQAS operate in LMICs with a specific focus on the 
surveillance of medicines quality.  
 
A2.3 Describing and defining medicines quality 
As discussed in chapter 1, medicine quality is typically defined in terms of one or more of the 
legal, technical and clinical paradigms.   
At the national level, the legal paradigm is particularly important for regulatory action and the 
recent World Health Assembly standardised definitions [57] may provide NMRAs and law 
enforcement agencies with the basis to develop their national medicines regulatory framework 
to include a judicial process for dealing with falsified and substandard medicines producers 
and distributors. However, to quantify the extent of the problem of poor quality medicines for 
health systems to act to mitigate the risk to public health, evidence on the chemical content 
and pharmaceutical properties of a medicine (technical paradigm) is also required. 
Internationally accepted definitions for poor quality medicines may also enable comparisons 
between regions, between countries at a regional level and within a country at a national level. 
Nonetheless, these recent definitions are overarching and appear more pertinent at a global 
level and aim to address some of the previous discourse centred on definitions of poor quality 
medicines between different actors such as legal professionals, policy makers, academics and 
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the pharmaceutical industry. They are less relevant to the national level context in which legal 
frameworks (especially in LMICs) for addressing poor quality medicines are lacking or not 
consistently applied. Furthermore, as mentioned previously, many LMICs have inadequate 
technical and regulatory capacity and hence may struggle to provide reliable results upon 
which legal action can be taken against producers and distributors of poor quality medicines. 
Therefore, to effectively determine the vulnerabilities in the MQAS and the actions that need 
to be taken to counter this threat, there is a need not only to detect poor-quality medicines, 
but also to correctly classify how a medicine fails to meet quality standards, in order to 
determine the likely cause and thus to enforce the preventive measures which will be of most 
benefit. To do this, requires the following:  a) robust MQAS with stringent medicine regulation, 
a robust sampling strategy and sufficient technical capacity for testing medicines quality 
underpinned by good governance; b) a legislative framework for action against producers and 
distributors of poor quality medicines; c) sustainable financing and d) adequate human 
resource.  
Chapter 3 of this thesis discusses how medicines quality is defined and described by examining 
the perceptions of medicine quality and the degree of confidence of MQSS organisation 
representatives, treatment providers and pharmacists in Senegal have in the quality of 
medicines in circulation. There is little evidence on the perceptions of medicines quality 
amongst individuals responsible for quality assurance at a national level. Their perceptions are 
important as they may influence the enactment of policy with regard to medicine quality, as 
well as the routine operation of the MQSS. 
 
A3. Monitoring of medicines quality within the context of health systems – a 
theoretical framework 
A MQSS operates within a wider medicine quality assurance system which is part of a much 
broader health system. Many of the challenges presented earlier in this section that constrain 
the effective functioning of a MQSS include those of finance, governance and human resource. 
These factors are also fundamental to the functioning of the health system as a whole. 
Therefore, to evaluate the function and operation of the MQSS and its perceived effectiveness 
in reducing the risk of poor quality medicines in Senegal, this section of the thesis will make 
use of a theoretical framework that is commonly used to evaluate the structure and 
performance of health systems. [58-60] This framework identifies six building blocks of health 
systems;  governance, financing, service delivery, products and technologies, health 
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information and human resources. [61] The WHO have described the six building blocks as 
serving three purposes; 1) to define the attributes of a health system, 2) to define health 
systems priorities and 3) to identify gaps that require support within a health system. [61] 
Within health systems there is a degree of interaction and/or interdependence between these 
building blocks that impacts upon the performance and effectiveness of the system. 
In this thesis, these building blocks were examined for their prominence, their level of priority 
and those which require addressing within the context of the MQAS and MQSS in Senegal (see 
figure A4). 
 
Figure A4: Medicine quality surveillance as a component of medicine quality assurance and the wider health 
system.  
The six building blocks of health systems impact on the operation and the function of the overall health system 
but are also applicable to its components including the MQAS and MQSS.  
 
Processes around the quality assurance of medicines will shape, and be shaped by, the 
perceptions that all stakeholders have of the quality of medicines and the factors which they 
believe affect medicine quality. For example, this perception may impact upon the priority that 
is placed on the formation and enactment of policy for medicine quality at the authority level. 
At the point of care, health professionals and drug outlet owners may procure, sell and supply 
medicines based on their own perceptions of quality. Furthermore, individual perceptions of 
quality may influence the purchase and use of medicines by the public. These decisions at all 
levels of the health system are thus influenced by the extent of confidence that policy-makers, 
treatment providers, drug sellers and consumers have in the quality of medicines available 
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within their country, and the confidence they have in the medicines quality assurance system 
to control medicines quality.  
 
A4. Aims and Objectives 
The aim of the qualitative study in this section is to generate evidence for strengthening 
medicine quality surveillance systems in LMICs, through a focus on the processes involved in 
assurance of the quality of the medicine supply in Senegal, the roles and responsibilities of and 
relationships between different stakeholders, and their perceptions of the functionality of the 
system and the quality of medicines nationally. 
A4.1 Objectives 
1. To explore stakeholder perceptions relating to the strengths and weaknesses of the 
medicines quality surveillance system and its ability to control the quality of medicines 
in Senegal. 
 
2. To explore the perceptions of a range of stakeholders involved in monitoring of 
medicine quality and provision of antimalarial treatment in Senegal regarding their 
understanding of the term ‘medicine quality.’ 
 
A5. Methods 
This section is the preceding methodology for chapters 2 and 3 for which the same qualitative 
data set was used but analysed from a different thematic viewpoint in each of the chapters. In 
chapter 2 a thematic framework approach was used to arrange and analyse the data. In 
chapter 3 an open coding approach (thematic analysis without a framework) was used. These 
approaches are described further in each of chapter 2 and 3 under the respective methods 
sections. 
A5.1 Study setting and participants 
Medicine quality surveillance in Senegal 
In response to the findings of the existence of poor quality antimalarials from an antimalarial 
quality survey conducted by USP in 2009, the Ministry of Health (MoH) established a medicines 
quality surveillance coordinating committee, in 2011, in order to strengthen medicines quality 
surveillance in Senegal. [62] This committee included the Pharmacie Nationale 
d'Approvisionnement (PNA), Direction des Pharmacies et des Laboratoires (DPL) and 
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Laboratoire National de Contrôle des Médicaments (LNCM), as well as the national agencies 
tasked with overseeing control and treatment of tuberculosis, HIV and malaria. [63]  
The authorities involved in the operation of the MQSS also have other roles in the health 
system. The DPL authorises wholesalers for importing medicines into Senegal and medicines 
for marketing, regulates outlets (public health facilities and private regulated pharmacies) that 
sell or supply medicines and oversees pharmacovigilance activities. The LNCM and DPL are also 
collaboratively responsible for national medicines quality control. At the national level the PNA 
is responsible for the procurement and distribution of medicines, medical devices and other 
commodities. As the primary focus of this thesis was on the quality of antimalarial medicines, 
the agency responsible for malaria control and treatment, namely the Programme National de 
Lutte contre le Paludisme (PNLP) was also included in the study. [64] Funding, logistical and 
technical support for the MQSS has been provided by the United States Agency for 
International Development (USAID) through its implementing partner USP. [53] Senegal has 
been using the GPHF MiniLab® to screen the quality of medicines including antimalarials since 
2004 in sentinel site laboratories, with confirmatory analysis using methods such as HPLC, 
taking place at the LNCM in Dakar. As of 2011 there were nine sentinel sites across the country 
where staff have been trained to operate the MiniLab®.  
The structure of the health system in Senegal  
The health system in Senegal can be compartmentalised into 3 sectors; public, private and 
informal. The public sector includes hospitals, centre de santé (large health clinics), poste de 
santé (small health clinics) and community health workers who provide preventative and 
curative services including health promotion and education, treatment of malaria, acute 
respiratory infections and diarrhoeal diseases. [65] At the time of the study there were around 
88 health clinics (centre de santé and poste de santé) in Senegal. [66] A further 1,703 health 
huts staffed by community health workers represented the primary point of care, especially in 
rural areas. [67] Since 2008, a new type of village based health worker provides testing with 
rapid diagnostic tests (RDTs) and treatment with artemisinin based combination therapies 
(ACTs) through the home-based management of fever program, Prise en Charge à Domicile 
(known as PECADOM). [64] The private sector includes pharmacies that are licensed and 
regulated by the DPL and operated by a pharmacist registered with the National Pharmacy 
Board as well as private health clinics. In 2009, there were approximately 870 private 
pharmacies (ten times as many as public health facilities) in Senegal. [68] Little is known about 
the unregulated sector (referred to as informal sector throughout this chapter) in Senegal but 
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evidence suggests that medicines are available in market stalls in many of the major urban 
centres in Senegal. [69] 
The study was undertaken in Senegal from April-May 2013 in the capital city Dakar and two 
nearby towns, Thies and Mbour, both of which are representative of urban centres outside of 
the capital (see map below, figure A5). Stakeholders of several organisations involved in 
medicine quality monitoring as well treatment providers and pharmacists were recruited. The 
former group comprised representatives of the PNA, DPL, PNLP, LNCM, University of Cheikh 
Anta Diop (UCAD), USAID and USP. Treatment providers including doctors and nurses from 
public health facilities only, and pharmacists from public health facilities and private providers 
were recruited.  
 
      Figure A5: Map of study sites in Senegal. The red stars indicate locations where interviews were conducted. 
 
A5.2 Study procedure and sampling   
All the aforementioned organisations were identified through consultation with research 
partners in Senegal as the key stakeholder authorities of the MQSS. Individuals from each of 
these authorities as well as former employees were purposively selected for the study to 
represent the views of those primarily responsible for the strategic and operational function of 
the MQSS. Undertaking interviews with both current and former employees of the MQSS 
authorities provided a broad spectrum of perceptions as the participant sample included 
individuals with intimate knowledge and experience (both current and historical) of medicines 
quality surveillance in Senegal. Former employees were selected to participate as it was 
thought they would provide views that represented their personal experiences which may 
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contrast with those of current employees. Such an approach is encouraged in qualitative 
research studies to increase the validity or trustworthiness of the data obtained. [70] In 
qualitative studies, researchers aim to obtain a maximum variation sample but, the findings 
are not intended to be numerically representative. A purposive sampling approach is intended 
to demonstrate the diversity in responses, including those that are divergent. [71]  
For the MQSS authorities, a senior representative of each organisation was contacted by the 
local research coordinator who explained the nature of the study. This representative then 
designated themselves or another individual(s) they deemed appropriate for the interview. 
Despite lodging a request, the MoH were not able to provide a representative for interview. 
Interviews conducted with treatment providers included district health officers, poste de santé 
officers (public sector) and private pharmacy owners (pharmacists) in Dakar, Thies (40km east 
of Dakar) and Mbour (60km south east of Dakar). A list of all public providers (centre de santé 
and poste de santé) was provided by the DPL but at the time of the study it was outdated and 
incomplete. Hence, outlets were selected based on logistical convenience in the selected 
districts. A list of regulated private pharmacies in the three locations was obtained from the 
DPL and verified by the National Pharmacy Board. Private pharmacies were randomly selected 
for participation from the list using a random number generator.  
Semi-structured interviews were conducted in English and French by the researcher (Mirza 
Lalani) and a local research assistant respectively. My relevant experience to this study was 
knowledge of the subject matter (medicine quality) and previous experience of working in 
Senegal and therefore, some familiarity of the health system. I also had practical experience of 
conducting interviews gained during my MSc project, interviewing drug shop operators in 
Uganda. The research assistant was a Senegalese national, who spoke fluent English with an 
undergraduate degree in Medical Anthropology and experience of using qualitative methods 
on research projects in Senegal. Interviews lasted between 45-90 minutes and were usually 
conducted at the interviewee’s place of work, in a private office (when available) with only the 
participant and researchers present (n=26); two were conducted over Skype™ and one at the 
home of the interviewee. Written informed consent was obtained from each interview 
participant.  
Interview guides were designed to be iterative allowing exploration of emergent issues from 
the interviews. An inductive approach was taken throughout the study, field notes were 
discussed and reviewed by the principal researcher and the research assistant at the end of 
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each interview, and emergent themes from one interview incorporated into the guide for 
further exploration in subsequent interviews. [70] 
All audio recorded interviews were transcribed verbatim in the language they were recorded 
in. Interviews conducted in French were transcribed and then translated into English. Interview 
data was entered into NVivo version 10* for management and analysis. An individual external 
to the research team was employed to undertake translation. The quality of translation of 3-4 
transcripts was verified by the research assistant.  
Ethical approval for the undertaking of this study was granted by the London School of Hygiene 
and Tropical Medicines Research Ethics Committee (see annex 1) and the National Council for 
Health Research, Senegal (annex 2). 
 
A6. Results 
This section presents the characteristics of the study participants and participation of the 
MQSS authority representatives and treatment providers in the study which is the same for 
chapters 2 and 3. The results section included in each of chapters 2 and 3 describes the 
qualitative data itself, presenting the emerging themes.  
A6.1 Characteristics of participants 
A total of 29 semi-structured interviews were held with a range of stakeholders from various 
levels of the health system in Senegal. This included current and previous employee 
representatives of the key MQSS authorities (Table A1), other stakeholders (e.g. UCAD) and 
treatment providers (Table A2). The treatment providers interviewed were doctors, nurses and 
pharmacists from the regulated public (n=6) and private (n=10) health sectors in Senegal.  
Table A1: Representatives of the MQSS authorities 
Authority Number of interviewees 
Current 
employees 
Former 
employees 
Direction des Pharmacies et des Laboratoires (DPL) 2  
Laboratoire National de Contrôle des Médicaments (LNCM) 2 1 
Programme National de Lutte contre le Paludisme PNLP 1 1 
Pharmacie Nationale d'Approvisionnement (PNA) 1  
University of Cheikh Anta Diop (UCAD) 2  
United States Pharmacopeia (USP) 1  
United States Agency of International Development (USAID) 1 1 
Total 10 3 
                                                          
* NVivo qualitative data analysis Software; QSR International Pty Ltd. Version 10, 2012. 
60 
 
Table A2: Treatment provider by location and sector 
Treatment Provider City/District Number of 
treatment 
providers (n=16) 
Sector Outlet/Facility 
Medical doctor/District Health 
Official 
Dakar 2 Public Centre de santé 
Thies 1 Public Centre de santé 
Nurse Dakar 2 Public Poste de santé 
Pharmacist Dakar 1 Public  Hospital 
Dakar 5 Private Pharmacy 
Thies 3 Private Pharmacy 
Mbour 2 Private Pharmacy 
 
A6.2 Participation 
None of the MQSS authority representatives or public sector treatment providers refused to 
be interviewed. For the private pharmacies, of the 27 that were initially selected for interview, 
16 interviews were successfully arranged. Reasons for failure to arrange an interview included; 
incorrect contact details (n=4), pharmacist absent (n=4), unable to arrange a day convenient 
for the pharmacist (n=2) and refusal to participate (n=1). If the pharmacist was absent at time 
of first contact, the research team made one further attempt to contact them but if told that 
the pharmacist was still absent, then no further attempts were made. For those pharmacists 
with which it was not possible to organise an interview at their convenience, several 
alternative days were offered but none were deemed suitable.   
Despite reaching a degree of response saturation after around 10/13 interviews with the 
MQSS authority representatives, all interviews were completed. After just 12 interviews with 
treatment providers, responses had started to converge, and no new themes were emerging, 
thus, the research assistant and I deemed that response saturation was reached. Despite 
reaching response saturation, four additional interviews were conducted with treatment 
providers based on specific outlet characteristics to further sample diversity. Two of these 
additional interviews were conducted in Mbour (town outside Dakar) and the other two in 
more socio-economically deprived districts of Dakar. This purposive approach was designed to 
capture any differing views from treatment providers with slightly different characteristics to 
those already sampled (geography and socio-economic status of local population), yet, no new 
themes emerged.  
Of the treatment providers interviewed, 5 were male and 11 female aged between 35 and 53 
years, and all but one had university level education. The selected outlets were primarily in 
urban or peri-urban areas. 
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A7. Section summary 
Senegal was selected as a country case study as antimalarial medicine quality has been well 
documented there over the last 20 years [72] subsequent to which it established a MQSS 
which is currently operated by the NMRA and a MQCL both of which are government agencies 
under the auspice of the Ministry of Health. USP’s Promoting the Quality of Medicines 
programme has been active in Senegal since the beginning of the century with continued 
investment over many years resulting in an existing infrastructure for medicines quality 
assurance. Therefore, the focus on Senegal in this thesis provided an opportunity to explore 
what an MQSS in a LMIC can achieve. By examining how the MQSS functions, the roles and 
responsibilities of its stakeholders and characterising the challenges the system faces in 
minimising the risk of poor quality medicines circulating in the country, this thesis provides 
evidence for other countries in sub-Saharan Africa who seek to establish and sustain an 
effective MQAS. 
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Chapter 2: Assuring the quality of medicines in low to middle 
income countries; a health systems perspective from Senegal 
 
2.1 Background 
Poor quality medicines are a challenging issue for public health globally and at a national level, 
especially in low to middle income countries (LMICs). The World Health Organization (WHO) 
and United States Pharmacopeia (USP) have provided recommendations on how countries can 
assure the quality of medicines through guidance on (i) establishing regulatory mechanisms, 
(ii) building technical capacity (through the WHO prequalification of medicines quality control 
laboratories) and (iii) specific suggestions on how to sample and analyse the quality of 
medicines. [1-3] However, these overarching recommendations do not account for the 
complexity of individual health systems and the nuances of the country context. 
At the national level in many LMICs, there are several risk factors for the existence of poor 
quality medicines as described in the introduction to section 1. These risks can be minimised 
through the establishment and effective operation of a medicines quality surveillance system 
(MQSS) within a broader medicines quality assurance system (MQAS). A review of the 
literature on medicine quality identifies four major components of a MQAS that need to 
perform effectively to assure the quality of medicines used for treatment, namely; 
comprehensive and robust medicines regulation, authorised and secure medicines supply 
chain(s), regular and representative medicines sampling, and accurate and timely medicines 
quality analysis (figure A2, section 1). 
Forming a MQAS is challenging in LMICs as it requires significant sustainable financial and 
human resource as well as political will. [4] Effective regulatory mechanisms for medicines 
quality control and building technical capacity in the form of a national medicines quality 
control laboratory (MQCL) fully equipped with sophisticated analytical equipment and well-
trained staff are essential for ensuring the quality of medicines available to the public are safe 
and effective. This chapter discusses the MQSS in Senegal, West Africa through exploring 
stakeholder perceptions relating to its strengths, weaknesses and its ability to control the 
quality of medicines in the country. 
As mentioned in Chapter 1, the gap in knowledge and understanding of how a MQSS functions 
in a LMIC against the backdrop of constrained resources requires further investigation. Whilst 
most countries in sub-Saharan Africa will have some regulatory mechanism for marketing and 
authorisation of medicines, registration and accreditation for wholesalers and manufacturers 
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and oversight of the safeguarding of medicines supply chains, few have a system to monitor 
medicines quality through post-marketing surveillance and fewer still have the capacity to 
control medicines quality at the point of entry. [5, 6] The case study of Senegal provides an 
opportunity to explore what can be achieved and the challenges faced in terms of monitoring 
medicines quality in a LMIC. This study set out to generate evidence on strategies for 
strengthening the MQSS in Senegal by establishing stakeholder perceptions relating to the 
strengths and weaknesses of the MQSS and its ability to control the quality of medicines in the 
country. 
 
2.2 Theoretical Framework 
A realist epistemological approach was undertaken using qualitative interviews to produce 
knowledge relating to various aspects of the MQSS. In philosophical terms the realist paradigm 
acknowledges an external reality which is independent of the researcher. [7] Therefore using a 
realist approach provided a ‘window’ into the world of the interviewee in terms of their 
perceptions (external reality) and revealed important facts (reality) relating to various 
components of the MQSS. [8] Realist researchers often have preconceptions that guide them 
in selecting interviewees and topic areas for discussion. In this study, the main MQSS 
authorities in Senegal were selected for inclusion in the study and predetermined interviews 
themes were created based on the limited pre-existing literature about medicines quality 
monitoring and regulation in LMICs as well as through discussion with research partners in 
Senegal.  
For the interview guide for interviews with the MQSS authority representatives (see annex 3), 
a priori codes were centred on context and purpose of the MQSS (roles and responsibilities, 
background, strengths and challenges) and the four major components of a MQAS (medicines 
regulation, supply chain monitoring, medicine sampling, and medicines quality analysis). This 
study aimed to explore the perceptions of stakeholders in Senegal in relation to the MQSS, 
ascertaining which components of the system needed improvement, as well as those that 
were performing well. The MQSS is part of a wider MQAS operating as component of a 
broader health system. To evaluate the functioning and operation of the MQSS and its 
perceived effectiveness in reducing the risk of poor quality medicines in Senegal in the context 
of a health system, a coding framework based upon the six building blocks of health systems;  
governance, financing, service delivery, products/technologies, health information and human 
resources, was applied. [9] Using a health systems lens, the study identified the key roles and 
responsibilities of the MQSS, examined the strengths and weaknesses of the four components 
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of the MQAS and identified gaps that may require additional support. A modified interview 
guide (annex 4) was used for interviews with treatment providers with a focus on specific 
aspects of medicines including national policy for treatment of malaria, procurement 
approaches, perceptions of medicines quality and their knowledge and interaction with the 
system for monitoring medicines quality.   
 
2.3 Methods  
See section 1, A5 for the methods for this chapter. The approach to coding and analysis is 
described below. 
2.3.1 Coding and analysis  
A thematic framework approach was undertaken for analysis at two levels (see figure 2.1). The 
first level included the a priori codes. The second level of the framework included the six 
building blocks of health systems; governance, finance, human resources, products and 
technology, health information and service delivery [9]; a framework that can be particularly 
useful in understanding the structure and performance of a health system of which a MQAS 
and hence, a MQSS are components. The responses from each interviewee in relation to the 
primary themes of context, function, strengths etc. were coded for the six building blocks.  
 
2.4 Results 
The characteristics of the study participants and participation of the MQSS authority 
representatives and treatment providers in the study are described in section 1, A6.  
2.4.1 Emerging themes 
After the process of familiarisation of the data [10] thematic analysis was used to identify 
emerging sub-themes within the six building blocks of health systems. Throughout the process 
of coding the first and second levels of the framework were largely applicable. However, for 
some of the first level a priori themes, codes for health systems building blocks were less 
relevant. Furthermore, a few themes emerged from the data as a result of the inductive 
approach taken, such as confidence in the MQSS and its capacity to assure medicine quality in 
Senegal. The research assistant also undertook coding of a few transcripts using the original 
coding framework and a second iteration of the framework was produced. The framework was 
reviewed by an LSHTM staff member who formed part of the PhD advisory panel subsequent 
to which a final version was produced for analysis (figure 2.1).  
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Figure 2.1: Final version of coding framework with first and second levels  
The solid blue and red boxes are a priori themes. Themes in boxes with dashed outline are those emerging during 
the course of data collection and analysis.  
 
2.4.2 Context and function of the medicine quality surveillance system 
The context of the MQSS and its function impact upon its capacity to work effectively at 
minimising the risk of poor quality medicines appearing in Senegal. The main aspects of the 
system that were explored were its history and background, institutional roles and 
responsibilities, and its strengths and challenges. As strengths and challenges specifically 
address the functioning of the system, it was appropriate to apply the framework of the six 
building blocks of the health system as codes. However, during the coding process it was found 
not to be a useful framework for the analysis of the data relating to context (historical and 
roles and responsibilities) and an open coding approach of emerging sub-themes was 
undertaken. The various sub-themes emerging from the data are presented below under each 
primary theme, together with quotes from interviewees in inverted commas. 
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Historical 
Three main sub-themes emerged from the data: rationale for the system, capacity building, 
and main actors in the inception and development of the MQSS. 
Rationale for system: Three main reasons for the conception and development of the MQSS 
were suggested. Firstly, toward the end of the 1990s a handful of ad hoc research surveys of 
antimalarials conducted by UCAD found the presence of poor quality medicines (primarily 
chloroquine). Secondly, it was proposed that the growing problem of chloroquine resistance, 
identified by instances of treatment failure was perhaps attributable to the availability of poor 
quality formulations of the medicine. Thirdly, the USP/WHO survey of 2009 which suggested a 
problem of poor quality antimalarials in Senegal, resulted in heightened awareness of the issue 
especially within the MoH. The MoH requested immediate clarification from the existing 
authorities responsible for surveillance of medicines quality on the survey findings as well as 
how the problem would be addressed. 
Capacity Building: The USAID through its implementing partner USP assisted in the 
establishment of sentinel sites across Senegal, equipped with the MiniLab® for medicine 
quality screening. They were involved in the strengthening of technical capacity at the LNCM. 
Further, those initially involved in ad hoc medicine quality surveys undertaken by the analytical 
chemistry department at UCAD were now employed in prominent positions in the DPL and 
LNCM. 
Main Actors:  MQSS authority stakeholders acknowledged that the role of the PNLP and USAID 
was paramount to the inception and development of the MQSS in its early stages. The former 
acted as a conduit for the latter’s technical and financial support which may explain the 
continued focus on antimalarial medicine quality and malaria more generally. 
‘The malaria program earlier benefited from the support of some partners especially 
USAID and USP. They really boosted the national control laboratory and DPL, which has 
enabled them to carry out a lot of quality control activities in Senegal.’ MQSS authority 
representative  
 
Roles and Responsibilities 
Despite the historical involvement of other authorities, the general consensus amongst MQSS 
authority representatives was that the LNCM and DPL were most central to its function and 
operation. As the national MQCL, the LNCM was seen to provide the technical evidence upon 
which the DPL (national medicine regulator) could act. The role of the PNA was to supply 
medicines to the public sector, and the PNLP and USAID/USP continued to provide financial 
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and technical support. At the time of this study UCAD’s role was seen as historical and centred 
on involvement in establishing the system, from around 2001 onwards.  All stakeholders 
acknowledged the MoH as the overarching steward of the MQSS. However, it was suggested 
that USP/USAID’s role remains as significant currently as it was historically and without their 
funding the MQSS would be weaker. 
‘We are not decision makers, we just produce technical results and the authority, which 
in this case is the Minister, makes the decisions.’ MQSS authority representative  
 
‘If USP withdrew from Senegal tomorrow the MQSS would still operate but not at a 
level that is required, it needs USP’s support.’ MQSS authority representative 
  
Figures 2.2 and 2.3 contrast the structure described in the PNLP strategic plan 2011-2015 
(figure 2.2) with the perceived structure of the MQSS and the roles and influences of the key 
organisations (figure 2.3). This plan stated that USP/USAID had a supporting role in the MQSS 
and that the other four national authorities were collaborative and equal partners in its 
operation. In contrast, figure 2.3 shows that the role of the PNA in the MQSS is perceived to be 
quite minimal and the DPL and LNCM are thought to be integral to the function of the MQSS. 
Additionally, it illustrates that whilst the PNLP are not seen to be as influential as they were 
historically, the role of external partners, particularly USP/USAID, was regarded as essential to 
the ability of the MQSS to maintain its current standard and function  
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 Figure 2.2: Structure of MQSS as stated in the PNLP strategic document (2011-2015)  
 Connecting solid lines represent the integral role of some of the organisations in the MQSS. The connecting dash    
 line indicates lesser involvement of the organisation in the MQSS. 
 
 
 
 
Figure 2.3: Perceived organisational structure of the MQSS in Senegal as summarised from interviews with 
authority representatives.  
Connecting solid lines represent the integral role of some the organisations in the MQSS. The connecting dash 
line indicates lesser involvement of the organisation in the MQSS. The lightly connecting dashed line shows 
minimal involvement in the MQSS. 
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Strengths and challenges  
Strengths and challenges of the MQSS have been compartmentalised into the building blocks 
of health systems.  
Governance: From the interview data there was a common notion that Senegal had a sound 
health infrastructure with good collaboration, particularly between the DPL and LNCM. 
Medical regulation as a component of the MQAS was viewed as a strength by all interviewees. 
MQSS authorities also believed that the existence of a formal MQSS acted as a deterrent to 
manufacturers of poor quality medicines.   
‘But now at least the system is a barrier that discourages those who are tempted to 
make bad medicines, because we can control any type of producer or any manufacturer 
and any type of product.‘ MQSS authority representative 
   
Additionally, all MQSS authority interviewees referred to the LNCM as competent and efficient, 
often exceeding expectations in its performance especially in light of its limited resources. This 
was attributed to strong leadership, relevant expertise and support from USP. Moreover, it was 
suggested that the health system in Senegal was underpinned by a robust national governance 
structure allied to political and economic stability. 
‘One of the main messages is good governance and this means everything at all levels is 
done the right way. I think it’s an important message. In all different parts people are 
confident of good governance in Senegal.’ MQSS authority representative  
 
Despite good collaboration and a sense of shared ownership, a lack of coordination and 
communication were frequently cited as challenges associated with governance. 
Communication in Senegal was perceived by all interviewees to be limited, at all levels and in 
many institutions (not just the health sector). Coordination and communication problems can 
be categorised into two groups; i) communication among the MQSS authorities and ii) 
communication between MQSS authorities and treatment providers. Despite reported 
improvements in coordination and communication in recent years, inter-authority medicine 
quality meetings were infrequent, and primarily held in response to major issues such as 
concerns relating to the detection of a batch of poor quality medicines. Coordination and 
communication bilaterally between two-three authorities was quite common but was 
infrequent multilaterally (cross-authority). Interviewees also suggested the working 
relationship between the DPL and LNCM required improvement. At the time of the study, 
MQSS authority representatives suggested a closer working partnership between the LNCM 
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and USP had been formed and was focussed on achieving accreditation for the LNCM to 
become a WHO prequalified laboratory for which USP were providing support and expertise. 
‘There's a connection between the lab (LNCM) and USP. The LNCM coordinates with 
DPL and with PNA but this is not necessarily a cross coordination, the bodies do not 
meet all the time, except in the context of malaria but even for this it is bilateral. It is 
not multilateral, which would be ideal to discuss these issues.’ MQSS authority 
representative  
 
Most treatment providers from both the public and private sector suggested that the 
coordination and communication between authorities and themselves was inadequate. Some 
treatment providers (particularly private sector pharmacists) felt isolated and on the periphery 
of the health system. Treatment providers also suggested communication between health 
authorities and the public was limited. Furthermore, they claimed that there was no official 
feedback mechanism for medicines that they suspected to be of poor quality. This was a 
specific concern for private sector pharmacists who were professionally regulated by the 
National Pharmacy Board and obtained their medicines from private wholesalers. Private 
sector pharmacists had little interaction with the DPL other than occasional visits by medicine 
inspectors.  
‘There is a communication problem between the operational level and the central level 
because the pharmacy, laboratories or the DPL, which manages these products do not 
give us the feedback on the information they receive on these products from the 
districts.’ Treatment provider (private sector) 
  
Interestingly, only half of the treatment providers (from both sectors) interviewed knew that a 
MQSS existed, although all had heard of the DPL and LNCM. Even some of those treatment 
providers (from both sectors) who were aware of the LNCM, were unclear as to its role and 
purpose as evidenced by the following exchanges: 
 ‘Do you know a system for monitoring medicine quality exists in Senegal?’ Interviewer 
‘No, I did not know this.’ Treatment provider (public sector)  
‘Have you heard of the DPL or LNCM? What do you think they do with regard to 
medicine quality?’ Interviewer 
‘I have heard of them. The DPL is the medicine regulator and gives licenses for the 
pharmacy. The LNCM tests the quality of the medicines. But I don’t know of a working 
system. I have never heard of this.’ Treatment provider (public sector) 
 
In terms of governance and leadership arrangements, some of the MQSS authority 
representatives wished for the MQSS to become an independent system, not directly 
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governed by the MoH, believing the system would function more effectively if it operated 
autonomously. MQSS authority interviewees claimed to have a better grasp of aspects of 
medicines quality and its monitoring and were concerned that they were implementing 
irrelevant or outdated MoH policies, in some cases. This was compounded by the perceived 
lack of interest from the MoH in medicine quality activities, and inadequate financing. 
Finance: MQSS authority representatives mentioned inadequate funding for the MQSS as a 
major challenge and part of a widespread issue of limited financial resources for medicines 
regulation. Limited funding was suggested as a reason for minimal medicines quality control at 
the point of entry, for only bi-annual post-marketing sampling and for not collecting and 
testing medicines from the informal (unregulated) sector. Limited funding was also cited as 
reason for a shortage of functional equipment at the LNCM (e.g. HPLC machines) and an 
insufficient number of medicine inspectors at the DPL (numbering just 2-3 nationally). The 
MoH was held almost entirely responsible for the perceived funding shortfall. In contrast, a 
few of the MQSS authority representatives were encouraged by the MoH’s decision to 
increase funding for medicine quality activities in 2011 and by the continued financial 
commitment of USP/USAID which was viewed as vindication for a well performing MQSS. 
Products and technologies: Two prominent challenges were stated, an inadequate number of 
medicine reference standards and limited medicine quality control analytical equipment. Both 
these challenges are crucial to enable a MQCL to operate efficiently and to produce results 
that are reliable and accurate. Medicine reference standards are expensive but essential for 
verifying the quality of sampled medicines. [11] Furthermore, insufficient functional technical 
equipment would also limit the capacity of the laboratory.  
Human Resources: Individuals working at senior levels within the MQSS were seen as a 
strength for their knowledge and expertise. Several individuals in key positions within the 
MQSS, had previous experience of medicine quality research from UCAD, when the system was 
in its infancy. This had enabled the MQSS to build capacity in personnel, providing the system 
with specialists from academic backgrounds who had knowledge and experience in the field of 
medicine quality with expertise in analytical chemistry, pharmacy and public health. 
Nonetheless, at lower levels in the system, a shortage of skilled workers was reported as an 
important challenge for the MQSS. For example, whilst a sound level of expertise and 
knowledge existed amongst the current staff at the LNCM, their numbers remained insufficient 
to ensure optimal operation of the laboratory. USP have invested in staff training at the LNCM 
over many years to build capacity and enable the LNCM to provide ‘in house’ training for 
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medicine quality work. Since 2010, LNCM staff have been delivering training and development 
for new employees.  
Service delivery: Treatment providers mentioned that providing health related information to 
their patients was a key aspect of their role and a potential strength to the MQAS if the system 
appropriately cascaded information to them to disseminate to the public. Treatment providers 
suggested they were highly regarded by the public for their health knowledge especially as 
Senegalese culture encourages the respect of individuals in positions of authority, particularly 
health professionals. However, some treatment providers suggested that the MQSS did not 
sufficiently utilise their position at the point of care in the health system and their experience 
in disseminating information to the public and felt that this was a missed opportunity for the 
MQSS and the health system as a whole. 
Health Information: There was some discussion of the validity of the findings of poor quality 
antimalarials from the USP report of 2009 which were widely disputed by the MQSS authority 
interviewees. This scepticism was as a result of a perceived small sample size (n=141) of 
antimalarials collected and tested which was seen as not representative of the true picture of 
antimalarial quality in Senegal.  Nonetheless, the study was thought to have facilitated several 
positive outcomes including: 1) increased awareness of the issue of medicine quality amongst 
the MoH, 2) a public health information campaign in 2009 (coordinated with the National 
Board of Pharmacists) warning about the dangers of purchasing medicines from the informal 
sector, 3) the retention of funding from USAID and 4) initiation of the process of WHO 
accreditation for the LNCM laboratory in Dakar. 
‘The main issue was the way in which the findings were shared. The media publicised 
the interesting results – the 40% failure, but this was not the real picture of medicine 
quality in Senegal. It complicated matters with the Ministry. But maybe there is 
something positive that has come from this. It has opened the eyes of the authorities to 
a problem, and so sampling activities have increased and there is an intention to 
improve the technical capacity of the laboratory.’ MQSS authority representative 
 
Interviewees cited challenges of information flow within the MQSS centred on the lack of 
information shared with the public on matters associated with medicine quality, admitting 
dissemination was infrequent. Indeed, most treatment providers could only recall a single 
public health information campaign in 2009 called ‘Street medicines kill’ which focussed on 
dissuading the public from purchasing medicines from the informal sector. [12] Prior to this, 
pharmacists alone were largely responsible for raising awareness about the dangers of 
purchasing medicines from informal sellers through personal communication and small-scale 
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dissemination activity. However, a spate of violent robberies targeting pharmacies in 2009 in 
which stolen medicines were then allegedly discovered for sale in the informal sector, led to 
this larger scale public engagement exercise. [13]  Perspectives of all treatment providers and 
the MQSS authorities on public understanding of health issues differed. MQSS authority 
representatives claimed that sharing health information with the public may be ineffectual as 
the majority were not educated enough to appreciate its significance. Conversely, treatment 
providers believed that the public were becoming increasingly aware about health issues due 
to greater access to health associated information on the internet.  
Overall, MQSS authority interviews perceived strengths as measures of success of the MQSS 
against a backdrop of challenges typically faced by LMICs; limited funding and resources. Many 
of the mentioned challenges were outside of the interviewee’s sphere of influence e.g. funding 
issues (table 2.1). 
Table 2.1: Perceived strengths and challenges of the MQSS arranged by theme 
Health system 
building blocks 
Strengths Challenges 
Governance Sound health infrastructure 
 
 
 
Good national governance structure 
 
Limited coordination and 
communication at all levels and 
between levels. 
 
MQSS not independently operated – 
governed by MoH 
Finance External agency support Lack of national funding for 
medicine quality activities 
Products/technologies Improving technical capacity – 
working toward WHO accreditation  
Few medicine reference standards 
and technical equipment at LNCM 
Health information 
 
Paucity of information sharing 
 
Service delivery Relationship between treatment 
providers and public 
 
Human Resources Strong leadership in key positions Inadequate human resources (need 
for more technical expertise) 
 
2.4.3 Components of a medicine quality surveillance system 
Medicine regulation, medicine supply chains, medicine quality sampling and medicine quality 
analysis have been identified as key components of the MQAS which if compromised, may lead 
to the circulation of poor quality medicines in a country. Medicine regulation and the 
management of the medicine supply chain are also key components of the wider health 
system. Within each component, themes were arranged by the health system’s building blocks 
with several sub-themes emerged incorporating varying degrees of prominence.  
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Medicines regulation 
Governance: Within the MQAS, the DPL was responsible for authorising and registering 
medical products for use in Senegal, as well as providing licenses for manufacturers and 
wholesalers. Regulatory policies and procedures were only applicable to the public and 
regulated private sectors with limited influence on medicines and medicinal products in the 
unregulated informal sector. Medicine regulation was generally regarded as a major strength. 
Three main sub themes that emerged relating to governance were authorisation, post-
marketing surveillance and the informal sector. All interviewees deemed the process of 
marketing authorisation and registration of medicines as being undertaken diligently by the 
DPL such that if a medicine was not registered by the DPL it should not be available in the 
regulated sectors.  
‘…we have a health system that works on laws and regulations, and a regulatory 
authority, a Directorate of Pharmacy and medicine that allows the flow of medicines 
through licensing and granting of marketing authorisations.’ Treatment provider (private 
sector) 
 
Nonetheless, some treatment providers (from both sectors) raised concerns that despite post-
marketing surveillance, unregistered products were available in Senegal and that the 
‘upstream monitoring (at the point of distribution) of medicines for their registration status 
was better than downstream (at the point of care).’ 
The theme of the informal sector (primarily referred to by the interviewees as informal 
medicine sellers) was further compartmentalised as follows; risks posed by the sector, 
legitimacy, ignorance, illegal trade and socio-cultural elements. All interviewees mentioned the 
informal sector as the foremost risk factor for poor quality medicines in Senegal. Interviewees 
believed that the informal sector trade of selling medicinal products was illegal.  It was thought 
that medicines available in this sector had not been registered by the DPL and may have been 
brought into Senegal through illicit means. Interviewees perceived all people transacting in this 
sector (suppliers of medicines, business owners and workers) to be committing a criminal act. 
All interviewees suggested that MoH action against the informal medicine sector was 
challenging in isolation and that a collaborative effort with customs and the police was needed 
with coordinated action by central government through engagement with the Ministry of 
Justice, the Interior Ministry and the MoH. At the time of this study, government action against 
the informal sector was viewed as ineffectual and inadequate, particularly by treatment 
providers. Pharmacists especially derided the informal sector and perceived it as both a threat 
to public health and to their own livelihood. 
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‘They (informal sellers) just have to pay a small fine, of around 100,000 CFA (approx. 
€150), it's not enough to dissuade people. The act of selling illegal medicines should be 
heavily penalized with a ten-year prison sentence plus many millions to pay. 
Pharmacists are advocating for the decree to be signed. For over ten years we are 
fighting for that, but it has not yet been adopted… The commitment to this policy is 
lacking.’ Treatment provider (private sector)  
 
Despite widespread concerns about the informal sector it transpired that the MQSS did not 
monitor the quality of medicines in this sector and sampling activities ceased in around 2010, 
soon after the USP report was published. [6] The main reason provided for ceasing sampling 
was fear of legitimising informal sector trade. 
‘Let’s suppose we controlled the quality of the medicine in the informal sector and we 
found that there are good quality medicines….what would we do? Would we tell 
everyone that the medicine at the illegal market is of good quality? This would be a 
way to promote the sector; in fact, if people find that there are good quality medicines 
in this market, they will rush there, and we would have legitimised the market.’ MQSS 
authority representative 
 
An additional reason for not sampling was related to the socio-political and cultural context 
within which the informal sector operated. Senegal is a predominantly Islamic country in which 
religious brotherhoods have a key role in society and politics. These brotherhoods were 
thought to be the main proponents of the informal sector, operating a large proportion of 
street markets and employing many people from the lowest socio-economic groups in 
Senegalese society. A few interviewees suggested that apprehending operators and halting 
informal sector trade may have grave political ramifications for government officials who 
relied on support from religious brotherhoods. Additionally, targeting the informal sector may 
be regarded as discriminatory as the sector employed people from and catered to, the lowest 
socio-economic group in society. 
‘The politics involved in the informal sector were also a bit of a risk and that made it 
very tricky, for the ministry to regulate the informal sector. It was clear that this sector 
had the ability to scare off ministry people through their connections. Also, if you think 
about it, if you are riding hard on the informal market you were seen as kind of an 
elitist.’ MQSS authority representative 
 
Despite these issues a few of interviewees expressed the view that medicine quality in the 
informal sector had to be monitored, as it posed a potential risk to public health. 
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‘The informal sector, they are not sampling? Why? That is not good. MQSS authority 
representative 
 ‘They said that by sampling there it’s legitimatising their work.’ Interviewer 
‘The problem is that some people are continuing to buy their medicines from 
this sector….sampling their medicines, showing there is an issue…the official 
can say ‘’look these medicines you are buying in these sectors are not good. 
We have made a scientific evaluation.’’ I don’t agree with decision to stop 
sampling. It’s not legitimisation, it’s a process to verify and be comfortable in 
the message you deliver to the population’ MQSS authority representative 
 
Additional risks relating to the informal sector that were mentioned included; sellers lacking 
appropriate knowledge, improper medicines storage conditions, origin of medicines and 
registration status of medicines (not having passed through the appropriate channels and not 
being registered with the DPL). These are discussed in further detail in chapter 3. 
Finance: Insufficient funding was seen as another significant reason for not monitoring 
informal sector medicine quality, although there was no suggestion that if additional funding 
were available, that medicines would be collected and tested from this sector. Some 
interviewees considered the informal sector economy as quite lucrative. Sellers were thought 
to prioritise financial gain over the potential negative public health consequences of selling 
unregistered medicines. Some private pharmacists suggested that a small proportion of their 
peers may be selling their own stock to informal providers for profit, describing such 
individuals as a scourge on the profession who should face harsh penalties for such actions. 
Service delivery: Stakeholders reported that a large proportion of the population from lower 
socio-economic groups frequently purchased medicines from the informal sector due to their 
lower cost in comparison to regulated private sector pharmacies. 
Human Resources: Concerns among stakeholders about the robustness of post-marketing 
surveillance activities in Senegal arose from the supposed low number of drug inspectors 
nationally. The role of a drug inspector is in part to visit public and regulated private sector 
pharmacies checking on registration status of the outlet and health worker as well as 
monitoring compliance with national medicine policy. 
Medicine supply chain 
Governance: The official medicine supply chain in Senegal has two distinct channels; public 
sector and the regulated private sector. Public sector outlets obtained medicines from the 
PNA. Larger hospitals ordered direct from the PNA, whereas centre de santés and post de 
santés would obtain medicines from district wholesalers supplied exclusively by the PNA. 
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Private sector pharmacies and clinics were supplied by 4 or 5 private independent wholesalers 
who were licensed and registered with the DPL. In addition to these channels, there were 
medicines donated by external organisations e.g. antimalarials donated by the Chinese 
Cooperation. [14]  
Most interviewees felt that the supply chain was secure for the sectors regulated by the DPL 
(public and regulated private sector) (see ‘confidence’ section below). Nonetheless, it was 
thought that despite stringent medicine regulation and robust supply chains, the porosity of 
Senegal’s borders for goods and commodities (including medicines) may still compromise 
medicine quality. Furthermore, stakeholders believed that preventing illegal medicines 
entering the country needed to be addressed through inter-agency collaboration (between 
health, justice and customs) as the MQAS authorities were not powerful enough alone to 
prevent (or act) against this trade. 
‘The borders are porous to an extent and so a joint effort is needed between law 
enforcement agencies and the health authorities to monitor and act, the DPL cannot do 
this alone, they need the law behind them.’ MQSS authority representative  
 
Products/Technologies: Emerging sub themes relating to the quality of medicines in the supply 
chain were: origin (country of manufacture), storage, procurement, generic medicines and 
shortages. With the exception of medicine procurement, the other sub themes are described 
in detail in chapter 3. According to treatment providers, customer demand for specific 
medicine brands, low cost medicines and sometimes ‘better quality medicines’ dictated their 
procurement strategy. Treatment providers stocked certain brands of a medicine even if it was 
more expensive than a generic alternative to meet the demands of their customers who 
preferred well-known medicines made by familiar manufacturers. Moreover, most 
interviewees believed that medicines available in the regulated private and public sectors were 
of good quality in contrast to poor quality or unknown quality in the informal sector (see 
chapter 3).  
Health information: A supposed lack of awareness amongst the public of the risks of buying 
medicines from the informal sector was also a key issue. Interviewees stated that promoting 
the ‘good’ quality of medicines available in the public and regulated private sectors was 
required, aligned with messaging that warned of the risk of purchasing medicines from the 
informal sector. 
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Medicine sampling 
Governance: Medicine quality sampling activities were undertaken by the LNCM.  In general, 
medicines in Senegal were sampled through post-marketing surveillance as part of periodic 
national medicine quality surveys. Additional sampling was also undertaken to further 
investigate any batches of a medicine of poor quality that were detected through the testing of 
samples collected as part of the routine field surveys. Sampling for the national surveys was 
from public sector facilities or regulated private pharmacies in a variety of locations. [15] There 
was also ad hoc sampling, and quality control at the point of entry into Senegal at the PNA for 
medicines procured for the public sector. Sampling of medicines for the regulated private 
sector at the point of entry was unknown. A few MQSS authority interviewees mentioned that 
point of entry sampling took place. Those that did, suggested that it was performed when 
medicines were acquired from a new manufacturer or supplier. An accredited WHO 
prequalification laboratory would have the legislative and technical authority to conduct such 
inspections of medicines, [16] although at the time of the study, the LNCM held no such 
accreditation. 
Among MQSS authority representatives, there was little consensus on the sampling strategies 
employed for collecting medicines. Random sampling was mentioned and was perceived to 
produce fairly representative and reliable data, but none of the interviewees could provide 
details on the precise process. Moreover, no documentation on sampling strategies was 
available or supplied when requested. Treatment providers (from both sectors) suggested that 
sampling approaches were vague and hence, they were sceptical about the representativeness 
of findings from medicine quality surveys. They accepted that testing every medicine in 
circulation was not possible but emphasised that sampling activities needed to be enhanced at 
the point of entry and for post-marketing surveillance by collecting a larger sample of 
medicines, randomly and from the informal sector in addition to the regulated sectors. 
Finance: According to the MQSS authority representatives, an increase in funding for medicine 
quality activities would result in a more systematic sampling strategy with a greater number of 
sites and medicines collected, with the possibility of sampling additional medicine classes. 
‘But I'm sure that if they had a little more money, they would make a much more 
representative sample of the overall situation. I think the weakness is that they do not 
have enough resources to go to a maximum number of sites that are representative, 
and also to ensure maximum output at the sites to collect samples and bring them to 
the laboratories to determine the dosage.’ MQSS authority representative  
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Products and technologies: The four main medicine classes collected through post-marketing 
surveillance were antiretrovirals, antituberculosis, antimalarial and oral contraceptive 
medicines. With the exception of antimalarials, which were collected annually, medicines from 
these other classes were collected biannually. An interesting emerging theme was a concern 
that the sampling strategy was restricted to just these four medicine classes. Some 
interviewees mentioned that other commonly supplied or purchased classes such as 
antibiotics and analgesics should also be routinely sampled and tested. This is discussed 
further in chapter 3. 
Medicine quality analysis 
Governance: All MQSS authority interviewees believed that technical capacity at the LNCM was 
a key strength of the MQSS, although most treatment providers did not agree with this view. 
MQSS authority representatives also repeatedly mentioned the work being conducted by USP 
and the LCNM to acquire WHO ISO 17025 accreditation for the laboratory in Dakar. Only a 
handful of such accredited laboratories exist in sub-Saharan Africa (Zimbabwe, Kenya, 
Tanzania, Uganda and South Africa), none of which are in Francophone West Africa. [17] 
Working toward accreditation appeared to be a shared purpose and goal for key individuals in 
the MQSS. It was thought that accreditation would enhance the reputation of the LNCM 
regionally and provide an opportunity to diversify its role; extending quality control to include 
vaccines and foodstuffs. One individual remarked that a key outcome of achieving 
accreditation; would be generating additional income from this diversification of quality 
control. 
‘The support of USP that may result in the accreditation of the lab, which is highly 
supported by USAID. This will be a step forward…. there will be further opportunities, 
notably in terms of revenue that may also permit the laboratory improve its 
functioning. Indeed, this is going to strengthen the health system.’ MQSS authority 
representative  
 
Products/technologies: The most recent medicine quality assessment procedures provided by 
the LNCM stated that collected medicines were screened by the MiniLab® at one of nine 
sentinel sites or the main LNCM laboratory in Dakar. [18] Suspect samples detected at this 
stage were re-analysed using HPLC, undertaken entirely at the LNCM in Dakar. The LNCM thus 
adhered to USP guidelines for medicine quality analysis. [2] The MiniLab® was perceived to be 
a quick, simple and fairly accurate screening technology that performs its primary function in 
indicating the quality of a medicine. It was viewed as a useful tool to employ at sentinel site 
laboratories where more sophisticated facilities were not available. Nevertheless, it was 
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recognised that only analysis conducted at the LCNM in Dakar using HPLC was the most 
accurate and reliable approach for determining medicine quality. 
‘It is a very good tool for that. It is functional, it is quick and you can work with this 
MiniLab® in different areas to do the medicine quality control. But it is only a small 
picture; the work needs to be done at the LNCM.’ MQSS authority representative  
 
Stakeholders also acknowledged that whilst the validity of findings from medicine quality 
assessments was highly dependent on technological capacity of the LNCM, the source of the 
samples being representative of the medicines used for treatment was also significant. 
Finance: A key challenge mentioned was a lack of funding for the LNCM hindering medicine 
quality analysis within the MQSS, although the high cost of operating a national MQCL was 
acknowledged. The LNCM owned three HPLC machines but only one was fully operational. A 
HPLC machine costs in excess of $20,000, hence their reliance upon the GPHF MiniLab® which 
costs significantly less at around $10,000. [19] 
 
2.4.4 Confidence  
Confidence emerged as a major theme throughout the course of the interviews. Varying 
degrees of confidence were described by interviewees in relation to different components of 
the MQSS and medicine quality. Interviewees also identified a level of confidence in other 
aspects of the MQAS and the wider health system. In general, interviewees had a higher level 
of confidence if they had a direct involvement in a specific component of the MQSS e.g. the 
MQSS authority representatives were quite confident in the LNCM’s capacity to monitor the 
quality of medicines in Senegal. In contrast treatment providers, who mentioned they had little 
interaction with the MQSS, were less confident in its capacity. Data relating to confidence has 
been organised into levels of confidence. 
Level of confidence- very good 
MQSS authority representatives and some older and more experienced treatment providers 
from both sectors, were very confident in medicine regulation. MQSS authority 
representatives expressed confidence in the DPL citing the experience of key individuals in the 
organisation and the capacity they had built thus far. Relating this to supply chains, MQSS 
authority interviewees were very confident in the work of the DPL who as part of their 
regulatory activities, conducted due diligence on both producers and suppliers and authorised 
(licensed) them accordingly. This is contrary to the concern expressed by all interviewees of 
the presence of the informal sector, which whilst unlikely to infiltrate the supply chains of the 
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regulated sectors, was not monitored and was perceived to be selling unregistered and 
potentially poor quality medicines. 
‘The supply system is much more secured. Medicines come from the factory to the 
distributing company to the PNA or other private wholesalers. They then go to 
hospitals and health posts and from the private wholesaler to the pharmacy. Not 
anyone can have access to these medicines. It is much more secured in this way.’ MQSS 
authority representative 
  
Moreover, the high level of confidence in certain aspects of the MQSS and the quality of 
medicines nationally was best illustrated by the common assertion that Senegal was the 
standard bearer for medicine quality monitoring among countries in West Africa. Specifically, 
Senegal’s desire to act against the threat of poor quality medicines and more broadly its 
perceived superior political and economic stability played a significant role in the reported 
success of the MQSS. Most interviewees purported that in contrast, many of Senegal’s 
neighbours had neither the volition nor the capacity to monitor the quality of medicines, and 
Senegal was therefore quite fortunate. 
‘In fact, all the structures are there, and it is a strength, so much so that we have 
always been envied by all neighbouring countries because they know that it exists here 
and not elsewhere. If we compare what is going on in some places in Asia and in the 
region in places like Nigeria, we can say that in Senegal the system is doing well and its 
improving and mainly the medicine quality is good.’ MQSS authority representative 
   
Level of confidence - moderate 
MQSS authority representatives were also quite confident in governance within the MQSS and 
the wider health structure, trusting in policies and procedures employed by the various MQSS 
authorities, the national health system and the government. Both MQSS authorities and 
treatment providers were moderately confident in the supply chains of medicines and trusted 
their suppliers to provide good quality medicines.  
‘I think we have a good system, a good organisation, with laws and the medicines are 
licenced and so the quality of medicines in Senegal is good, in general. For example, the 
ACTs, the PNLP help to get them, they are produced by prequalified manufacturers, so 
it is of good quality.’ MQSS authority representative  
 
Despite a lack of funding, MQSS authority representatives were quite confident in the 
technical capacity of the LNCM, especially its capability to operate within tight parameters 
whilst maintaining good standards and in its ability to produce reliable results on medicines 
quality as well as in the currently employed sampling strategy. 
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Level of confidence – less confidence 
All stakeholders indicated less confidence in the quality of generics and medicines made in 
Africa and Asia. Treatment providers also had less confidence in the quality of medicines from 
classes that were not routinely monitored by the MQSS. Pharmacists specifically queried the 
quality of medicines donated to the public sector by various external agencies. These aspects 
are discussed further in the next chapter. 
All treatment providers had less confidence in the MQSS as a whole and its capacity to control 
the quality of medicines in Senegal. They questioned the technical capacity of the LNCM and 
some of the younger treatment providers also questioned the regulatory capability of the DPL. 
They specifically cited the lack of medicine quality monitoring at point of entry into the country 
as well as the low number of medicine inspectors as concerns.  
‘Are they equipped well enough to do the job required? They need to do many 
inspections at the control laboratory before a medicine can be verified. Unfortunately, 
they do not have enough staff required to do the work properly, so I think the work is 
not well done.’ Treatment provider (private sector) 
 
This is contrary to the MQSS authority representatives view as they reported a greater 
confidence in medicines quality assurance as whole and its specific components. MQSS 
authority representatives generally only referred to the quality of medicines classes that are 
routinely sampled (e.g. antimalarials) as being of good quality. 
Level of confidence – lacking confidence 
There was distinct lack of confidence among all interviewees in the quality of medicines 
available in the informal sector for a multitude of reasons including i) the source of medicines - 
it was not clear where informal medicine sellers obtained products from, ii) the storage of 
medicines, especially exposure to sunlight and high temperatures and iii) the lack of 
monitoring of medicine quality and insufficient or absent regulation of medicines (sale of 
unregistered medicines) and sellers. This is also covered in greater detail in the next chapter. A 
brief overview of the level of confidence in aspects of the MQSS amongst the interviewees is 
provided in table 2.2. 
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Table 2.2: Level of confidence in MQSS and its associated processes 
Level of 
confidence 
MQAS component/process or related aspect Stakeholder group 
Lacking 
confidence 
Informal sector All 
Less 
confident 
Generic medicines All 
MQSS as a whole Treatment providers 
Regulatory capacity of DPL and technical capacity of LNCM Treatment providers 
Quality of medicine classes not monitored by MQSS Treatment providers 
Moderately 
confident 
Technical capacity of LNCM MQSS authorities 
Sampling strategies MQSS authorities 
Governance MQSS authorities 
Medicine supply chains (public and regulated private) All 
Very 
confident 
  
Medicine regulation MQSS authorities and 
some treatment 
providers 
Quality of medicines in public and regulated private sector All 
 
2.5 Discussion 
This study has provided insights into the health systems context of a MQSS and how medicine 
quality is monitored within this context in a LMIC. The findings have revealed key factors that 
affect the function and operation of a MQSS as perceived by its stakeholders, highlighting the 
challenges to be addressed and identifying strengths that can be harnessed to assure 
medicines quality.  
The study also points to some of the main internal and external risk factors for poor quality 
medicines that may be present in low-resource settings; medicine shortages, a vibrant 
informal sector, a lack of political will and financing, and powerlessness to apprehend and take 
action against falsified and substandard medicine producers and distributors. Nevertheless, 
based on the perceptions of those interviewed, Senegal was thought to have a sound medicine 
regulatory system and adequate medicine quality testing facilities which can reduce the risk of 
poor quality medicines circulating nationally. Particular points of weakness that emerged from 
the findings included the lack of surveillance of medicine quality in the informal sector and 
inadequate communication and information flow within the MQSS. The reminder of this 
section will summarise findings from the study that may provide important lessons and 
learning for MQSS in other LMICs. 
2.5.1 The role of external agencies 
The financial and technical support provided by USP’s Poor Quality Medicines programme in 
LMICs is intended to enable the improvement of technical capacity nationally with an ultimate 
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goal of ensuring the availability of acceptable pharmacopeial quality medicines for the 
public.[20] In Senegal, USP have built technical capacity at the LNCM, and have demonstrated 
an ongoing a commitment through support for WHO ISO/IEC 17025 accreditation, which may 
be of great benefit to the health system in terms of efficiency (reducing the need to outsource 
quality control work), productivity and income generation. [21] The findings indicate that USP’s 
influence is embedded in the MQSS and the system is highly reliant upon their financial and 
technical support. This is exemplified by the amount of funding provided for medicine quality 
activities by USAID. In the period 2011-2015 USAID provided around $825,000 for medicine 
quality monitoring, advocacy and pharmacovigilance. In the same time period the PNLP (on 
behalf of the MoH) allocated around $300,000 for medicine quality monitoring and 
pharmacovigilance for antimalarials, which was twice the amount from the previous period 
(2006-2011). [22-24]  Whilst this demonstrates a degree of commitment to medicines quality, 
one interviewee mentioned that it may be due to USAID persistently advocating to the MoH to 
increase funding for medicines quality activities.  
Nevertheless, there was some ambivalence of the significance of the role of USP in the MQSS. 
Some believed in the ability of the MQSS to operate without ‘external’ assistance expressing 
confidence in current technical and regulatory capacity at the LNCM and DPL. However, such 
perceptions overlook some of the challenges for the MQSS that have been presented in this 
study, such as limited financing from the MoH for medicine quality activities and the broader 
implications of divestment from USP. In contrast, there was also support for the role of USP in 
maintaining the current good standard of the system and concerns that disassociation of the 
MQSS would be unwise, as the system was not yet sustainable without USP’s support.  
2.5.2 Political will 
The study findings suggest the MoH views medicine quality as a lesser public health priority. 
Whilst this is concerning it is offset by the continued financial commitment of USP. Annual 
sampling surveys have shown a decreasing proportion of poor quality medicines available in 
the public and regulated private sectors, from 21% in 2011 to 6.2% in 2013, perhaps suggesting 
the measures taken by USP and the MQSS are proving effective. Whether this perceived 
success would lead to an eventual decrease in financial support both internally and externally 
(especially if the LNCM can become more self-sufficient through accreditation) was a concern 
for some. As the principal authority of the MQSS the MoH ought to be both engaged and 
involved in medicine quality, especially as a lack of political will has been mooted as a risk 
factor for poor quality medicines. [25] Even though interviewees perceived MoH 
disengagement as disinterest it is quite possible that external support may undermine 
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continued commitment from the national government. Indeed, external donor funding is 
perceived as not being without risk; undermining national agencies, increasing bureaucracy 
through additional reporting requirements and influence on programme strategy, content and 
outcomes to meet their own priorities. [26, 27]  
Some MQSS authorities expressed a desire for greater autonomy for the system with more 
responsibility for governance, management of funding allocation for the various medicine 
quality workstreams and the design and implementation of relevant medicine quality policies. 
Nonetheless, any departure from the status quo may require USAID to negotiate funding 
directly with the MQSS authorities, which may result in even less funding and commitment 
from the MoH. None of the authorities demonstrated a particular interest in assuming 
leadership of the MQSS, indeed each perceived their role as a quite specific component of the 
system whether it be regulatory, technical or logistical.  
2.5.3 Governance and information flow 
The study has demonstrated major challenges relating to governance and health information 
both of which are complex to address. Ineffective coordination among stakeholders may 
undermine the overall performance of the MQSS. [28] Coordination and communication 
between different agencies are frequently cited issues for public health surveillance 
systems.[29] In the context of medicine quality and assurance, inter-agency collaboration 
enabled by better communication and coordination would ensure that the appropriate 
regulatory and technical mechanisms are in place and operating effectively, to control 
medicine quality at a national level.  
In Senegal, the problem of ineffective communication and coordination is less apparent across 
agencies, but evident between the strategic and operational levels of the MQSS and the 
service delivery level (treatment providers). Treatment providers reported a disconnect 
between themselves and the MQSS authorities with a top down flow of information which was 
often inconsistent, infrequent or absent. However, treatment providers were more frustrated 
and concerned by the lack of acknowledgment for information they had fed back into the 
system e.g. the treatment provider reporting mechanism for pharmacovigilance. Senegal has 
established a pharmacovigilance system [30] with a reporting mechanism that can be used to 
feedback on potential adverse drug reactions or safety incidents, a component that was 
viewed positively by treatment providers. However, treatment providers suggested that there 
was little acknowledgment or further discussion of the safety incidents they had reported. This 
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in part may explain the apparent low levels of confidence of treatment providers in several 
aspects of the MQSS.  
Feedback mechanisms, and in particular, the closing of feedback loops and the involvement 
and engagement of treatment providers is perhaps of greater significance to medicines quality 
assurance and control. In comparison to other surveillance systems for public health, 
surveillance for medicines quality, even where it is rigorous and robust, cannot possibly 
contain all incidents of poor quality medicines and in LMICs heavily relies on less than 
comprehensive post-marketing activities. Hence, actively involving treatment providers in a 
MQAS through regular information sharing of data from medicine quality surveys and holding 
regular stakeholder meetings as well as acknowledgment of reporting, may act as a basis for 
provider-led post-marketing surveillance in LMICs, strengthening the MQAS as a whole. [31] 
This may address the issue of treatment providers inferred sense of detachment from the 
health system, especially among private sector pharmacists. If the MQSS and the health 
system in general are to operate effectively there must be good working relationships 
between health authorities and treatment providers.  
Moreover, in many African countries, pharmacies are at the forefront of healthcare and 
treatment seeking by the public (reflected by their larger representation in this participant 
sample compared to other providers).  In Senegal, the public perceive pharmacies as accessible 
and convenient with no user (consultation) fees providing care for minor injuries and 
illnesses.[32] Health systems in LMICs can capitalise on the wide availability of pharmacists 
given their extensive clinical, pharmacological and healthcare knowledge and location, both 
geographically and conceptually in communities. The provider level is effectively the first line 
in detecting poor quality medicines. Treatment failure, unexpected adverse events, suspect 
medicine packaging and visibly diminished medicine formulations could all be identified at the 
provider level. There is a need for provision of adequate training for treatment providers to 
recognise and report such instances. The MQSS would benefit greatly from poor quality 
medicines being identified at the provider level as part of post-marketing surveillance. 
2.5.4 Informal (unregulated) sector  
The informal sector was viewed as a considerable threat to public health in Senegal. There 
were also several references to insufficient governmental action against the informal sector. 
There was contempt for informal medicine sellers who were frequently referred to as ‘illegal 
traders.’ Indeed, informal medicine sellers were perceived to be contravening national 
medicine regulatory policy (and law), yet there was no concerted effort by law enforcement 
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agencies to apprehend them. Such action can only be authorised by the national government 
and their apparent reluctance in light of potential socio-cultural and political consequences for 
doing so, means that ultimately the DPL are powerless to act. Inept legislative procedures and 
an inability to apprehend manufacturers and distributors of poor quality medicines have been 
suggested as risk factors for poor quality medicines in LMICs. [33] 
Addressing issues with the informal sector in LMICs is challenging. Approaches to improving 
the treatment provided in the private retail sector (both regulated and unregulated) include 
programmes such as the Management Sciences for Health Sustainable Medicine Seller 
Initiative which focusses on improving access to acceptable pharmacopeial quality medicines 
and services in parts of Uganda and Tanzania in which few pharmacies or health facilities exist, 
through accreditation of medicine shops that are not part of the formal health system. [34] In 
Tanzania, these medicines shops have become known as ADDOs (Accredited Medicine 
Dispensing Outlets) and operators have been provided with training and business incentives 
and have been subject to regulatory enforcement. Evidence suggests that ADDOs have had a 
positive impact on health outcomes for the local population. [35] The appropriateness of such 
an initiative in Senegal is questionable as most informal sellers operate in large urban markets 
that sell a range of contraband goods including medicines, [36] hence these itinerant sellers 
have no fixed location (unlike medicine shops) making monitoring and regulation difficult.  
To address the perceived problem of the informal sector, MQSS’ must provide empirical 
evidence of the quality of medicines, good or poor, especially as the study findings suggest 
that the sector was perceived to be accessed by a large proportion of the population. A lack of 
funding and fears of legitimising informal sector trade are barriers to sampling medicines to 
assess their quality from this sector. A convenience and covert sampling approach (where the 
seller is unaware of the purchaser’s reason for buying medicines, assuming them to be a 
customer/patient) from known informal providers (such as those operating from large markets 
in major urban centres) on a periodic basis may suffice and would be affordable. Such surveys 
as a minimum would indicate the quality of medicines available in the informal sector. [37] 
Moreover, fears of legitimacy can be addressed by carrying out formal assessments on the 
knowledge and practices of informal providers such as the reported practice of storing 
medicines improperly. [38] If the MQSS authorities were able to prove that there were gaps in 
the general health and medicines knowledge and practices of informal medicine sellers (as 
suggested by interviewees) this would demonstrate to the public that regardless of the quality 
of medicines available in this sector, inappropriate medicines storage practices (which may 
affect their quality), non-adherence to national clinical and medicines guidelines and a lower 
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standard of healthcare expertise compared to that of treatment providers in the regulated 
sector all pose a risk to public health. [38]  
There was overwhelming confidence in several elements of the system. Firstly, medicine 
regulation was perceived to be approached in a systematic manner through a robust process 
of marketing and registering all medicines entering the country, at least for the regulated 
sectors. [3] Secondly, the procurement of medicines from WHO prequalified manufacturers 
ought to validate the belief of a robust supply chain, for the public sector. Thirdly, the national 
MQCL (LNCM) was thought to employ a geographically representative sampling strategy and 
test medicines using recommended screening and analytical technologies, in a relatively well 
equipped laboratory. [39] Fourthly, with the help of USP, Senegal has built capacity in terms of 
monitoring medicine quality with significant evidence based input through academic research 
in the early stages of the development of the MQSS. Finally, all stakeholders illustrated a 
commitment to assuring medicine quality in Senegal and a desire to develop and improve the 
system, regardless of political will. 
2.5.5 Strengths and limitations 
A limitation of the study was that representatives from the MoH were not available for 
interview even though a request was made for their specific participation in the study. 
However, the views of each of the main MQSS authorities were captured by conducting 
interviews with senior individuals in each organisation The MQSS authorities implement MoH 
policies on medicine quality and are responsible for the system’s day to day function, thus they 
are best placed to identify strengths and weaknesses of the system and of the overarching 
policies. Yet, an interview with a MoH representative would have provided an opportunity to 
explore some of the emerging salient themes such as political will and commitment to 
addressing medicine quality nationally. 
Additionally, due to restrictions in study funding and resources, only treatment providers in 
urban and peri-urban areas close to the capital were interviewed. Therefore, the sample may 
not be representative of the views of treatment providers in more distant cities, provincial 
towns and rural locations. Nonetheless, despite geographical proximity of this sample to the 
capital, weaknesses in communicating information to providers from MQSS authorities still 
emerged as a major concern. Unfortunately, the researchers were not permitted by the 
national ethics committee from interviewing informal medicine providers. The views of actors 
from this sector would have provided some useful and comparative insight into their trade, 
knowledge and awareness of poor quality medicines.  
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Overall there was a 41% (11/27) non-response rate amongst treatment providers. However, 
just one private pharmacist refused to participate. Non-response was largely as a result of 
private pharmacists being unavailable for an interview. Nevertheless, a range of treatment 
providers in terms of profession and sector (public and regulated private) were recruited. Of 
further interest, most interviewees who consented were from ‘downtown’ Dakar which 
generally has a higher socio-economic status than peripheral districts of the city. However, it is 
unlikely that perceptions would have differed amongst pharmacists given the homogeneity of 
the regulatory system for medicines and the profession as a whole.  
It is acknowledged that although the interviews were with key informants (representatives of 
the MQSS authorities with the benefit of insider knowledge), a few seemingly provided elite 
accounts and tended to speak on behalf of their organisation providing aligned views, overall. 
[8] Such public accounts are often unavoidable and in the context of this study their inclusion 
was deemed absolutely necessary. Senior stakeholders are sometimes less willing to be candid 
in their responses due to a strong organisational identity or simply a lack of familiarity with the 
researcher. [40] However, the five interviewees (three former MQSS employees and two 
individuals employed by UCAD) without a current involvement in medicine quality or the 
MQSS in Senegal nationally, provided ostensibly private accounts and these are often 
represented in the study as the contrasting or even deviant views. It is plausible that in this 
study, such elite accounts presented a few of the MQSS authority stakeholders as advocates 
and proponents of the system, whereas treatment provider accounts and those of the 
stakeholders less involved with the MQSS, were a comparative reflection of their true beliefs 
and perceptions.  Overall, the treatment providers (especially private pharmacists) were more 
at ease once it had been established that the interviewers were independent (not authority 
affiliated) researchers and that the main interviewer was also a pharmacist by training.   
It is also important to highlight that as a pharmacist in the United Kingdom, my experiences of 
medicine regulation and medicine quality control are based on a more robust, well financed 
and resourced system in a high income country. This is in contrast to the approaches to 
regulation and quality control in LMICs. This was considered when interpreting the data. In 
addition, as some interviewees mentioned, I was an ‘outsider’ and Senegal’s health systems 
(and medicine quality) issues can only be solved internally. This may have affected the 
openness and honesty of some interviewees as well as their willingness to engage. The findings 
were interpreted in the context of my knowledge of health systems in LMICs and their 
associated challenges and through drawing upon my previous work in Senegal and other low 
income settings. 
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Finally, the analysis of the study was largely conducted by the main researcher. However, to 
maximise reliability several steps were taken. Transcription and translation of a sample of 
transcripts was verified by the research assistant. The coding framework was shared, discussed 
and agreed amongst myself and two other colleagues. Finally, in the process of data collection, 
myself and the research assistant discussed the content of all interviews (with the exception of 
the two conducted over skype) and compared field notes. 
 
2.6 Policy implications for medicine quality surveillance systems 
The study findings provide the basis for a series of suggestions for the MQSS but are not 
necessarily specific to Senegal. Whilst, findings from qualitative studies are seldom 
generalisable, the learning from this in-depth country case study provides useful insights and 
may offer some transferable recommendations for MQSS in LMICs more generally. [8] This is 
enhanced by the inclusion of a range of interviewees at all levels of the health system, 
extending to a few individuals working for external agencies who had an overview of MQSS’ in 
several other African countries. Furthermore, the MQSS ‘model’ in Senegal has been 
supported in its development by USP who are implementing similar approaches to building 
technical, logistical and resource capacity for medicines quality in other African countries 
where their Poor Quality Medicines programme operates. 
The recommendations are based on approaches to strengthening health systems in LMICs 
taking into account potential constraints in both financial and human resource: 
1. Improving communication and coordination amongst authorities. 
Despite the MoH acting as steward of the MQSS, the system maybe be better coordinated if 
one of the authorities (e.g. DPL, LNCM) assumed a leadership role in which they could act as an 
interface between the MoH and the rest of the MQSS and have oversight of the whole system. 
Alternatively, a transformation in the governance structure of the MQAS could be undertaken, 
whereby representatives from each authority would form a partnership board (as opposed to 
a coordinating committee). This board could be responsible for funding allocation to relevant 
MQSS activities and have collective accountability for medicines quality in Senegal. This type of 
governance structure is employed in several high-income settings to enable accountable care 
in health and social care systems through the bringing together of several different 
organisations to form a collaboration. [41] This type of structure would provide the MQAS with 
more power to lobby to the MoH, as a partnership and a collective voice in national public 
health agendas and strategies. 
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2. Improving communication between the authorities and treatment providers 
(especially pharmacists). 
For the MQSS to operate effectively the authorities must actively engage with treatment 
providers, including private pharmacists. Establishing regular communication through 
information sharing with the regulated private sector would benefit the health system as a 
whole. The appointment of a representative of the National Board of Pharmacists to the MQSS 
coordinating committee may facilitate this engagement. Furthermore, a reporting mechanism 
for suspected events relating to medicine quality needs to be implemented. Utilising the 
existing pharmacovigilance system may be a viable option. [30] 
3. Addressing the perceived problem of the informal sector 
The MoH through the MQSS needs to take a two-pronged approach to address the problem of 
the informal sector. Firstly, the precise status of medicine quality should be established by 
adapting the current sampling strategy to included collections from informal sellers. If 
medicines are found to be of poor quality, there should be a resolute effort by government 
agencies to apprehend illegal traders and seize unregistered medicines. However, evidence 
suggests that punitive actions are not always successful. [34] Therefore, the second approach 
should be a focus on raising awareness and facilitating engagement to inform and educate the 
public about the potential risk posed to their health of purchasing medicines from the informal 
sector. Even if good quality medicines are detected, the MQSS authorities must make the 
public aware that informal medicine providers may lack sufficient health care knowledge and 
that the origin or status of medicines from the sector cannot be verified. This approach 
assumes that informal medicine sellers are not concerned about the quality of the products 
they sell. The opposite maybe true and further research is required to establish the quality of 
medicines available in the less regulated health sectors in LMICs as is the need to explore the 
perceptions of medicines quality amongst informal medicines sellers and their understanding 
of the impact of poor quality medicines on their clients. 
 
2.7 Conclusion 
This study has illustrated how an LMIC can address medicine quality issues through the 
collaboration of different national authorities and a shared purpose in controlling the quality 
of medicines. According to the interviewees in this study, Senegal has made substantial 
progress in assuring medicine quality through the establishment of a functioning MQSS and 
can be regarded as ‘standard bearer’ for other countries in the region. However, the MQSS and 
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the engagement of stakeholders in controlling medicine quality are undermined by the 
challenges highlighted in this chapter. 
Strengthening health systems in sub-Saharan Africa is a complex task for multiple reasons. 
Challenges for health systems in LMICs often evolve from a lack of finance and resources and 
both of these issues are prominent for the MQSS in Senegal. This study has demonstrated the 
significance of the role of external agencies, such as USP, and USAID, in medicine quality 
monitoring in Senegal, yet their support alone is insufficient.  Poor quality medicines must be 
viewed as a public health priority on a global scale to enable international donor funding to be 
directed to address the problem. A concerted international effort to tackle poor quality 
medicines manufacture and distribution as well as a commitment to the ongoing surveillance 
of medicines quality through the establishment of statutory legal frameworks and robust 
evidenced based research of the prevalence of poor quality medicines, may encourage 
individual governments to address the problem at a national level. 
Moreover, pharmaceutical companies could invest more resources, especially in LMICs, to 
tackle medicine quality issues including sharing of expertise and building of technical and 
regulatory capacity. Medicines quality should be viewed as a shared responsibility to maintain 
provider and public confidence in the quality and efficacy of the medicines most commonly 
used for medical treatment. Efforts need to embrace all sources of treatment, whether located 
in the public, private or informal sector. Though surveillance and control of medicines in the 
informal sector raises particular challenges, the sheer volume of medicines purchased here 
mean that, in many LMICs, medicine quality in the informal sector cannot be overlooked.  
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Chapter 3: The quality of medicines available in Senegal; 
perspectives of health system stakeholders  
 
3.1 Background 
Defining medicines quality has been the subject of much debate over the last decade with an 
inability to reach consensus amongst policy makers, academic researchers, lawyers, medicine 
manufacturers etc. [1, 2] Until very recently there was no universally agreed definition of 
medicines quality. However, in May 2017 the World Health Assembly (WHA) Member State 
mechanism agreed on definitions that categorise medicines quality as falsified, substandard 
and unlicensed/unregistered. [3] The individual definitions for each of these have already been 
discussed in previous chapters. These recent definitions possibly fit the legal and technical 
paradigms of medicines quality.  
However, other studies from low-middle income countries (LMICs) [4-6] have highlighted an 
important clinical paradigm that is of greater relevance to the perceptions of treatment 
providers and the public and considers medicine quality in terms of the impact on the health of 
the population. [7] These, studies have explored perceptions of medicines quality among 
treatment providers and consumers and have found that respondents tended to characterise a 
medicine as good quality, if it alleviated symptoms with minimal side effects (efficacy and 
safety), if it was a brand name medicine (made by a reputable company) and if it was high in 
cost. Furthermore, treatment providers have expressed greater confidence in the quality of 
medicines made in Europe in comparison to those manufactured in countries in Asia and 
Africa. [5, 8, 9] In high income countries studies have shown mixed opinions about the quality 
of generics with most health professionals perceiving generic medicines to be comparable in 
quality and efficacy to the original brand version. [10] Nonetheless, a minority have expressed 
concerns that generics are manufactured to a poorer quality with potential implications for 
patient safety. [11]  
At the strategic and operational levels of medicine regulatory and quality assurance systems in 
LMICs there is limited information on views about medicine quality. The perceptions of 
individuals working at these levels is important as it may shape their approach to medicines 
quality assurance. This may include their motivation to address pertinent issues, their specific 
focus on certain components of the system, their overall confidence in the medicine quality 
surveillance system (MQSS) and subsequently, the quality of medicines controlled by the 
system. We have discussed in chapter two that MQSS authority representatives had greater 
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confidence in the surveillance system, this chapter will explore the perceptions of the 
understanding of medicines quality of a range of health system stakeholders including 
representatives of the MQSS authorities and treatment providers. 
 
3.2 Methods 
See section 1, A5 for the methods for this chapter. The approach to coding and analysis is 
described below. 
3.2.1 Coding and analysis 
Thematic analysis of the data was undertaken and three overarching themes relating to the 
perceptions of medicine quality emerged; 1) the source of drugs 2) the type of medicine, and 
3) the perceived impact of health systems on medicine quality. Within each of these several 
further sub-themes also emerged as illustrated in figure 3.1 below. 
 
          Figure 3.1: Coding framework of emerging themes related to medicines quality 
 
 
 
Source of Medicines
Origin
Medicine donations
Informal sector
Regulated sectors
Types of medicine
Generics
Medicine cost
Impact of health systems
Medicine storage
Medicine shortages
Samping strategies
Funding for surviellance 
approaches
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3.3 Results 
The characteristics of the study participants and participation of the MQSS authority 
representatives and treatment providers in the study are described in section 1, A6.  
3.3.1 Source of medicines 
Perceptions relating to the source of medicines and their quality included: country of 
manufacture or origin, donated medicines, the informal (unregulated) and regulated (public 
and private) sectors. 
Country of manufacture/origin 
All interviewees mentioned a preference for medicines manufactured by European and North 
American companies as these were judged to be of reliable quality. This perception was 
founded on three main premises; 1) these medicines were produced by reputable 
manufacturers, 2) these were thought to undergo strict regulatory controls in the country of 
manufacture before export and 3) these must have been of a high standard since these 
medicines were the same as those that were consumed by European and American citizens. In 
contrast, treatment providers expressed negative views of medicines made in India, China and 
Nigeria citing that these posed a risk to medicines quality.  
‘I was in the rural area; Vélingara where you can see many products entering 
Senegal…There were a lot of fake products coming from Nigeria……. I do not know if all 
of them are not of good quality because as they say, drugs come from Asian countries 
like India and China, but why not from France, Belgium, which are countries that have 
the means to control these products.’ Treatment provider (private sector) 
 
Medicine donations 
The Chinese Cooperation, an international aid organisation donates antimalarials to Senegal 
periodically. [12] However, the quality of these donated medicines was queried by one 
treatment provider, who suggested that these were not sampled and analysed by the LNCM in 
the same manner as other medicine imports.  
‘Public health facilities receive donations; but do those medicines have marketing 
authorisation? Now I'm not saying donations are bad, otherwise it would be returned 
immediately. But among the donations, we do not know what happens, the expiry 
date, storage conditions, and the person who has given these products.’ Treatment 
provider (public sector) 
 
In fact, one MQSS authority stakeholder provided an example of the difficulties faced when 
quality issues are detected with donated medicines and the results of medicine quality 
assessments at the LNCM are scrutinised by external experts. In this instance, the results were 
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disputed by the manufacturer, who claimed the medicines were of good quality when they left 
the factory and that their quality was compromised due to improper storage in Senegal or that 
the LNCM’s findings were questionable as, in their opinion, the technical capacity of the LNCM 
laboratory was inadequate. Indeed, the interviewee admitted that a higher standard of 
technical capacity at the LNCM such as accreditation for WHO prequalification (which the 
laboratory was working toward), would have meant less scrutiny of their findings.  
‘Once we were granted drugs by the Chinese. We took these drugs to the laboratory 
[LNCM] and after testing, found a problem. Then the Chinese came in with their quality 
experts. The laboratory could not continue this debate because of many problems with 
the procedure, and the Chinese went off saying that we were mistaken.’ MQSS authority 
representative  
 
Informal sector 
Senegal has a large informal sector in the guise of vast open markets such as Keur Serigne Bi in 
Dakar and similar structures in other principal cities, such as Touba. There was a general 
consensus that medicines available in this sector were more likely to be of poor quality for two 
main reasons. Firstly, the conditions under which medicines are stored here were deemed 
inadequate as they were available as loose tablets in transparent plastic bags and exposed to 
direct sunlight and high temperatures for prolonged periods. Secondly, the origin and status of 
the medicines available in this sector was questionable as medicines may have been brought 
into the country illegally and thus not subject to national regulatory measures. 
‘Drugs sold in this market are of poor quality. When you go to Keur Serigne Bi you see 
drugs exposed to the sun, lying on the ground which may damage them…They are not 
registered, we know nothing about the origin, who manufactured them and when they 
made them.’ MQSS authority representative 
 
Public and private sectors 
The perception of medicines quality available in the regulated sectors was in stark contrast to 
the informal sector. As mentioned in chapter 2, all stakeholders were quite confident in 
medicines quality in the public and regulated private sector mentioning that medicines 
regulation was stringent and supply chains robust. In particular, the source of medicines in 
these sectors (manufacturers and wholesalers) were deemed trustworthy. A LNCM report 
from medicine quality surveys in Senegal from 2012 found that 93.8% of 481 antimalarial 
samples collected from the public and regulated private sectors passed the MiniLab® screening 
test for medicines quality. [13] 
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‘You know the tenders were done, there was better traceability, you know who was 
making the drug and providing it and so the public sector I felt really comfortable, the 
private sector – quite comfortable, the illicit sector – not very comfortable.’ MQSS 
authority representative  
3.3.2 Type of medicine 
Perceptions about medicine quality were also expressed in relation to the type of medicine i.e. 
generic or brand as well as its cost. Generic medicines were widely available in both public and 
regulated private sectors and were generally cheaper than their brand versions. Most 
interviewees doubted the quality of generics. In addition, treatment providers suggested that 
patients were less trusting of generics, perceiving them as less efficacious than the brand 
version. The lack of familiarity with the ‘name’ of a generic and its manufacturer raised doubts 
with all interviewees and reportedly with patients and consumers as well. Treatment providers 
also mentioned that patients associated quality with cost, perceiving more expensive drugs to 
be more effective at treating their symptoms and hence of better quality. 
‘Sometimes because when the drug is not expensive they think it is not good. This is 
Senegalese mentality…They think that drugs sold here are cheaper in price and 
quality… As we are here in town, there are some wealthy people who prefer to buy in 
pharmacies.’ Treatment provider (public sector) 
 
Several interviewees provided anecdotes of supposedly ineffective generic medicines which 
compromised patient safety. The most frequently cited example was that of diazepam (a 
benzodiapine with anxiolytic and sedative properties).  
‘If I take diazepam for example which is a drug that is prescribed against convulsions 
in children, it has since been said that it does not work in generic form properly.  
When you put it on a convulsing child, he would still convulse; whereas if you give him 
Valium®, convulsion would stop.’ MQSS authority representative  
 
3.3.3 The perceived impact of health systems on medicines quality 
Three main sub-themes relating to medicine quality as an outcome of the health system 
emerged, including medicines storage, medicine shortages and sampling strategies. The MQSS 
itself was thought to have partly been established upon the perception of the suspected 
quality of the antimalarial medicine, chloroquine. MQSS authority representatives suggested 
that the emergence of chloroquine resistance indicated by a decline in its efficacy was linked 
with poor quality samples collected in the same geographical locations as the resistant foci. A 
similar hypothetical link between poor quality chloroquine and treatment failure attributed as 
an indication of drug resistance has been reported in Cameroon. [14] 
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Medicine storage 
All interviewees mentioned that medicine quality was directly affected by conditions of 
storage (especially at the outlet level). This is a well-known issue in the tropics given high 
temperatures and humidity, especially in rural areas where power supplies may be 
intermittent. [15] Quality was thought to be acceptable when medicines arrived at a facility 
but improper storage conditions contributed to their degradation. Despite this being a major 
concern, interviewees appeared resigned to accepting improper medicine storage, suggesting 
the most obvious approach to overcoming this challenge was to install cooling systems to 
regulate temperature and humidity whilst acknowledging that such systems were unaffordable 
to individual facilities in most cases. 
‘We realised that the quality of the drugs stored at the PNA was better than the quality 
of drugs stored in health facilities. This means that the environment, the temperature 
etc. at the facility has an impact on the quality.’ But individual facilities cannot pay for 
equipment to make the temperature acceptable.’  MQSS authority representative 
 
Medicine shortages  
Interviewees reported that medicine stock outs may affect the availability of good quality 
medicines. If medicines were in short supply in the public sector then patients would have to 
seek alternative sources, such as the informal sector. One MQSS authority representative 
believed that prolonged stock outs had forced some nurses working in rural facilities to obtain 
medicines from the informal sector to address the shortfall, thereby exposing patients to 
medicines that have not been through national regulatory processes and hence, their quality 
cannot be verified. Public sector treatment providers mentioned that in instances where 
medicines or medical appliances were not available from the PNA, they would contact 
authorised private wholesalers. Regulated private sector pharmacists suggested that 
medicines shortages were a rarity in the private sector due to the larger number of private 
medicines wholesalers (4-5) and deemed it to be an entirely public sector problem.  
Medicine sampling strategies 
Many stakeholders expressed concerns that the LNCM only collected samples from the 
regulated sectors as part of post-marketing surveillance, and not the illicit informal sector. The 
four main classes routinely collected were antimalarials, antiretrovirals, anti-tuberculosis 
drugs, and oral contraceptives. With the exception of antimalarials, which were collected 
annually, the other medicines were collected twice a year, as the MQSS authorities were more 
reassured by antimalarial quality since preceding surveys had indicated very low proportions of 
poor quality samples. [16] The sampling of these four medicine classes alone was a concern for 
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some interviewees who felt that they were not entirely representative of the national 
medicines market. Treatment providers in particular expressed concern about the lack of 
quality control of other medicines they sold in high volumes such as antibiotics and analgesics. 
They acknowledged that the MQSS had restricted financial resources but felt that a sampling 
strategy also encompassing these other medicine classes was required. 
‘I know they (LNCM) control some drugs, like for malaria. But what about the others? I 
sell many drugs for pain and antibiotics. They do not check these drugs. We need to 
know about their quality as well.’ Treatment provider (private sector) 
 
3.4 Discussion 
The findings from this study illustrate that medicine quality was an important consideration 
among all those interviewed, revealing a wide variety of perceptions relating to the quality of 
medicines available in Senegal. The findings presented here are mainly pertinent to the clinical 
paradigm, framing medicine quality in terms of its efficacy (the ability of the medicine to 
alleviate physical symptoms). Furthermore, the findings contrast how generic medicines are 
believed to be inferior in quality than their brand versions and that medicines from the ‘east’ 
(China/India) are perceived less favourably (in terms of their quality) than those from Europe 
and North America. The study findings also reveal perceptions of how certain aspects of the 
health system such as storage conditions, medicine shortages and sampling strategies may 
affect the quality of medicines available in a country. 
The source of the medicine, type of medicine (generic or brand), its cost, its perceived efficacy 
and safety are factors which may be considered by treatment providers and consumers when 
supplying or purchasing a medicine. [17] In this study, the country of manufacture of a 
medicine was often viewed as a proxy for quality, with suspicion of medicines originating from 
or made in India, China and Nigeria. Distrust in the quality of generic medicines and those 
originating from the ‘east’ mirror similar findings from other countries [4, 8, 18, 19] and there 
is some objective evidence to support this view with some reports of the discovery of poor 
quality medicines, including antimalarials made in India and China. [20-22] Other studies have 
also found poor quality artemisinin based medicines (both substandard and falsified) and other 
antimalarials (substandard) in Nigeria. [23, 24] Of interest, in one of these studies, the source 
of the medicine as a risk factor for poor quality artemisinin based medicines was found to be 
higher where the medicines were stated on the packaging to be manufactured in North 
America, compared to Africa or Asia. [23] Regional media reports about Nigeria’s problems 
with poor quality medicines and a prominent incident reported in the international press of 
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‘fake’ antimalarials found in Angola that arrived from China, may further fuel the suspicion of 
the quality of medicines from these countries. [25-27] Conversely, medicines from Europe or 
North America were typically thought to be of good quality, echoing similar findings amongst 
consumers in urban Tanzania. [28] The superior quality of medicines manufactured in Europe 
was a perception predicated on assumptions of a more robust approach to quality and 
regulatory control within European countries, as well as the international reputation of 
‘western’ pharmaceutical companies.   
Generic medicines were often seen as inferior in quality to their brand versions, a view that 
has also been reported in other studies. [29, 30] Brand name medicines are usually marketed 
by reputable pharmaceutical firms based in Europe and North America and are more 
expensive, and it may be difficult to disentangle perceptions of quality of generics, from 
concerns about place of origin, manufacturing standards and cost.  Nonetheless, brand 
versions have usually been on the market longer than generics due to the length of patent, 
establishing a good record of efficacy and safety. Conversely generics are less well known and 
recognised, they cost less and most of those available in at the time of the study in Senegal 
were reported to have been made in India and China. Treatment providers reported that 
patients equated cost with quality and therefore preferred brand name medicines. The 
efficacy of generic medicines was also associated with quality. Brand versions were thought to 
be more efficacious and hence of superior quality which confers with perceptions of treatment 
providers in studies conducted in other LMICs. [4, 6]  
However, there is little evidence to evaluate whether these perceptions are warranted. If 
treatment providers were to convey these views to consumers this would only substantiate 
pre-existing negative preconceptions of generics. The view that generics are of doubtful quality 
or less efficacious because they cost less could act as a barrier to their use; and effectively 
undermine international efforts to increase access to affordable medicines for the world’s 
poor. This is contrary to the premise of the WHO essential medicines list that was established 
to promote the use of those medicines that were more essential than others, highlighting that 
many medicines in LMICs were not useful and those that were useful were not always 
accessible, where they were needed most. [31] Nevertheless, findings from a recent study 
conducted in Nigeria found samples of one generic dihydroartemisinin combination product to 
be 2.4 times more likely to not have the recommended stated active pharmaceutical 
ingredient than other brand versions of the same drug. [23] Such a finding may provide some 
credence for the belief in the superior quality of brand versions. 
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Although the cumulative ‘negative’ beliefs of generic medicine quality may ultimately make 
them less desirable to the consumer, treatment provider and regulator [4, 18], the demand for 
generics globally is huge, with some Organisation for Economic Co-operation and Development 
(OECD) countries reporting a 75% market share nationally in 2011. [32] Market dominance 
can be partly attributed to the lower cost of generics. Indian pharmaceutical companies 
accounted for 17.7% of medicine imports (mainly generics) in 2011 in sub-Saharan Africa (up 
from 2.2% in 2002) [33] and if this increase in market share continues along the same 
trajectory, there will be an even greater number of generic medicines available in health 
facilities and pharmacies. Indeed, a notable proportion of medicines (especially generics) in 
Senegal are made in India and China. [13]  Generic medicines are not a homogenous entity, 
although in terms of perceptions of their quality, they may be viewed as such. Suspicions 
about generic medicine quality and country of manufacture need to be grounded in objective 
empirical evidence. Detailed medicine quality studies using epidemiologically sound sampling 
methods to investigate the quality of generics in use at the point of care and studies that 
quantify the scale of the problem, can provide the much-needed evidence to either 
substantiate or allay these widely-held concerns. The market share of generics is already 
substantial and may continue to grow over the next few years, hence their quality should be 
investigated scientifically to reassure regulators, health professionals and consumers. 
The doubts expressed regarding the quality of donated medicines highlights another important 
issue faced by LMICs. The supposed altruistic nature of medicine donations means that often 
the recipient has limited control over the product received and is in a weak position to express 
doubts or dissatisfaction. Donated medicines can sometimes be industry surpluses with 
packaging and medicine information in a language not appropriate to the local population or 
be medicines which are close to their expiry date or may have even expired [34, 35], raising 
additional concerns for the recipients.  
The informal health sector in sub-Saharan Africa provides a convenient alternative for 
consumers, especially in locations where regulated health facilities (public or private) are 
difficult to access. [36] Medicines sold through this sector are thought to be both available and 
affordable in comparison to the regulated sectors, where medicines can be more expensive 
(regulated private sector) and stock outs are common (public sector). [37] In this study, there 
was considerable disdain toward the informal sector which was viewed as a significant threat 
to medicine quality in Senegal primarily as a result of improper medicine storage practices and 
a lack of authentication of source or origin of the medicines available. Data on medicine quality 
in the informal sector in Senegal is scarce. A study conducted by the USP in Senegal in 2010 
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found that 68% (13/19) of samples of antimalarials in the informal sector failed quality control 
testing (stated as confirmatory analysis as listed in the drug monograph) in comparison to 25% 
(3/12) and 35% (11/31) in the public and regulated private sectors. [38] The MQSS ceased 
sampling from the informal sector in 2010, therefore there were no reliable estimates of 
medicine quality from this sector at the time of this study in 2013. As outlined in chapter 2, 
sampling from the informal sector was ceased for three main reasons; 1) a fear of endorsing 
their existence, 2) concerns relating to the cultural and political influence of the religious 
brotherhoods that were involved in the operation of the sector and 3) a lack of funds to extend 
medicine quality monitoring activities to the informal sector. Contempt for this sector is not 
uncommon and is thought to be driven by concerns that informal medicine sellers are 
motivated by financial gain which threatens both the business income of formal sector 
providers and the health of the population. [39] Similar perceptions among regulated private 
sector pharmacists were also apparent in this study, as discussed in chapter 2.  
In contrast, both public and regulated private sector interviewees were quite confident in 
national medicines regulation and in medicines supply chains. A degree of this confidence was 
attributed to the WHO prequalification programme which assures the ‘quality, safety and 
efficacy’ of medicines prior to their distribution to recipient countries. [40] However, a recent 
medicine quality review paper found that 8.2% of 2813 antimalarial samples that failed 
chemical/packaging analysis tests were labelled as being from a WHO prequalified 
manufacturer. [41] Trust in the quality assurance of prequalified medicines, relies upon the 
quality control work of external agencies such as the WHO, manufacturers and wholesalers. 
The quality of medicines arriving in Senegal cannot be officially verified as the LNCM was not a 
WHO prequalified quality control laboratory at the time of the study but was working toward 
the accreditation.  However, as mentioned in chapter 2, MQSS authority representatives and 
treatment providers had confidence in the ability of the national medicines regulator to 
regulate and authorise manufacturers and wholesalers and the products they supply as well as 
a degree of confidence (mainly MQSS authority interviewees) in the MQSS as a whole to 
assure the quality of medicines in Senegal.  
Confidence in external agencies such as medicine manufacturers and wholesalers may result 
from manufacturing facilities meeting Good Manufacturing Practice (GMP) standards as well as 
the medicines they produce and distribute meeting WHO prequalification programme 
criteria.[42, 43] In addition, at a national level WHO accreditation for a medicines quality 
control laboratory coupled with the capacity to implement point of entry medicines quality 
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screening as well as robust post marketing surveillance would provide confidence in the 
capability of a national MQSS to minimise the risk of poor quality medicines.  
The perceived association between medicine stock outs and medicine quality is based on the 
notion that if a prescribed medicine is not available in the public sector, the patient may 
purchase it from elsewhere. [44] Using artemisinin based medicines as an example (which are 
free in the public sector in Senegal), if medicines were not available in the public sector, 
patients were advised to visit a private sector pharmacy but some reportedly chose to visit an 
informal seller instead (as antimalarials are reportedly cheaper than in private pharmacies). 
Given that the quality of informal sector medicines in Senegal cannot be verified, stock outs 
pose a potential risk to public health.  
Another notable concern for all stakeholders was the effect of storage conditions on medicine 
quality. Medicine degradation and loss of activity may be accelerated by storage conditions 
such as exposure to sunlight, high temperatures (greater than 30°C) and high humidity. Indeed 
the antibiotics, clarithromycin and erythromycin and antifungals, ketoconazole and 
itraconazole have been demonstrated to be sensitive to these extreme conditions. [45] In this 
study, inadequate storage was perceived as a reality of the climatic situation in the tropics and 
therefore there was an ambivalence about what could be done to address the issue. Potential 
solutions such as air conditioning units for cooling were deemed impractical as they are 
seldom affordable for most outlet owners to operate regularly. Yet, a recent study assessing 
the stability of half tablets of dihydroartemisinin-piperaquine over a three month period when 
exposed to 30°C and 70% humidity found that the stated active pharmaceutical ingredients 
remained at around 95% and hence quality was maintained. [46] Nevertheless, there is 
currently not enough empirical evidence to substantiate or disprove climatic effects on 
medicine degradation. Hence, more research exploring the degradation of medicines, 
especially of generic medicines needs to be conducted to establish the effect of tropical 
environmental conditions on medicine quality. This ought to be conducted by manufacturers, 
who should endeavour to test the quality of each new product following exposure to 
environmental conditions similar to those in the tropics. Manufacturers should state relevant 
information (such as the temperature at which sustained exposure would increase the risk of 
degradation) on the medicine’s packaging so as to enable medicine providers and sellers to 
store medicines appropriately.  
The MQSS in Senegal has been sampling and testing the quality of antimalarials, 
antiretrovirals, anti-tuberculosis medicines and oral contraceptives for several years and these 
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are generally perceived to be of acceptable pharmacopeial quality which is validated by results 
from recent medicine quality surveys. [13, 16] However, the quality of medicine classes not 
sampled by the MQSS is unknown. The USP Poor Quality Medicines Programme promotes the 
integration of the monitoring of medicine quality into national malaria, HIV and tuberculosis 
programmes. [47] An expansion of the sampling strategy to encompass other medicine classes 
would require additional funding, but MQSS stakeholders believed that the MoH did not 
perceive medicine quality as a public health priority. Hence, MoH funding for medicine quality 
surveillance activities was limited and sampling strategies restricted, to those recommended 
by the USP programme.  
Nonetheless, the appropriateness of the current sampling approach must be considered 
against the context of more pressing public health priorities in Senegal. The estimated HIV 
prevalence rate in 2013 for adults aged 15-49 in Senegal was just 0.5% with deaths due to 
HIV/AIDS recorded as 14 per 100,000. [48] Antiretrovirals are sampled twice a year. In 
contrast, in 2012 an estimated 34% of all-cause mortality in Senegal was attributable to non-
communicable diseases. [49] There is no known sampling for medicines used to treat non-
communicable disease such as anti-hypertensives or anti-diabetics. Verification of the quality 
of other medicine classes would alleviate stakeholder concern. The case of inefficacious 
generic diazepam purportedly associated with its quality mentioned by some interviewees, 
illustrates how readily such instances can undermine confidence in a particular medicine.  
3.4.1 Strengths and limitations  
The data for analysis in this study was drawn from a representative sample of stakeholders of 
the MQSS including representatives in strategic and operational roles within the authorities 
responsible for operating the system and treatment providers from the public (doctors, nurses 
and pharmacists) and private sector (pharmacists only). Previous studies examining 
perceptions of medicines quality have primarily sought views from health providers and 
consumers and have seldom explored the beliefs of representatives at senior levels in the 
health system. These views may also be transferable to health systems in other LMICs 
especially as Senegal shares some similar features with other sub-Saharan African countries. 
Firstly, Senegal is one of several countries in sub-Saharan Africa that is supported by the USP’s 
Promoting the Quality of Medicines Programme. Secondly, Senegal imports the majority of its 
medicines (including generics) from India, China and Nigeria. Finally, Senegal also has a 
reportedly burgeoning informal sector for medicines.  
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This study was limited by the findings being extracted from a data set obtained using questions 
not directly linked to the perceptions of medicines quality and overall, this study has mostly 
considered views of those responsible for supplying medicines. Any perceptions of consumers 
or patients referred to in this study are effectively one step removed as they are relayed by 
treatment providers. The views of patients and consumers are important as they provide 
insights into how demand for medicines is shaped by views on their quality. A better 
understanding of these views may inform relevant public health campaigns to educate the 
public on how there is scarce evidence to prove factors such as origin/source, cost and type 
(generic/brand) affect medicine quality and that the vast majority of generics are safe and 
effective as they are approved by the WHO prequalification programme or similar 
initiatives.[43] Furthermore, as with chapter 2, this study does not include perceptions of 
informal medicine sellers which are also significant, especially as interviewees perceived the 
inadequate storage and non-verifiable source of medicines in this sector as prominent risk 
factors for medicines quality in Senegal. 
 
3.5 Conclusions 
Perceptions of medicine quality are likely to be informed by personal experience, knowledge 
of empirical evidence (known facts), physical appearance of the medicine and hearsay, 
especially from peers or colleagues. Medicine quality studies are generally conducted in the 
technical paradigm, yet the perceptions of medicine quality do not fit this model but align 
better to the clinical paradigm which involves the impact of medicine quality on population 
health and the effectiveness of medicines in treating symptoms of illness. 
This study has also illustrated the complexity of the perceptions of medicine quality and 
presents some contradictory views. For example, generics were thought to be of inferior 
quality to their brand versions, yet, treatment providers had confidence in the quality of 
medicines they sold and supplied to the public and many of these were generic products. Also, 
patients were thought to view cost as an indicator of quality, yet it was reported that patients 
bought medicines from the informal sector because they were cheaper which perhaps gives 
credence to the perception that medicine cost is thought to be a risk factor for poor quality 
medicines. The heterogeneity of these views provides challenges for policy makers, 
pharmaceutical companies and regulators in educating treatment providers and consumers 
about the realities of medicine quality.  
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Public information campaigns by pharmaceutical companies and national regulators supported 
by research-based evidence of generic medicine quality may change these perceptions. 
Furthermore, the publicising of epidemiologically sound data for medicines quality that is in 
format suitable for the lay reader is needed. This will clarify the status of generic medicines 
and the quality of medicines manufactured in newly-emerging economies, such as China, India 
and Nigeria, as recent reports only act to undermine confidence in generics which are vital to 
improving access and affordability of modern medicine for the world’s poorest.  
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Section 2: Screening technologies and surveys for assessing the 
quality of antimalarial medicines  
 
B1. Introduction 
Having considered the international context for medicines quality as well as providing, an 
assessment of a national medicines quality assurance system (MQAS), this section focuses on 
the technical parameters of how medicine quality is monitored. It describes in particular, a 
fundamental aspect of a medicines quality surveillance system (MQSS), the laboratory analysis 
of medicines quality, with emphasis on an appraisal of the currently available screening 
technologies for assessing the quality of antimalarial medicines. The negative impact of poor 
quality medicines on public health warrants the need for their swift detection ideally before 
they enter a national supply chain (at the point of entry) or as part of a post-marketing 
surveillance system (often at the point of care). [1] Unfortunately, most LMICs lack the 
capacity to implement point of entry screening and some have a limited system of post-
marketing surveillance to enable detection of poor quality medicines circulating within their 
country. This exemplifies the need for screening tests that can be used as part of routine post-
marketing surveillance in remote locations, in field surveys and at the point of care.  
As a background to this section, the role of screening technologies is discussed in relation to 
how the technical component of a MQSS functions to detect poor quality medicines, set 
against the backdrop of the key technical challenges faced by health systems in low-middle 
income countries (LMICs). An overview of the current screening technologies that can assess 
antimalarial medicine quality (with a focus on artemisinin combination therapies (ACTs) as the 
first line medicines in treating uncomplicated P.falciparum malaria) is also provided in this 
section, together with an assessment of these devices, their cost, practical utility, accuracy 
compared to the gold standard technique and potential for integration into a MQSS. Chapter 4 
comprises our published systematic review [2] which provides an overview of the types of 
screening technologies used to assess antimalarial medicine quality, the survey methods that 
have been used to assess antimalarial quality in field surveys and the standard of reporting. 
We also devised a template for reporting future studies. Chapter 5 presents the results of a 
pilot study carried out in Senegal to evaluate the practical utility of a new screening test, 
comprising two assays, both of which specifically detect the artemisinin derivative in mono 
and combination therapies (the artemisinin derivative test, ADT). The chapter assesses the ADT 
in operational use in a LMIC, including perceptions of its usefulness and acceptability by 
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laboratory staff working at the national medicine quality control laboratory (MQCL) who were 
routinely involved in analysing the quality of antimalarials collected from field surveys 
nationally. The performance of this new test was also evaluated in comparison to the Global 
Pharma Health Fund MiniLab® (discussed in detail later in this section), the screening test 
currently used in Senegal to assess the quality of artemisinin based medicines (and other 
medicine classes). The approach to the evaluation of the ADT was designed to establish its 
requirements in terms of utility and acceptability to enable its use in malaria endemic 
countries as a component of a MQSS.  
 
B2. The technical component of medicines quality monitoring 
The previous chapters have outlined the importance of technical capacity within a national 
health system in identifying poor quality medicines and providing reliable findings upon which 
a National Medicines Regulatory Authority (NMRA) can act to minimise the likelihood of such 
medicines circulating in a country. An efficient, effective and functional MQAS should have a 
fully equipped MQCL consisting of: 1) confirmatory testing equipment (high performance 
liquid chromatography (HPLC) systems; also referred to as the gold standard test), so that 
international pharmacopeia methods can be used to assess the quality of medicines; 2) 
quality-assured drug reference standards and 3) staff with the expertise and experience of 
operating specialist technology. [3, 4]  
However, MQCLs have high capital and maintenance costs that may deter national 
governments in LMICs from initial or continued investment. This was mentioned in the 
interviews with MQSS representatives in Senegal (presented in chapter 2) where the national 
MQCL (the Laboratoire National de Contrôle des Médicaments (LNCM)) had three HPLC 
machines, but only one was fully operational. The other two machines were not operating 
having developed faults to components that were not repaired as result of insufficient funds 
allocation in the annual budget. Yet, the findings presented in chapter 2 from interviews with 
MQSS stakeholders (representatives of the key authorities of the system and treatment 
providers) also revealed a common perception; that the health system in Senegal benefitted 
from a sound medicines regulatory system (which provides the foundation for an effective 
MQAS) and that the MQSS was an asset to the health system. This was because of the 
undertaking of periodic medicines quality sampling of certain medicine classes and testing at 
the LNCM which was further strengthened by gradual improvements in technical capacity 
supported by United States Pharmacopeia (USP). 
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To improve technical capacity whilst trying to overcome the challenge of a lack of funding for 
medicines quality control, the LNCM in Senegal (with support from USP) was working towards 
WHO prequalification accreditation at the time of data collection in 2013/2014. The World 
Health Organization (WHO) operates a prequalification programme for MQCLs in LMICs 
providing accreditation for prequalification through ISO (ISO/IEC17025) certification. [5] To 
achieve accreditation a MQCL must pass an assessment that satisfies requirements for ‘good 
practice for pharmaceutical quality control laboratories.’ [6] Prequalification accreditation has 
a two-fold benefit for an MQCL; 1) it enables participation in WHO prequalification monitoring 
projects that assess the quality of medicines procured by UN agencies and 2) it reassures 
potential users of the service that the laboratory meets international standards. From 
interviews with the MQSS authority representatives, it was suggested that attaining 
prequalification status could enable the LNCM in Senegal to generate additional income from 
undertaking quality control of medicines, medical devices, vaccines and foodstuffs for NMRAs 
from neighbouring countries, non-governmental organisations and other external agencies. As 
of July 2017 there were only eight WHO accredited laboratories in just five countries in sub-
Saharan Africa with three in South Africa, two in Kenya and one each in Zimbabwe, Uganda, 
Tanzania. [7] This suggests a need for greater investment in prequalification processes with 
cooperation between the WHO, USP and individual countries to enable the establishment of 
local prequalified laboratories. [8] 
The limited technical capacity in LMICs presents a challenge for medicines quality assurance 
and surveillance nationally, regionally and internationally. In part, this challenge can be 
addressed by using medicines quality screening technologies, not as a replacement for 
confirmatory methods but for both to work in tandem. In some LMICs, screening tests are a 
key component of a MQSS. USP through its Promoting the Quality of Medicines programme 
encourage the use of screening technologies for rapid assessment in the field. Countries in 
which USP are active, employ the MiniLab® as the first stage in the screening of medicines 
quality. [9] The USP testing guidelines suggest that any failing or doubtful samples along with 
5-10% of ‘passed samples’ ought to be sent for confirmatory testing. [10] Such an approach 
reduces the need for analysis of all samples collected through periodic medicine quality 
surveys by confirmatory testing which would be time consuming and expensive. In countries 
where confirmatory testing is not available screening technologies may play a crucial role in 
assessing medicines quality. Screening tests indicate that a problem exists with a medicine (or 
batch of medicines) which can then be further investigated at MQCLs. [2] Screening 
technologies can also be used in non-laboratory settings such as health facilities or border 
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posts (at the point of care and point of entry). However, their use in these settings has not 
been widely implemented and evaluated yet. 
Screening tests that are employed as part of a MQSS or for assessing the quality of medicines 
as a component of post marketing surveillance need to have certain key attributes. In the 
screening and diagnosis of diseases and infections the accuracy of the test is important and 
should ideally be highly sensitive (able to correctly identify those patients with a disease) and 
highly specific (able to correctly identify those patients without the disease). However, it is 
accepted that in the context of medical screening there is often a trade-off between sensitivity 
and specificity. [11] In terms of medicines quality, a key attribute of a screening test is its 
capacity to detect a poor quality medicine. Poor quality medicines have negative clinical 
implications at the individual and population level. [12, 13]  Hence, an ideal medicine quality 
screening test needs to be highly sensitive and give accurate results i.e. produce minimal ‘false 
passes’ hence, allowing the lowest proportion of poor quality medicines to go undetected as is 
possible. Additionally, given the large number of samples requiring testing, a screening test, 
needs to be inexpensive to purchase and maintain, easy to use and portable (preferably 
handheld). 
 
B3. Medicine quality screening technologies for antimalarials 
There are several screening technologies currently available for assessing the quality of 
antimalarial medicines, at varying stages of development from initial product testing to pilot 
feasibility studies on the ground in LMICs with a view to evaluating their potential for wider 
use as part of a MQSS either through post-marketing surveillance such as through routine 
medicines quality surveys or for assessment at border posts, at the point of entry into a 
country. Basic tests for medicine quality are primarily based on, but not restricted to, 
chromatographic and spectrometric techniques with the addition of visual inspection. Product 
recognition by comparing the packaging with that of the accredited product, counterfeit 
identification, detection of the stated active pharmaceutical ingredient (SAPI) and determining 
composition are just some of the approaches adopted by current screening technologies. [14] 
These technologies are summarised in Table B1 below, which compares the method of 
detection for medicine quality used by each test, approximate cost and practical features such 
as portability, simplicity of operation etc.  
The WHO medicine testing guidelines recommend combining qualitative and quantitative 
approaches to analysis, to establish the identity, content and disintegration of a medicine. [15] 
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Qualitative tests that rely on a subjective interpretation by the operator include visual 
inspection, colorimetric tests and tablet or capsule disintegration. Visual inspection involves 
assessment of the medicine packaging, patient information leaflet and the medicine itself.  
Misspellings, absence of an expiry date or batch number and obvious signs of deterioration of 
the product itself may indicate a poor quality medicine. [16] Colorimetric tests involve a simple 
colour reaction to verify presence of the SAPI. The disintegration test requires the 
tablet/capsule to disintegrate in water heated to 37°C, within 30 minutes. If this does not 
occur, it could indicate a poor quality product. Thin layer chromatography (TLC) is an example 
of semi-quantitative testing and is described further in the MiniLab® section below. [17] Used 
in combination, these basic tests provide an indication of the quality of a medicine. Visual 
inspection alone may suggest a medicine is falsified or counterfeit. Disintegration testing 
provides an indication of deficiencies related to medicine solubility and bioavailability. The 
next step of carrying out a colour reaction indicates if the SAPI is present before carrying out a 
TLC run for verification of whether the quantities of medicine claimed on the label are in the 
sample.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
123 
 
Table B1: Comparison of key features of screening devices used to assess the quality of antimalarials 
Device Method of 
detection for 
medicines quality 
Approximate 
Cost 
Portability Training 
required 
Other 
medicine 
classes 
Other 
Comments 
MiniLab® Visual inspection; 
disintegration; 
TLC  
$10,000 
(capital 
investment) 
 
Commercially 
available 
Not 
handheld 
(laboratory 
only) 
Yes - 
several 
days 
Yes Toxic reagents 
 
Previous 
laboratory 
experience 
essential 
TruScan® 
(Raman 
spectroscopy 
device) 
Identification of a 
unique spectral 
‘fingerprint’  
 
$17000-50000 
 
Commercially 
available 
Handheld, 
no 
additional 
reagents 
Some - 
one day 
Yes  
SCiO (Near 
Infrared 
device) 
Identification of a 
unique spectral 
‘fingerprint’ 
 
$250 
 
Commercially 
available, but 
not for 
antimalarials as 
yet 
Handheld, 
no 
additional 
reagents 
Some - 
one day 
Yes  
Counterfeit 
detection 
device 
Optical 
wavelength 
testing 
$1000 
 
Commercially 
available 
Handheld, 
no 
additional 
reagents 
Minimal 
– a few 
hours 
Yes  
Paper Test 
Cards 
Paper-based 
chromatography 
$0.50 per card. 
 
Not 
commercially 
available 
Handheld None Yes Water required - 
immersion of 
bottom part of 
card 
 
Mobile phone 
with camera to 
capture results 
ADT TLC 
chromatography 
and colorimetry 
To be decided 
when kit is 
formatted 
 
Not 
commercially 
available 
Handheld, 
minute 
amounts 
of two 
reagents 
needed 
Minimal 
– a few 
hours 
No 
(artemisinin 
derivatives 
only) 
 
 
GPHF MiniLab® 
Visual inspection, tablet/capsule disintegration and thin layer chromatography (TLC) are 
incorporated into the GPHF MiniLab®. A key component of the MiniLab® is the TLC test which 
requires a spot of the test solution of a sample to be compared to two reference spots 
representing the concentration range of an SAPI (80% and 100%). For the sample to pass the 
TLC test, the spot must travel as far as the reference spot representing the lower working limit 
(80%) and be of the same shape, size and intensity (see figure B1).  
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The MiniLab® is capable of screening the quality of 85 WHO essential medicines and is 
reported to be used in around 95 countries globally. [18] Initial feasibility studies were carried 
out in four countries in Africa and Asia in 1997 [19] and by 2009 USP had identified the 
MiniLab® as a key component of its Promoting the Quality of Medicines programme in a 
number of LMICs. [9] The MiniLab® is reported to be currently available in 27 countries in sub-
Saharan Africa but information on its utilisation is unknown. The manufacturers of the 
MiniLab® state that it can be used in laboratory and non-laboratory settings as part of a MQSS, 
in particular for post-marketing surveillance activities including the testing of medicines 
collected through routine medicines quality surveys. The manufacturers regard it as a simple 
and inexpensive testing kit requiring minimal training and no electricity to operate, which is 
contrary to some of the attributes of the test presented in table 1. Indeed, week long training 
sessions on its procedures and use are suggested for health professionals and treatment 
providers. Those with some knowledge of analytical chemistry may require less training. [20] In 
addition, in terms of its routine utilisation, the MiniLab® uses several hazardous reagents for 
testing medicines quality including sulphuric acid solution, glacial acetic acid and toluene. The 
cost per test for the MiniLab® is around $1.50 (cost of undertaking the test on one sample, 
using visual inspection, disintegration and TLC). [21] However, the initial capital investment in 
a MiniLab® could be as much as 10,000$. [19] 
Furthermore, there is limited evidence for the accuracy of its TLC component with just two 
studies having conducted sensitivity and specificity calculations and no relevant data published 
to date by the manufacturer. One of these studies, a WHO multi-country survey in sub-Saharan 
 Figure B1: The GPHF MiniLab® with results of screening of dihydroartemisinin using the TLC test 
125 
 
Africa reported the TLC component MiniLab® as having low sensitivity, passing medicines that 
had actually failed the gold standard technique (HPLC) for chemical content analysis of the 
SAPIs. [22] The second study compared the performance of another screening device, the 
Counterfeit Detection Device (CD3+) with the MiniLab® (and is described in the CD3+ section 
below). [23] In terms of identifying poor quality medicines the MiniLab® has been described as 
only being able to detect falsified or grossly substandard medicines (those with zero SAPI or 
very little SAPI). [24] For assessing the quality of ACTs, the MiniLab® has TLC procedures for 
detecting all artemisinin derivatives in mono and combination therapy formulations.  
The MiniLab® was the first screening kit developed and remains the only method in 
widespread use at the current time. In some LMIC countries it plays an important role in 
medicines quality surveillance acting as the first stage of medicines quality testing providing an 
indication of the quality of sample. However, compared to other screening devices currently 
available, it is quite bulky, weighing 40kg and despite it being promoted for use outside of the 
laboratory by the manufacturer, the need to use toxic reagents and degree of training (around 
one week) for its optimal use, renders it a technology that can only be safely used in a 
laboratory setting.  
Handheld spectroscopy – Raman and Infrared devices  
Raman and infra-red devices such as the 
TruScan® (figure B2) and SCiO (figure B3) 
scan medicine samples through the blister 
pack to identify a unique spectral 
‘fingerprint’ for a medicine. [23, 25]  
These devices require a comprehensive 
database of spectra of each medicine 
(including every brand), from every 
manufacturer, which is not available at 
present and thus effectively limits their 
actual utility. Although, the TruScan® was shown to be capable of detecting ‘counterfeit’ 
antimalarial medicines, authors in one study cautioned against its use for certain fixed dose 
combinations of antimalarials such as ACTs citing that its capability depends on the nature and 
strength of the dosage form tested. [26] This was as a result of the device producing spectra 
for samples that matched the signature of a comparator of a different brand resulting in a false 
pass result which can occur if the intensity of the Raman signal is overwhelming. Hence, testing 
of medicines containing SAPI that produce either very strong or very weak Raman scatter may 
Figure B2: Image of the Raman Truscan® device  
Source: Thermofischer website 
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be challenging. This is particularly important in the case of fixed-dose combinations where one 
SAPI may have a strong Raman scatter that can mask the Raman signal of the other SAPI(s). 
Thus the authors suggested that the Truscan® cannot be used to detect substandard medicines 
that have some SAPI content thus giving a weak spectra which may not be detected by the 
device. [26] Hence, based on the evidence available it is not clear on whether the Truscan® 
could be used to assess the quality of ACTs. 
In contrast, the SCiO screening device was 
found to be capable of detecting all of the 
varying brands of falsified ACTs as well as 
identifying substandard amounts of 
artesunate but not amodiaquine in the 
ACT, artesunate-amodiaquine. This was 
due to the spectra of the reference 
standard amodiaquine not being 
distinguishable in the spectral signature of 
combination therapies containing 
amodiaquine.[25] The SCiO device is much 
less expensive than Raman handheld 
devices, with an approximate cost of $250 compared to between $17000 - $50000; but 
information on the sensitivity and specificity is not available yet for the SCiO device with 
regard to antimalarials as minimal product testing with this group of medicines has been 
undertaken. There is minimal data available on the sensitivity and specificity of the Truscan® 
for antimalarials apart from one study which compares the device to the MiniLab® and the 
CD3 and is discussed in detail in the section below. Both the Truscan® and SCiO devices do 
require some training (up to one day) to operate them effectively but this is not as extensive as 
the training needed for the MiniLab® which may be up to a week long. Both devices are 
handheld and can be used in non-laboratory settings. Indeed, the Truscan® has been employed 
in the testing of medicines in Nigeria at the point of entry where it was previously reported to 
have detected a shipment of fake antimalarial tablets. [27] The extent of its use in LMICs as 
part of routine medicines quality testing is not known.  
Figure B3: The Consumer Physics NIRS research model SCiO.  
This image shows the integrating attachment (a), the NIRS 
spectrometer (b) and (c) which indicates the location of the 
light source and sensor on the NIRS. A dose of Lumartem® is 
shown for scale. 
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Counterfeit Detection Device  
The United States Food and Drug Administration (FDA) have developed a counterfeit detection 
device known as CD3+ (figure B4) which was awarded a patent in 2017. It works by illuminating 
a sample with a range of wavelengths of light to provide a visual comparison of an unverified 
product with an authentic product. [28] 
The device has an inbuilt LED and digital 
camera. The light from the LED interacts 
with the inks and tablet colours on 
sample packaging and dosage form 
surfaces. The operator’s eye observes 
differences between the suspect dosage 
form and packaging and an authentic 
medicine which may take the form of 
changes in colours, shading, contrast, 
fluorescence, or a combination of all of 
these. The differences observed in the suspect sample may be attributed to chemical 
differences between the products such as variation in the SAPI and excipients, colours used in 
coatings, or packaging materials. Differences between suspect and authentic dosage forms can 
also be observed through the blister package which allows for rapid screening of samples. The 
greater the number of visual differences observed between suspect and authentic samples, 
the more likely the medicine sample is counterfeit. [28]  
The manufacturers suggest it is designed for use in non-laboratory settings and it has already 
been field tested in Ghana by the NMRA in the screening of two ACTs, artemether-
lumefantrine and artesunate-amodiaquine [29] but there is no information available on 
whether the device can detect dihydroartemisinin-piperaquine, another commonly used ACT 
in sub-Saharan Africa.  Indeed, its capability to test a sample in a few minutes and its cheaper 
cost compared to similar devices that screen the chemical compositions of medicines such as 
the Truscan®, make it a viable option for resource limited NMRAs in LMICs. During product 
testing it was found to exhibit a high level of inter-observer agreement of 100%. [28] There is 
currently limited information on the inter-operator variability of other medicine quality 
screening devices. Also, in field testing, it was shown to be effective at detecting counterfeit 
antimalarials. [30] The CD3 is handheld, battery or mains operated and requires minimal 
training (a few hours) for effective operation. The cost of materials to produce a CD3+ are 
thought to be around $1000. [31] 
Figure B4: The Counterfeit Detection Device (CD3+) 
Source: from United States Food and Drug Authority 
website. 
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In one study, comparison of the CD3+ device with the MiniLab® and Raman Truscan® 
suggested that the CD3+ (1.00) had a superior sensitivity in detecting counterfeit/substandard 
antimalarial products compared to the other two screening technologies (both 0.79) but a 
much lower specificity for quality assured medicines, 0.59 vs 0.99 (MiniLab®) and 1.00 
(TruScan®).[30, 32] The CD3+ is more likely to correctly classify counterfeit antimalarials than 
either the MiniLab® or Truscan®, although separate specific data indicating results for 
substandard products was not provided in the study. However, due to a lower specificity for 
quality assured medicines the CD3+ is more likely than the other two tests to classify 
medicines of acceptable pharmacopeial quality as poor quality. Information on the parameters 
of screening tests, (which is presently limited) is needed to enable policy makers and 
medicines regulators to determine which tests are most appropriate for use within their 
country. However, data on such parameters may vary depending on the operators of the test, 
participating in feasibility studies. Sensitivity and specificity of screening tests has been shown 
to be affected by the experience of an operator in terms of their ability to adhere to test 
procedures and particularly in their interpretation of results. [33] According to the United 
States FDA the specificity of the CD3+ for quality assured antimalarials may increase (or 
improve) the more experienced an operator becomes at using the device [30], although this 
would be the case with any screening test. 
Paper test cards 
A relatively new screening tool are paper 
test cards (figure B5) that use separation 
techniques employing paper-based 
chromatography which allows the testing 
of multiple SAPIs on a single piece of card 
(known as multiplexing). [34] In field 
testing they have demonstrated the 
ability to detect and distinguish between 
‘authentic’ and very poor quality (very 
low SAPI) non-artemisinin based 
antimalarials. [35] Nevertheless, they have a low accuracy in terms of their sensitivity and 
specificity in comparison to the gold standard and it is not possible to quantify the amount of 
SAPI in a sample. These test cards are useful for testing some antimalarials (chloroquine, 
doxycycline, quinine, sulphadoxine, pyrimethamine, and primaquine) but they cannot 
currently detect ACTs. 
Figure B5: Image of an operator using a paper test cards  
Source: Weaver et al (2015).  
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Advantages of the tool include its ease of use, minimal training (a few hours or less) rapid 
results (within 10 minutes) and potential for use outside of a laboratory setting such as border 
posts and health facilities. They also have very low manufacturing costs at just $0.50 per test 
card. [35] A further advantage is the ability of the tool to test multiple samples at the same 
time which is cost effective and may facilitate rapid processing of medicine samples collected 
as part of medicine quality surveys.   
Artemisinin derivative test 
The artemisinin derivative test (ADT) is chromatographic and colorimetric utilising TLC silica gel 
sheets and minute volumes of either 2,4 dinitrophenylhydrazine (DNP) or 4-Benzoylamino-2, 5-
dimethoxybenzenediazoniumchloride hemi (zinc chloride) salt (Fast Blue Salt – FBS) as 
reagents to detect artemisinin based medicines (artemether, artesunate and 
dihydroartemisinin only) producing specific pink (DNP) and blue (FBS) colours, only if the 
artemisinin derivative is present. In addition, the tests have been proven to be able to detect 
as low as 10% of the SAPI. A patent for the test was filed by London School of Hygiene & 
Tropical Medicine and awarded in 2013.† 
This test has not yet been evaluated in the field which is one of the aims of this research. The 
findings from the evaluation of the test relating to its practical utility and perceptions of its 
usefulness and acceptability to staff working in a MQSS in a malaria endemic country are 
presented in chapter 5. Chapter 5 also presents data on the sensitivity and specificity of the 
ADT. Initial product testing at LSHTM confirmed that the test is simple to operate and requires 
minimal training (a few hours). The equipment required is shown in figure B6. The test could 
be used in laboratory and non-laboratory settings. These and other key attributes of the ADT 
are discussed further in chapter 5. 
                                                          
†Bulletin 2013/21 (22.05.2013 ). Kaur H; Ioset JR. ASSAY, KIT AND APPARATUS FOR DETECTION OF 
ARTEMISININ DERIVATIVES UK Intellectual Property Office, 2007; WO2007077444(A1) 
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The ADT test has not yet to be formatted into a ‘kit’. A potential ‘kit’ will consist of test tubes 
(to solubilise the tablet), droppers to transfer the solutions to the TLC plates and a reagent 
bottle. Analysis of one tablet will require one test tube, one dropper and one TLC plate. The 
white box in figure B6 above contains a TLC plate with a window in which the test solution and 
reagents can be applied to develop the sample. Each TLC plate is for one test only. 
Currently, aside from the MiniLab® none of the devices described above are in routine use as 
part of an MQSS in LMICs or even for post-marketing surveillance activities. Moreover, despite 
their merits for use as part of a MQSS, findings from the various studies cited above 
demonstrate a gap in evidence of the accuracy of screening technologies in detecting poor 
quality antimalarials. [22, 30] A specific concern is their limited capability to detect 
substandard antimalarials, although screening tests have been demonstrated to be capable of 
detecting counterfeit antimalarials. Additionally, little is known about the parameters of 
screening tests in terms of their sensitivity and specificity in identifying/distinguishing between 
poor quality and acceptable pharmacopeial quality antimalarials. This exemplifies how 
confirmatory testing using methods listed in pharmacopeia are fundamental to detecting poor 
quality medicines and should, where possible, form the basis of the medicines quality analysis 
component of a MQSS. Moreover, apart from the two studies [30, 36] utilising the CD3+ device 
there is no published literature on the potential for inter-operator variability in terms of 
adherence to test procedures and in the interpretation of results for the other screening tests 
described in this section. Both these aspects are thought to affect the performance of 
screening tests and will be explored further in chapter 5 using the MiniLab® and ADT as 
examples. [37] 
Figure B6: Potential components of an ADT kit 
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B4. Aims and Objectives 
The aim of this section is to appraise the current screening technologies available to assess the 
quality of ACTs and to provide suggestions for improving the quality of future evidence in 
medicines quality studies and surveys.  
B4.1 Objectives 
1. To review the screening technologies and survey methods that have been used in 
LMICs to assess the quality of antimalarial medicines (ACTs in particular) in common 
use, as well as how findings have been reported.  
 
2. To evaluate the practical utility of the ADT and perceptions of its usefulness and 
acceptability to local laboratory technicians engaged in national medicines quality 
surveillance in a malaria endemic country context. 
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Chapter 5: An evaluation of a new screening test for assessing the 
quality of artemisinin based medicines 
 
5.1 Introduction 
Poor quality medicines are those that do not comply with pharmacopeia tolerance limits and 
may contain sub-therapeutic or a greater amount of the stated active pharmaceutical 
ingredient (SAPI) resulting in treatment failure, the propagation of drug resistance (in the case 
of anti-infectives) or an increase in adverse effects. [1, 2] Focussing on antimalarial medicines, 
a recent review indicated that 30.1% (2,813) of 9,348 antimalarial medicines sampled in low-
middle income countries (LMICs) failed chemical/packaging quality. [3] This is of concern in 
LMICs who may have minimal regulatory and technical capacity to control and monitor the 
quality of medicines entering and circulating nationally. Indeed, the World Health Organization 
(WHO) estimated that 30% of countries in Latin America, Asia and Africa had ‘no medicine 
regulation or a capacity that hardly functions.’ [4] Estimates for the proportion of countries 
with adequate technical capacity are lacking. In the context of medicines quality, an effective 
medicines quality assurance system (MQAS) requires robust regulation that can prevent poor 
quality medicines entering a country and the capability to undertake post-marketing 
surveillance that detects poor quality medicines and acts to remove such medicines from 
national medicine supply chains.  
A medicines quality surveillance system (MQSS) is an integral component of a MQAS and relies 
upon adequate technical capacity including; 1) a medicines quality control laboratory (MQCL) 
with equipment and expertise to carry out confirmatory testing (as listed in drug monographs 
in pharmacopeia), 2) screening technologies employed in sentinel sites to assess the quality of 
a larger volume of medicines and 3) effective post-marketing surveillance with periodic 
medicines quality surveys using robust sampling techniques.  Hence, the quality of medicines 
available cannot be assured (even where regulation operates effectively) unless adequate 
technical capacity is available.  
MQSS in LMICs employ screening devices at the preliminary stage for medicine quality 
assessment to identify those medicines that need more detailed (and expensive) laboratory 
investigation. Some of these devices are handheld, simple to use and relatively inexpensive, 
making them suitable for screening large volumes of medicines. However, screening devices 
only provide an indication of the quality of a medicine and are useful in detecting falsified or 
grossly substandard medicines (with an absence of or very low SAPI) but cannot identify 
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substandard medicines. [5-7] Screening tests can be employed at any point of the distribution 
chain from entry of a consignment of medicines at the port to its point of sale as well as in 
laboratories as part of routine post marketing surveillance activities such as periodic medicines 
quality surveys. Subsequent to screening tests, medicines should always be analysed using 
confirmatory tests following methods described in an international pharmacopeia so as to 
obtain a definitive result on the quality of a medicine in terms of its content in comparison to 
tolerance limits for the medicine stated in its drug monograph. [8] However, medicine quality 
analysis using confirmatory methods is expensive, resource intensive and requires engagement 
at the level of the national government, all of which maybe seldom available in LMICs. [9] 
Thus, by default, screening technologies may play a pivotal role in the surveillance of 
medicines quality especially as the majority of LMICs have limited regulatory capacity to assure 
the quality of medicines entering a country coupled with, in some LMICs, multiple entry points 
for medicines (official and unofficial) which in turn increases the reliance upon post-marketing 
surveillance. Thus, the capability to analyse medicine quality outside of an established 
laboratory setting is a necessity. [10]  
The merits of screening technologies currently available on the market have been outlined in 
the introduction to section 2. This chapter focusses upon the evaluation of a new screening 
test comprising two new screening assays, namely the artemisinin derivative test (ADT) which 
specifically detects the artemisinin derivative (AD‡) component and is thus useful in 
determining the quality of artemisinin based medicines in both their monotherapy and 
combination formulations. This chapter also assesses the performance of the ADT against the 
currently more widely utilised technology namely the Global Pharma Health Fund (GPHF) 
MiniLab®, reportedly available in around 95 countries globally, the vast majority of which are 
LMICs. [11] The MiniLab® is also promoted for use by the United States Pharmacopeia (USP) 
Poor Quality Medicines Programme, as a key component of a MQSS and is currently the only 
screening technology used as part of periodic medicines quality surveys in several LMICs. [11, 
12] 
                                                          
‡ In this chapter the term ADs encompass artemisinin derivatives in both their monotherapy (e.g. 
dihydroartemisinin and combination therapy forms (dihydroartemisinin-piperaquine). ACTs refer to 
artemisinin combination therapies only in which the artemisinin derivative is partnered with another 
drug. 
153 
 
5.1.1 The GPHF MiniLab® 
The GPHF MiniLab® is a medicine quality screening toolkit, containing both qualitative and 
quantitative testing techniques. The qualitative tests include visual inspection and 
tablet/capsule disintegration and the quantitative test is a version of thin layer 
chromatography (TLC). [13] According to the manufacturer’s technical specifications, the TLC 
component of the MiniLab® provides a semi-quantitative analysis of medicines content (see 
figure 5.1) in which a spot of the medicine sample is applied to a TLC plate and should migrate 
at the same rate as the reference standard of the SAPI. If the spot formed by the sample is 
obviously different to the reference spot in distance travelled, shape and size this may indicate 
a poor quality sample. This is shown in figure 5.1 where ‘Run no. 3’ represents a sample of 
poor quality dihydroartemisinin and is visibly different in shape and size in comparison to the 
other three reference samples. Additionally, the TLC test must show that the sample contains 
more than 80% SAPI to be considered as a ‘pass’ according to MiniLab® guidelines. This is 
represented in figure 5.1 as ‘Run no. 4’, lower working reference standard of 
dihydroartemisinin representing 80% SAPI. [14]  
 
Figure 5.1: Image of a TLC run for a sample of dihydroartemisinin  
Run No.1: Upper working standard representing 100% of total dihydroartemisinin. Run No.2: A drug product of 
good quality with acceptable drug content. Run No.3: A drug product of poor quality with unacceptable low 
drug content. Run No.4: Lower working standard representing 80% of total dihydroartemisinin. Source: GPHF 
MiniLab® manual (2010). 
 
Chromatographic plate observed at daylight and under UV light after H2SO4 staining 
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5.1.2 Artemisinin Derivative Test  
The ADT comprises two simple assays developed at the London School of Hygiene and Tropical 
Medicine (LSHTM) to detect the artemisinin component of a monotherapy or combination 
formulation containing an artemisinin derivative and have not as yet been formatted into a kit 
for sale. The assays have been patented by LSHTM§, which was granted in 2013. 
These colorimetric assays utilise TLC silica gel sheets and either 2,4 dinitrophenylhydrazine 
(DNP) or 4-Benzoylamino-2, 5-dimethoxybenzenediazoniumchloride hemi (zinc chloride) salt 
(Fast Blue Salt – FBS) as the reagents to detect ADs. The principal of the test involves dissolving 
the pulverized tablet in methanol and applying a very small amount (5 µl x 2) of the resulting 
solution to a TLC sheet followed by either of the reagents (5 µl) and allowing the reaction to 
proceed at room temperature. The reaction(s) will produce a pink colour with the DNP or blue 
colour with FBS if an AD is present in the sample. Both colours should appear within 40 
minutes. The test comprises two assays so as to provide corroborative evidence of the 
detection of an AD. During product testing no medicines on the WHO essential medicines list 
or non-AD antimalarials or excipients produced a pink colour with DNP (aside from the ADs), 
only the antibiotic erythromycin did produce a blue colour (similar to the ADs) with the FBS 
reagent. Erythromycin did not produce the pink colour when tested with DNP. 
The ADT is chromatographic and colorimetric and provides an alternative to the GPHF 
MiniLab® for screening the quality of ADs (artemether, artesunate and dihydroartemisinin 
only). The development of the assays at LSHTM, demonstrated total specificity for ADs. [15] In 
addition, the test is also capable of detecting concentrations of ADs in formulations as low as 
10% of the SAPI (figure 5.2).  
                                                          
§ Kaur H; Ioset JR. Assay, kit and apparatus for detection of artemisinin derivatives. UK Intellectual 
Property Office, 2007; WO2007077444 (A1. Date of publication and mention of the grant of the patent: 
22.05.2013 Bulletin 2013/21 
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Figure 5.2: Detection of the artemisinin derivative component from 100% (which is the tablet containing the 
correct amount of the SAPI on the packet) down to 50% and 10% (which will imply that the product is substandard 
or grossly substandard) in formulations of artesunate/amodiaquine (AS/AQ;100%  =  50 mg, 50%  = 25 mg and 10% 
 =  5 mg), artemether/lumefantrine (AM/LUM, Coartem®; 100%  =  20 mg, 50%  = 10 mg and 10%  =  2 mg), and 
dihydroartemisinin/piperaquine (DHA/PIP, Duocortexin®; 100%  =  40 mgs, 50%  = 20 mg and 10%  =  4 mg). BL = 
Methanol as blank 100% = each tablet dissolved in 2 mL methanol corresponds to the acceptable dose; 50% = 
each tablet dissolved in 4 mL methanol corresponds to a substandard dose; 10% = each tablet dissolved in 20 mL 
methanol corresponds to a grossly substandard medicine. 
 
The ADT is rapid, simple to use, handheld, inexpensive and requires no previous laboratory 
experience. Nonetheless, as with the MiniLab®, it relies on a subjective assessment for results 
interpretation. Comparison of practical aspects of the GPHF Minilab® (TLC) and ADT are listed 
in table 5.1 below. 
 
 
 
 
 
 
 
 
 
156 
 
Table 5.1: A comparison of the practical aspects of the MiniLab® TLC test and the ADT test for the screening of 
artemisinin derivatives 
 
GPHF MiniLab®® (TLC) ADT 
Time for assay 
preparation (for 
one sample) 
Up to 30 minutes 5 minutes  
Time (minutes) for 
development of 
results 
30 minutes 40 minutes minimum  
Total time per test 60 minutes 45 minutes minimum 
Reagents/solvents 
required 
Sulphuric acid solution 96% 
Ethyl acetate 
Methanol 
Ammonia solution 25% 
Acetone 
Glacial acetic acid 
Toluene 
Methanol 
Dinitrophenylhydrazine (DNP assay) 
4-Benzoylamino-2, 5-
dimethoxybenzenediazonium-
chloride hemi (zinc chloride) salt (FBS 
assay) 
Test result Needs a UV lamp to visualise The pink colour (DNP assay) or Blue 
colour (FBS assay) are visible to the 
naked eye 
Size Large suitcase (40Kg) To be formatted – size equivalent to 
pregnancy testing kit (15cm x 8cm x 
2cm) and weight < 0.5 kg 
Interpretation of 
results 
Relies on subjective assessment Relies on subjective assessment 
Training Formal training course required 
Laboratory experience is advantage  
Minimal training 
No laboratory experience needed 
 
We explored aspects of the test that had not been assessed during initial product testing. 
Firstly, just a handful of individuals at LSHTM had used the ADT in controlled laboratory 
conditions. Secondly, an instruction manual for the test had not been designed nor had a 
detailed test procedure or reference guidance on results interpretation (e.g. colour chart) been 
produced. Finally, for the ADT to be used in malaria endemic countries it required feasibility 
testing by individuals who had no prior knowledge of the test. A field evaluation of the test 
included an assessment of its practical utility, usefulness and acceptability.  
Design of a manual for the ADT test 
A manual (see supplementary file 1) was designed by us and included the assay procedures, 
interpretation of results, a colour chart, bench aids (outlining test procedure, steps 1-4 as in 
figure 5.3) and a summary description of the laboratory investigations based on the published 
work by the inventors of the test, Ioset and Kaur. [15] The manual was designed to be similar 
in structure and language to the TLC test procedures of the MiniLab® manual so as to be 
simple to follow for the laboratory technicians, given their experience of having previously 
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used the MiniLab®. The manual included a detailed description of various aspects of the test 
(illustrated in figure 5.3 below) including; a list of equipment, the test procedure (steps 1 and 
2; sample and TLC plate preparation), spotting of test solution (step 3), development of results 
(step 4) and results interpretation (step 5). The manual also included a bench aid which 
provided a concise summary of steps 1-5.  
 
Figure 5.3: ADT test developed at LSHTM to check the quality of artemisinin based medicines  
The text in red shows the major steps for carrying out the test: steps 1 and 2 - preparation of the sample and TLC 
plate; step 3 - spotting of solution on matrix on TLC plate; step 4 - development of the results; step 5 - 
interpretation of resulting colours.  
 
To enable step 5 (results interpretation) a colour chart (included in the manual) was designed 
to reflect the range of depth of colours produced using samples of ACTs collected from multi-
country medicine quality surveys that had already been tested using confirmatory content 
analysis by High Performance Liquid Chromatography with photodiode array detector (HPLC-
PDA) at LSHTM. [16] All ACTs were solubilised in methanol and diluted to obtain solutions with 
concentrations of 10, 40 and 100 % SAPI as this produced the best distinguishable colours 
when viewing the analysis results of the ADT. 
This study aimed to evaluate the practical utility of the ADT, perceptions of its potential 
usefulness and acceptability following ‘field’ testing in an LMIC. It assessed the performance of 
the ADT in the hands of laboratory technicians, who had no prior knowledge of this test, at the 
Laboratoire Nationale de Controle de Medicaments (LNCM) in Senegal. This approach was 
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designed to establish the acceptance of the test by laboratory technicians in malaria endemic 
countries for use as a component of a MQSS.  
This study was conducted through three specific objectives: 
1. To assess the ease of use and accuracy of the ADT for detecting the artemisinin 
derivative component of the formulation when used by laboratory technicians in 
the field.   
 
2. To explore the acceptability and perceived usefulness of the ADT, and its potential 
role in a national system to monitor the quality of ACTs.  
  
3. To compare the performance of the ADT and the GPHF-MiniLab® TLC test in terms 
of their accuracy when used by laboratory technicians in the field.  
 
5.2 Methods and results 
5.2.1 Study Setting and participant characteristics 
The study was undertaken at the LNCM in Dakar, Senegal in February 2014 over the course of 
five days. All laboratory technicians employed by the LNCM (in Dakar) were invited to 
participate in the study. Senegal was chosen as an appropriate study site as a national MQSS 
has been in operation since around 2001. This provided an opportunity to assess the utility and 
role of this new screening test within a functioning surveillance system. Furthermore, the 
laboratory technicians at the LNCM were experienced users of the MiniLab® in the screening 
of samples collected as part of regular medicines quality surveys which had been ongoing in 
the country since around 2009 [17] with ad hoc use of the technology for a few years 
preceding the commencement of formal field surveys. 
Ethical approval for the undertaking of this study was granted by the London School of Hygiene 
and Tropical Medicines Research Ethics Committee (see annex 1) and National Council for 
Health Research, Senegal (annex 2). 
Information on age, gender, level of education, length of time at LNCM etc. of the participating 
technicians was collected. Eight LNCM technicians participated in the study; three males and 
five females, aged 30-52. With the exception of one technician, all had undertaken further 
education (diploma or university degree) after the completion of formal schooling. The period 
of employment at the LNCM ranged between 1-16 years. The average number of years of 
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experience in using the MiniLab® was five. Furthermore, all participating technicians had used 
the MiniLab® for testing ACTs in the three months prior to this study. 
5.2.2 Study materials 
Samples of ADs for testing were provided by the LNCM from a repository of medicines 
previously collected as part of routine medicine quality surveys conducted nationally. The 
laboratory manager stated that these samples had undergone HPLC analysis at the LNCM and 
confirmed to be of acceptable quality. MiniLab® equipment (for the TLC test only) and other 
materials required for the study were provided by the LNCM and, the two reagents and TLC 
plates for the ADT, were provided by Dr Kaur at LSHTM. A full list of equipment and 
procedures for the testing of ACTs using the MiniLab® is available in the GPHF MiniLab® 
manual. [14] The ADT test procedure and list of equipment was included as part of the 
aforementioned manual complied by myself. As Senegal is a francophone country, French 
versions of both manuals were provided to the study participants.  
5.2.3 Study description  
The test evaluation consisted of two laboratory exercises; i) an assessment of the practical utility 
of the ADT and ii) an evaluation of the test performance of both the ADT and the MiniLab®.  
Two focus group discussion (FGD) explored the perceptions of utility, acceptability and 
usefulness of the test. The outcomes of these exercises are structured as follows; 1) methods 
and results of the two exercises assessing the practical utility of the ADT and 2) methods and 
results of the evaluation of test performance of the ADT and the MiniLab®. Both these 
methods and results sections also include relevant data from the FGDs.  
Studies evaluating other screening approaches (primarily early detection for the screening of 
disease and infection) were consulted to inform this investigation and it was found that 
operator agreement in the interpretation of results and adherence to instructions is enhanced 
by consistency in training. [18] For example, a study assessing the measurement of waist 
circumference as part of diagnostic criteria of metabolic syndrome was subject to significant 
inter-operator variability which the authors reported may potentially lead to misclassifying 
patients. Variability was minimised through standardised and consistent training of health 
professionals on how best to measure waist circumference. [19]  Another study evaluating 
assays to detect antibodies of the Hepatitis C virus found that a lower level of agreement 
between operators performing a particular assay was a result of the assay being operated by 
both less experienced users and more knowledgeable laboratory medical technologists with 
the latter group more likely to interpret results correctly. [20]  
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Therefore, prior to undertaking this evaluation, the researcher (ML) liaised with key personnel 
at the LNCM to gain an understanding of local approaches to training on new laboratory tests.  
This learning informed the outlining of the ADT training programme and production of the test 
manual. The researcher (ML) then delivered a training programme consisting of a test 
demonstration, followed by an opportunity for the technicians to carry out the test under 
observation on ADs (provided by the LNCM) with feedback from the researcher.  This training 
was not part of the evaluation and was conducted prior to the formal commencement of the 
study.  
Two FGDs were held with participants one before and one after the laboratory testing of 
samples using the two screening tests. The FGD guides (see annex 8 and 9) were designed on 
the basis of themes relating to the practical utility of both screening tests and the usefulness 
and acceptability of the ADT. The first FGD assessed the perceptions of MiniLab® technology.  
The second FGD focussed on the participant experience of using the ADT alongside the 
MiniLab® test under operational conditions. Overall findings from the evaluation of the 
practical utility of the ADT and evaluation of performance of the two screening assays were 
shared prior to commencement of the second FGD. Where appropriate, responses garnered 
from questionnaires completed by technicians after the each of the two exercises undertaken 
as part of the evaluation of the practical utility of the ADT, were used as points of discussion 
for the second FGD. A research assistant facilitated the FGDs in French and also assisted with 
completion of questionnaires. The FGDs were audio-recorded, then transcribed verbatim in 
French before being translated into English.  
 
1. Assessment of the practical utility of the artemisinin derivative test 
The participants undertook two practical laboratory based exercises and completed a 
questionnaire after each exercise.  
Exercise 1: Test procedure  
This exercise aimed to assess the ability of each of the technicians to adhere to the test 
procedure. The first four steps of the test described previously in this chapter were assessed. 
This exercise did not evaluate step 5 of the test procedure - interpretation of the resultant 
colour reaction, or decision made following each of the test results. Each technician performed 
the ADT using a sub-set of ACT samples (n=10) comprising artemether-lumefantrine (AL) and 
artesunate-amodiaquine (AS-AQ) as these were the most commonly used ACTs in Senegal at 
the time of the fieldwork. Technicians were provided with all necessary equipment for the test, 
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the samples of ACTs, the manual (including the colour chart), and bench aid outlining the test 
procedure. They were assessed on their proficiency in conducting the test based on the 
procedure listed in the manual. A checklist of 16 actions (table 5.2) was created to gauge their 
ability to adhere to the test procedure. Each action was marked with a tick to indicate when it 
was carried out correctly, incorrectly or omitted.  
Table 5.2: Checklist of actions for assessing the adherence to ADT procedures  
Test 
procedure 
action 
Description 
1 Sample preparation (1); pulverise and dissolve in 10 ml of methanol 
2 Sample preparation (2): Sonicate for appropriate length of time (approx. 5 minutes) 
depending on pulverisation 
3 Sample preparation (3): Appropriate tablet breakdown/sedimentation and use of 
centrifuge if required 
4 Sample preparation (4): Appropriate labelling of sample (vial or Eppendorf tube) 
5 TLC preparation (1): Draw square or circular shapes roughly 1cm2 or 1cm in diameter 
6 TLC preparation (2): Correct labelling of squares/circles 
7 Spotting (1): Drawing up of supernatant 
8 Spotting (2): Correct spotting of methanol within square/circle (2x5µl) (volume) 
9 Spotting (3): Correct spotting of tab within square/circle (2x5µl) (volume) 
10 Spotting (4): Correct spotting of DNP to within square/circle (1x5µl) (volume) 
11 Spotting (5): Correct spotting of FBS to within square/circle (1x5µl) (volume) 
12 Development (1): Correct storage of plate away from sunlight 
13 Development (2): Plate read after 40 minutes 
14 Development (3): Appearance of plate after testing and development 
15 Additional steps (1): Pipette replaced after spotting of each methanol/sample 
16 Additional steps (1): Pipette replaced after spotting of DNP 
 
A questionnaire (annex 6) on initial perceptions of the ease of use of the test was given to each 
technician to complete after step 4 (the colour development). The questionnaire included a 1-
5 scale to rate specific aspects of the assays such as the ease of carrying out each action as well 
as broader open and closed questions relating to their overall perceptions of the test e.g. 
difficulties encountered with the assays and aspects of the test that they favoured. 
Each participant consecutively undertook the assessment conducting the test following the 
instructions outlined in the manual. For each sample tested, the researcher observed and 
recorded whether each of the 16 actions was performed correctly, scored as 1= action 
performed correctly or 0= action incorrect or omitted. For each technician, a total score out 10 
(representing the total number of samples tested) was assigned for each of the 16 steps 
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(maximum score 160). Any incorrect or omitted action at an early stage in the testing process 
would be expected to have an impact on the latter steps of the procedure i.e. result and 
interpreting the result of the colour produced for each assay. 
Technicians scored lowest on actions 4 and 6 which involved the labelling of sample vials and 
the test card (TLC plate) (see bar graph and annex 5). Overall, 50% and 37.5% of technicians 
either omitted or performed actions 4 and 6 incorrectly. There were no obvious reasons for 
this issue to arise when explored during the FGDs. Scores ranged from 120 (technician 2) to 
158 (technicians 4 & 6) with an average technician score of 143 (calculated from totalling all 
technician scores and dividing by number of technicians (n=8)). Time to completion for all 10 
samples ranged from 33 mins to 90 minutes. The average length of time to complete the tests 
(not including the time taken for the colours to develop) was 58.5 minutes (around 6 minutes 
per sample). Technician 6 had been in post at the LNCM for 16 years.  Technician 4 had the 
most advanced academic qualifications with a Master’s degree in Analytical Chemistry from 
UCAD. 
 
Figure 5.4: Bar graph representing total score for each technician for adherence to test procedure  
 
The questionnaire administered to each technician after the exercise requested a rating of 1-5 
(1= very difficult to use, 5 = very easy to use) of various aspects of the test procedure. The 
results suggested that overall the test procedure was simple to follow, illustrated by the 
average rating of 5 which was assigned to several aspects of the test including content of the 
training manual, the bench aids, preparation of sample and TLC plate, spotting of 
solution/reagents and the development of test results. The technicians were also encouraged 
by the negligible risk of reagent toxicity, as a result of using minute volumes.  
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‘It is a rapid test, the interpretation is easy, it does not necessitate many toxic solvents, 
and with good organization it can be done very easily. I do not need to be a laboratory 
person to use it.’ Technician  
 
A few technicians suggested the time taken for results to develop as a limitation of the test. 
The appearance of the pink and blue colour indicating the presence of an AD may take up to 
40 minutes. The technicians mentioned that after around 40 minutes both blue and pink 
colours had appeared but to view the true depths of colours took a few hours. Nonetheless, 
they suggested a longer development time was offset by a swift preparation time.  
 
Exercise 2: Results Interpretation 
This exercise focussed on step 5 of the test and aimed to establish the extent to which each 
technician correctly interpreted results from the ADT and their resulting decision in sending a 
sample for confirmatory testing. For this exercise each technician was provided with a pre-
prepared standardised set of results i.e. images from colours produced by AD samples 
following testing by the ADT. Hence, all technicians examined the same set of results.  
To aid in the interpretation of the test results, technicians were requested to refer to the 
colour chart included in the ADT manual. An extract from the chart is presented in figure 5.5 
below.  
 
Figure 5.5: Extract from colour chart showing dihydroartemisinin-piperaquine included as part of the ADT manual. 
Poor quality samples produce pale pink or pale blue/grey colours (some SAPI) or there is an absence of those 
colours (absence of SAPI).  
 
The technicians were requested to interpret the colours produced following the testing of 
ACTs at LSHTM. The colours from samples included in this exercise were selected purposively, 
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to include acceptable pharmacopeial quality and poor quality ACTs containing artemether, 
artesunate and dihydroartemisinin. The ACTs used for this exercise had all been previously 
tested at LSHTM using HPLC-PDA and were of acceptable pharmacopeial quality. The poor 
quality samples were created by Dr Kaur at LSHTM by diluting acceptable pharmacopeial 
quality ADs to create samples with some API (pale pink and blue colours) and methanol alone 
to create samples with zero SAPI. The resulting colours were subsequently photographed, and 
the images provided to the technicians for interpretation. The approach used in this exercise is 
similar to that used for evaluating the interpretation of results by operators for rapid 
diagnostic tests (RDTs) for detecting malaria parasites, whereby participants are blinded to the 
identity of the samples and only provided with the results. [21]  
Participants were requested to record their results including whether the colour produced 
represented (i) an acceptable pharmacopeial quality AD or (ii) poor quality AD that should be 
sent for confirmatory testing (by pharmacopeia methods). Furthermore, technicians were 
requested to state on the recording sheet for each of the ten colours a level of confidence 
between 1 (no confidence) – 5 (very confident) in their decision to send the sample for 
confirmatory testing (or not). A questionnaire (annex 7) on initial perceptions of the ease of 
interpretation of test was provided after the exercise. The questionnaire included a 1-5 scale 
for technicians to rate specific aspects of step 5 of the test (results interpretation) e.g. clarity 
of colours (images), ease of categorisation (acceptable/poor quality) etc. Broader open and 
closed questions were also included and related to their overall perceptions of interpreting 
results such as which colour they preferred to interpret and the extent in their confidence of 
making a decision in sending a sample for confirmatory testing (or not). 
The proportion of correct answers (see table 5.3) ranged from 37.5% (3/8 technicians) for 
colours 7 and 9 (poor quality ACT, some API) to 100% for colours 1 and 8 (acceptable 
pharmacopeial quality ACT). Furthermore, the mean confidence ranged from 4.0 (colour 5, 
acceptable pharmacopeial quality ACT) to 4.9 (colours 1 & 8, acceptable pharmacopeial quality 
ACT). Of the five colours (1, 3, 5, 8 and 10) representing acceptable pharmacopeial quality 
samples of ACTs, only two colours (1 & 8) were correctly identified by all technicians. The 
mean confidence of 4.9 for each of these colours indicated that the technicians had a high 
level of confidence in their decision to not send the sample for confirmatory testing. The 
remaining five colours of ACT samples (2, 4, 6, 7 and 9) represented poor quality samples. 
Colours 2 and 6 (zero SAPI) were correctly identified by 62.5% and 75% of technicians. Of the 
poor quality (some API) colours, two colours (7 & 9) received the lowest proportion of correct 
answers (37.5%) as these were misinterpreted as acceptable pharmacopeial quality. These 
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colours were obtained from quality assured ACTs that were intentionally diluted to contain 
some API, hence pale colours (blue and pink). The mean confidence for each these colours was 
4.1 indicating that some of the technicians were less confident in their decision to send the 
sample for confirmatory testing or not. The lowest confidence mean was for image 5, an 
acceptable pharmacopeial quality ACT, yet only one technician incorrectly identified this 
sample as poor quality.  
Technician 1 correctly identified each sample whereas technicians 3 and 5 only managed to 
achieve scores of 4/10 (40%). Overall, the average score for all technicians was 55% (5.5/10), 
suggesting the result interpretation of the ADT (step 5) is less straightforward than 
undertaking the preparation of the sample (steps 1-4).  
Table 5.3: Summary of results from results interpretation exercise  
Blue colours are produced from samples tested using FBS (3, 7, and 10). Pink colours are produced from samples 
tested using DNP (1, 4, 5, 8, 9). Deep blue and pink colours represent acceptable pharmacopeial quality (APQ) 
drugs. The pale pink and blue colours represent poor quality samples (with some SAPI). The absence of colour 
produced in no. 2 and 6 show that they do not contain any SAPI and are falsified. (** Mean Confidence obtained 
from average of individual confidence scores (out of a maximum total of 5) from each technician as follows: for 
each colour (sample) the confidence scores provided by each technician were totalled and then divided by the 
number of technicians (n=8).) 
Colour 
number  
1 2 3 4 5 6 7 8 9 10 
Quality of 
ACT sample 
and colour 
produced 
 
APQ 
 
 
 
 
 
Poor 
quality 
(zero 
SAPI) 
 
 
APQ 
 
 
 
 
 
 
Poor 
quality 
(some 
SAPI) 
 
 
APQ 
 
 
 
 
 
Poor 
quality 
(zero 
SAPI) 
 
 
Poor 
quality 
(some 
SAPI) 
 
 
APQ 
 
 
 
 
 
Poor 
quality 
(some 
SAPI) 
 
 
APQ 
 
 
 
 
 
Send for 
confirmatory 
testing 
No Yes No Yes No Yes Yes No Yes No 
Proportion of 
technicians 
correctly 
identifying 
colour (%) 
100 
(8/8) 
62.5 
(5/8) 
75 
(6/8) 
62.5 
(5/8) 
87.5 
(7/8) 
75 
(6/8) 
37.5 
(3/8) 
100 
(8/8) 
37.5 
(3/8) 
75 
(6/8) 
Mean 
Confidence 
** 
4.9 4.9 4.8 4.5 4 4.6 4.1 4.9 4.1 4.4 
 
Results from the questionnaire showed that the average rating on different aspects of results 
interpretation (step 5 of the test) were quite high overall (4/5 or 5/5 for all aspects) despite 
quite low scores achieved by some of the technicians. Overall the results showed a propensity 
for some technicians to incorrectly classify colours from samples of poor quality ACTs with 
some API (that would be regarded as substandard medicines) as acceptable pharmacopeial 
quality and worryingly high levels of confidence, even in the incorrect decisions made. This 
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inconsistency between perception and actual results from using the test was best exemplified 
by a finding from the questionnaire responses which showed an average rating of 5 for ‘overall 
confidence in decisions made.’ The free text responses from the questionnaire suggested that 
most ‘preferred’ the pink colour as it was more discernible than the blue.  
Responses from the FGDs suggested that the technicians thought that the acceptable 
pharmacopeial quality colours were easily identified. All stated they were less certain about 
the pale pink or blue colours (4, 7 & 9, with some API) as this caused confusion as to whether 
to classify them as acceptable pharmacopeial quality or poor quality and hence, whether to 
send for confirmatory testing. The average score of acceptable pharmacopeial quality samples 
was much higher than the poor quality samples, 87.5% compared to 45.8%. Indeed, one 
technician suggested that given the uncertainty over the depth of colours, the test specificity 
and sensitivity needed to be established for when the ‘KIT’ of the test is formatted. Another 
technician also highlighted that samples with more API (exceeding pharmacopeia tolerance 
limits) would also be substandard and that these would not be identified by the test as the 
colour maybe very deep and assumed to be of acceptable quality. Moreover, some felt that 
due to the variation in both colours in terms of depth it would be difficult to quantify the API in 
a sample. One suggested that an acceptable pharmacopeial quality sample could be validated 
by providing a colour chart with colours representing an API of between 80% and 100%. 
Another technician felt that the creation of a more comprehensive colour chart with all the 
reference standards for commercially available ARDs would simplify interpretation. 
‘We cannot quantify the active ingredient in a sample based on the image. The image 
shows us if the active drug is there or not, nothing else. The deeper it is the better 
quality of drug but it is difficult to be accurate.’ Technician  
 
Further insights from focus group discussions on the acceptability and usefulness of the ADT 
Technicians believed the test would be very useful for the MQSS in light of obtaining a visual 
result in the form of easily identifiable colours. It was suggested that the test could be used by 
drug inspectors to perform spot checks or follow up reports of poor quality medicines, or at 
the point of care where a treatment provider at a health facility level doubted the quality of an 
ACT. The technicians acknowledged that despite the test’s merits (rapid sample preparation, 
ease of use etc.) ultimately, its use in Senegal would be determined by their superiors but it’s 
relatively low material cost and portability may appeal to the Ministry of Health (MoH). With 
respect to usefulness and acceptability of the test, no limitations were identified.  
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‘In the regional hospitals, we have treated patients with artemether lumefantrine and in 
5 or 10 we did not see any improvement. If we had this test we can immediately contact 
the regional inspector who can come and do this test rapidly and take a decision. I think 
this test is for that, an urgent case.’ Technician  
 
2. Evaluation of the performance of the artemisinin derivative test and the MiniLab® 
TLC test 
Samples of ADs (comprising dihydroartemisinin as monotherapy and as part of various ACTs, 
including artemether-lumefantrine and artesunate-amodiaquine) collected in Senegal through 
routine medicine quality surveys were tested by each method: ADT and MiniLab® TLC test. At 
the time of the study in 2014, artemether-lumefantrine and artesunate-amodiaquine were 
first-line medicines for the treatment of uncomplicated P.falciparum malaria in Senegal. [22] 
Furthermore, ACTs had been adopted as first-line treatment by 14 countries in West 
Africa.[23] The testing of the samples was carried out by each laboratory technician 
participating in the evaluation (20 samples tested by each screening test, n=40). The 
performance of each test when carried out by local technicians under the environmental 
conditions typically found in LIMCs, was evaluated. Technicians were provided with samples of 
acceptable pharmacopeial quality and poor quality ADs to reflect a possible broad spectrum of 
the artemisinin based formulations available in Senegal. Acceptable pharmacopeial quality ADs 
provided by the LNCM were diluted by ML and the LNCM laboratory manager to create poor 
quality samples with some API. This was necessary as no substandard or falsified ADs were 
available at the LNCM for testing. The samples provided comprised AD tablets crushed and 
dissolved in methanol. This is the preliminary step in test procedures for ADs when using both 
the MiniLab® and the ADT.   
To reduce response bias, the technicians were blinded to the identity of the samples by 
labelling sample bottles 1-20 for the ADT and samples labelled as 21-40 for the MiniLab® (see 
table 5.4 and 5.5 below). To enable the technicians to carry out the appropriate test procedure 
for the ADs with the MiniLab® (which differs slightly depending on the AD) for each sample, 
they were provided with the name of the medicine and dosage e.g. artemether-lumefantrine 
20mg. No information on the quality of the sample was provided. The samples provided 
contained ADs of varying available dosages.  Overall, 5/20 samples were diluted to create poor 
quality medicines with some SAPI (10% and 40%). Paracetamol (white tablet) and amodiaquine 
(yellow tablet) were selected to represent dihydroartemisinin (white tablet) and artesunate-
amodiaquine (yellow tablet, due to the yellow amodiaquine component). These negative non-
AD controls represented the falsified (zero SAPI) ADs. They were labelled as dihydroartemisinin 
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40mg (n=1) and artesunate-amodiaquine 50mg (n=2) so as to blind the technicians to their 
actual identity.  
Participants were encouraged to follow the procedures outlined in the ADT manual. Use of the 
MiniLab® manual was optional as all participants were familiar with the outlined procedures. 
The evaluation of the performance of the two screening methods was undertaken separately. 
First, the technicians undertook testing of the samples using the ADT. Once this was completed 
they tested samples using the MiniLab®. Observation of adherence to test procedures was not 
undertaken for either test. In terms of classifying the results, the participants were asked to 
make a dichotomous decision; pass or fail for the MiniLab® (based on the 80% pass mark from 
TLC) and whether they would send a sample for confirmatory analysis (or not), for the ADT 
(further testing was unnecessary for the ADT if the appropriate depth colour was observed). 
Results from Performance of ADT 
All samples containing zero SAPI ((1, 6 and 17) poor quality representing a falsified medicine) 
were correctly identified by all the technicians and sent for confirmatory testing. Only half of 
the samples of acceptable pharmacopeial quality ADs (6/12) that contained the correct SAPI 
(samples 2, 5, 13, 15, 16, 18), were correctly identified by all technicians as not requiring 
confirmatory testing (table 5.4). The samples that contained some SAPI (with pale pink or blue 
colour) were less likely to be correctly allocated, a challenge highlighted by many technicians in 
the result interpretation exercise. Of the five ‘some SAPI’ samples, only sample 12 of AL 20mg 
(containing 10% SAPI) was correctly allocated as requiring further testing by all technicians. 
The three samples with 40% SAPI were the least likely to be classified correctly; sample 8 (25% 
of technicians), sample 10 (37.5%) and sample 14 (12.5%). These ‘some SAPI’ samples were 
more frequently misclassified as acceptable pharmacopeial quality, not needing to be sent for 
further investigation. 
Technicians were also requested to provide a level of confidence (1= low confidence, 5= high 
confidence) in whether they were making the correct decision to send the sample for 
confirmatory testing (or not). The highest mean confidence of 5.0 was for each of samples 1, 4, 
15, 18 & 20. Sample 1 was amodiaquine (zero SAPI) and the other samples (4,5, 18 & 20) were 
of acceptable pharmacopeial quality ADs. The lowest confidence mean was 4.3 for each of 
samples 3 & 8, both of which were poor quality (some SAPI) artesunate-amodiaquine. Of 
interest, the lowest scoring sample (14 - only correctly allocated by one technician) had a 
relatively high confidence mean of 4.9 suggesting that technicians had a high level of 
confidence in their incorrect decision. 
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Table 5.4: Summary of results from test performance of the ADT  
Proportion (%) represents responses correctly categorised by sample e.g. 37.5% indicates only 3 out of 8 
technicians recorded the correct response. The mean confidence was obtained from the average of individual 
confidence scores out of a total of 5 from each technician as follows: for each colour (sample) the confidence 
scores provided by each technician were totalled and then divided by the number of technicians (n=8). APQ = 
acceptable pharmacopeial quality 
 
Performance of the GPHF MiniLab® 
Of the 12 samples of acceptable quality, seven (22, 23, 25, 26, 30, 36, 37) were correctly 
identified and categorised as a pass (table 5.5) by all technicians. Of the three samples (24, 35, 
40) that contained zero SAPI only one individual technician incorrectly allocated sample 35, the 
remainder were correctly categorised. Poor quality samples that contained some SAPI were 
often allocated incorrectly. Indeed, only sample 38 (artesunate-amodiaquine 50mg, 10% SAPI) 
was correctly allocated as a fail by all technicians. The remaining samples were incorrectly 
allocated as being of acceptable pharmacopeial quality and hence passed (confirmatory testing 
not required); sample 27 (50% of technicians), sample 29 (75%), sample 31 (37.5%) and sample 
S
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Sample provided for screening (n=20) Correct classification  Proportion 
of samples 
classified 
correctly 
(%) 
Mean 
confidence 
AD type and dosage SAPI Quality Confirmatory 
testing 
required 
1 Amodiaquine No AD Poor quality  Yes 100 (8/8) 5.0 
2 Artemether-Lumefantrine 20mg Correct SAPI APQ No 100 (8/8) 4.9 
3 Artesunate-Amodiaquine 50mg 10% SAPI (diluted) Poor quality Yes 62.5 (5/8) 4.3 
4 Artemether-Lumefantrine 20mg Correct SAPI APQ No 87.5 (7/8) 5.0 
5 Artesunate-Amodiaquine 100mg Correct SAPI APQ No 100 (8/8) 4.9 
6 Amodiaquine No AD Poor quality Yes 100 (8/8) 4.8 
7 Artemether-Lumefantrine 20mg Correct SAPI APQ No 75 (6/8) 4.4 
8 Artesunate-Amodiaquine 50mg 40% SAPI (diluted) Poor quality Yes 25 (2/8) 4.3 
9 Artemether-Lumefantrine 20mg Correct SAPI APQ No 50 (4/8) 4.9 
10 Dihydroartemisinin 40mg 40% SAPI (diluted) Poor quality Yes 37.5 (3/8) 4.5 
11 Artesunate-Amodiaquine 50mg Correct SAPI APQ No 75 (6/8) 4.5 
12 Artemether-Lumefantrine 20mg 10% SAPI (diluted) Poor quality Yes 100 (8/8) 4.5 
13 Artemether-Lumefantrine 80mg Correct SAPI APQ No 100 (8/8) 4.9 
14 Artemether-Lumefantrine 80mg 40% SAPI (diluted) Poor quality Yes 12.5 (1/8) 4.9 
15 Artesunate-Amodiaquine 100mg Correct SAPI APQ No 100 (8/8) 5.0 
16 Dihydroartemisinin 40mg Correct SAPI APQ No 100 (8/8) 4.9 
17 Paracetamol No AD Poor quality Yes 100 (8/8) 4.9 
18 Dihydroartemisinin 40mg Correct SAPI APQ No 100 (8/8) 5.0 
19 Artesunate-Amodiaquine 50mg Correct SAPI APQ No 62.5 (5/8) 4.8 
20 Artemether-Lumefantrine 20mg Correct SAPI APQ No 87.5 (7/8) 5.0 
     Overall 
mean = 
78.8% 
Overall 
mean= 4.8 
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33 (75%). The lowest score was for sample 31 of dihydroartemisinin which contained 40% SAPI 
(poor quality). 
Samples 22, 26 & 36 were all acceptable pharmacopeial quality and each had the highest mean 
confidence of 5.0. The lowest confidence mean (4.0) was for sample 31 (dihydroartemisinin 
40mg with 40% SAPI) which also had the lowest score in terms of correct classification as a 
‘fail.’ 
Table 5.5: Summary of results from test performance of the GPHF MiniLab® 
 
S
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Sample provided for screening (n=20) 
 
Correct classification Proportion of 
samples 
classified 
correctly (%) 
Mean 
confidence 
AD type and dosage SAPI Quality Pass/Fail   
21 Artemether-Lumefantrine 20mg Correct SAPI APQ Pass 75 4.9 
22 Artesunate-Amodiaquine 50mg Correct SAPI APQ Pass 100 5.0 
23 Dihydroartemisinin 40mg Correct SAPI APQ Pass 100 4.6 
24 Paracetamol No AD Poor quality Fail 100 4.5 
25 Dihydroartemisinin 40mg Correct SAPI APQ Pass 100 4.6 
26 Artesunate-Amodiaquine 100mg Correct SAPI APQ Pass 100 5.0 
27 Artemether-Lumefantrine 80mg 40% SAPI (diluted) Poor quality Fail 50 4.5 
28 Artemether-Lumefantrine 80mg Correct SAPI APQ Pass 87.5 4.9 
29 Artemether-Lumefantrine 20mg 10% SAPI (diluted) Poor quality Fail 75 4.4 
30 Artesunate-Amodiaquine 50mg Correct SAPI APQ Pass 100 4.8 
31 Dihydroartemisinin 40mg 40% SAPI (diluted) Poor quality Fail 37.5 4.0 
32 Artemether-Lumefantrine 20mg Correct SAPI APQ Pass 87.5 4.6 
33 Artesunate-Amodiaquine 50mg 40% SAPI (diluted) Poor quality Fail 75 4.6 
34 Artemether-Lumefantrine 20mg Correct SAPI APQ Pass 87.5 4.8 
35 Amodiaquine No AD Poor quality Fail 87.5 4.5 
36 Artesunate-Amodiaquine 100mg Correct SAPI APQ Pass 100 5.0 
37 Artemether-Lumefantrine 20mg Correct SAPI APQ Pass 100 4.9 
38 Artesunate-Amodiaquine 50mg 10% SAPI (diluted) Poor quality Fail 100 4.8 
39 Artemether-Lumefantrine 20mg Correct SAPI APQ Pass 62.5 4.9 
40 Amodiaquine No AD Poor quality Fail 100 4.5 
 Overall mean = 
86.3% 
Overall 
mean= 4.7 
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Comparison of performance of both screening tests 
The average proportion of responses correctly categorised for each sample is slightly higher for 
the MiniLab® than the ADT (table 5.6) which may be attributable to the differing level of 
experience of using the two technologies. Prior to this exercise the technicians used the ADT 
on just two occasions yet they had an average of 5 years of experience of using the MiniLab®. 
Despite greater familiarity with the MiniLab® there was marginally less confidence in the 
results obtained with it than with the ADT.  
The average proportion of correctly allocated responses for acceptable pharmacopeial quality 
SAPI was slightly higher for the MiniLab®, although for both tests, proportions were quite low 
overall for the ‘some SAPI’ samples. The ADT showed marginal advantage over the MiniLab® in 
allocating poor quality ARDs (zero SAPI) for confirmatory testing. Generally, for both tests, 
technicians appear to be more confident in detecting samples of acceptable pharmacopeial 
quality as opposed to samples of poor quality (both some and zero SAPI). 
Table 5.6: Results summarised by quality of AD for both screening tests  
(The results presented here were not subject to statistical testing due to a small sample size) 
Quality of 
sample 
Acceptable 
pharmacopeial 
quality 
Poor quality (some 
SAPI) 
Poor quality (zero 
SAPI) 
Overall 
performance 
Screening 
Test 
GPHF 
MiniLab® 
ADT 
GPHF 
MiniLab® 
ADT 
GPHF 
MiniLab® 
ADT 
GPHF 
MiniLab® 
ADT 
Average 
proportion 
of responses 
correctly 
catergorised 
by sample 
(%) 
91.7 86.4 67.5 47.5 95.8 100 86.3 78.8 
Confidence 
mean 
4.8 4.8 4.4 4.9 4.5 4.5 4.7 4.8 
 
Practical utility of the MiniLab® - operator error 
Overall, the findings suggested a high level of confidence in the results obtained when using 
the MiniLab® even when these decisions were incorrect. Nonetheless, the notion of operator 
error was a prominent emerging theme from the FGDs with technicians believing that the 
MiniLab® was at higher risk of error at two stages of the testing process. Firstly, sample 
preparation consists of several steps, and technicians mentioned that a lack of adherence to 
test procedures might lead to erroneous results. Secondly, some technicians believed that a 
sample could be misclassified as a ‘pass’ when it was in fact doubtful or a ‘fail’ (and vice versa) 
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because the test operator had misinterpreted the result. This was shown to be the case in this 
study with some of the 40% SAPI samples allocated incorrectly as a pass and hence deemed to 
be of acceptable quality.  MiniLab® TLC instructions for all ADs are quite specific and state that 
spots from reference standards and the sample must correspond in terms of size, intensity, 
shape and distance travelled. This aspect of the test relies upon the subjective judgement of 
the operator and the technicians suggested that this could potentially lead to misclassification 
error and be the most common reason for any inter-operator variability.  
Technicians stated that the colorimetric basis of the ADT made it easier to interpret the 
results. Identification of the correct colour to indicate the presence of an ART may reduce the 
risk of misclassification error. That said, test performance results in this study were to the 
contrary and the ‘some SAPI (poor quality) samples’ were more often classified correctly by 
the MiniLab® than the ADT (67.5% vs 47.5%) which may have been due to the technician’s 
greater experience of using the MiniLab®. 
Sensitivity and specificity of the two tests 
Sensitivity and specificity parameters were realised as key attributes of screening tests as 
stated in the introduction to this section. Indeed, in the context of medicine quality screening a 
test ought to be highly sensitive and produce minimal ‘false passes’ i.e. pass the lowest 
proportion of poor quality medicines as is possible. The comparison with the gold standard in 
table 5.7 refers to the samples being of acceptable pharmacopeial quality following analysis by 
HPLC at the LNCM. 
Table 5.7: Sensitivity and specificity of the GPHF MiniLab® and the ADT 
 Gold Standard (HPLC) 
GPHF MiniLab®- pass or fail Pass Fail Total 
Pass 88 (86.3%) 8 96 
Fail 14 50 (86.2%) 64 
Total 102 58 160 
ADT – send for confirmatory testing Pass Fail Total 
No 83 (81.3%) 13 96 
Yes 19 45 (77.6%) 64 
Total 102 58 160 
 
The MiniLab® demonstrated a sensitivity of 86.3% (95% Cl, 78.0 %, 92.3%) and a specificity of 
86.2 (95% Cl, 74.6%, 93.9%). In comparison, the ADT sensitivity was 81.3% (95% Cl, 72.5%, 
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88.4%) and specificity 77.6% (95% Cl, 64.7%, 87.5%). The results suggest the MiniLab® is 
marginally more accurate than the ADT. In light of these findings, it was reassuring that during 
the FGDs the technicians acknowledged the importance of pharmacopeia methods and not 
relying solely on results from screening tests.  
Practical comparisons of the two tests 
Technicians described some of the positive and negative aspects about the MiniLab®. They 
mentioned that that once familiarity with test procedures was acquired, the MiniLab® was 
quite simple to operate. Another suggested advantage of the MiniLab® was its capability to 
test a wide range of medicines.  
There was debate regarding the amount of time taken to prepare and analyse samples, with 
some technicians suggesting the testing time was comparable between the two tests and 
others stating that the MiniLab® took up to 30 minutes longer (per sample). Overall the 
technicians thought the preparation phase of the MiniLab® was lengthy but the transition to 
the results phase was quite quick.  Personal experience of the two tests corroborates the view 
of a lengthier testing time overall with the MiniLab®. Furthermore, overall, the evaluation of 
the performance of the ADT was completed by the technicians more quickly in comparison to 
the MiniLab® evaluation. The hazardous nature of some reagents, lack of portability and the 
need to use a development chamber and fume cupboard, were identified as limitations of the 
MiniLab®. These characteristics limit its suitability for use in peripheral laboratories that are 
less well-equipped and in field surveys. For ADs, the technicians felt that overall, the ADT was a 
more preferable test to use than the MiniLab® especially in non-laboratory settings as it was 
quicker (in sample preparation), simpler to use, potentially lower in cost, more portable 
(handheld), safer and easier to interpret its results. 
 
5.3 Discussion 
The key attributes of screening tests make them a potentially integral component of post-
marketing surveillance activities. Given the large number of samples a screening test is likely to 
screen, it ought to be inexpensive to purchase and maintain, easy to use and portable 
(preferably handheld). [15, 24-27] Additionally, an ideal medicine quality screening test ought 
to be highly sensitive and produce minimal ‘false’ passes. Whilst the utilisation of screening 
tests as part of a MQSS is important, the accuracy of the results they provide must be better 
understood. All new tests that are developed must to be evaluated against confirmatory 
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methods as well as the most utilised screening test such as the MiniLab® to identify their 
relative merits and drawbacks in comparison with existing technologies.  
This chapter presents a study that aimed to evaluate the practical utility of the ADT as well as 
perceptions of its usefulness and acceptability following ‘field’ testing in an LMIC. It evaluated 
the performance of the test by a small sample of first time users with no prior familiarity, in its 
intended LMIC setting within the specific context of use by laboratory technicians in the 
national MQCL in Senegal, who are routinely engaged in medicine quality surveillance. In initial 
product testing under controlled laboratory conditions at LSHTM, the ADT was shown to 
specifically detect ADs (in monotherapy and combination treatments) producing distinct pink 
and blue colours. [15] In comparison, the MiniLab® produces generic spots for the ADs that 
lack a characteristic colour. The study findings suggest the laboratory technicians found it to be 
marginally easier to distinguish a poor quality sample with zero SAPI (absence of colour), with 
the ADT than with the MiniLab®. In contrast, the MiniLab® was slightly superior in detecting 
acceptable pharmacopeial quality AD samples.  
Furthermore, the MiniLab® was also shown to be somewhat superior in detecting the ‘some 
SAPI’ samples i.e. less likely than the ADT to classify them incorrectly as acceptable 
pharmacopeial quality samples.  The reason for this may partly be attributed to the previous 
experience of using the MiniLab® by the technicians, who did report some confusion in 
appreciating the resulting colour from the ADT. This may explain the slightly inferior sensitivity 
and specificity of the ADT (81.4% and 77.6%) in epidemiological terms compared to the 
MiniLab® (86.3% and 86.2%). The MiniLab® has previously been reported to overestimate 
(false passes) [28, 29] and underestimate the quality of a medicine (false fails) [28] and is 
thought to be ‘’only capable of detecting counterfeit (zero SAPI) or grossly substandard (very 
low SAPI) medicines.’’ [7] This was also found in this study as the three samples with some 
SAPI (40%) scored an average of 52.4% in terms of their correct classification. This average 
score was even lower for the ADT at just 25%. The detection of medicines containing the 
correct active ingredients, but at sub-therapeutic concentrations, thus remains a challenge for 
assessing medicine quality using screening tests in general.    
Hence, these findings confirm that TLC chromatographic screening tests can detect acceptable 
quality, very poor quality (with very low SAPI) and medicines with zero SAPI the majority of the 
time but risk allowing medicines with some SAPI (between 40% and 80 % SAPI) to ‘pass’ 
meaning that substandard medicines [30] may continue to circulate in a country. The impact of 
substandard antimalarials has been purported as detrimental to public health due to 
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inadequate treatment of infection, resulting in recrudescence with the risk of progression to 
severe disease. This in turn increases the burden on already strained health systems, wasting 
valuable financial and human resource. [9] Neither screening test can give definitive results on 
the amount of SAPI in a sample, and both are also at risk of operator error due to their reliance 
upon a subjective judgement which may lead to misclassification of medicines with some API 
as acceptable quality, when they are in fact substandard. This suggests that the fallibility of 
these screening tests may be a risk factor for the persistence of substandard medicines in a 
country. This is particularly concerning in light of recent findings of a higher prevalence of 
substandard as opposed to falsified antimalarial medicines detected using confirmatory 
tests.[31-33]  
Operator error has been documented as a problem in the diagnosis of infectious diseases using 
RDTs. In the case of HIV, RDT over interpretation by test users who viewed a weak reactive test 
as a HIV positive result led to misdiagnosis in some cases. [34] An apparent low specificity of 
some malaria RDTs has been attributed to misinterpretation of results by operators leading to 
a higher number of false positive results whereby individuals without malaria are thought to 
have infection and hence are inappropriately treated. [35] Additionally, in both these studies a 
lack of adherence to the test methodology was cited as a potential reason for error. Strict 
adherence to test instructions is vital when using point of care tests. [36] In our study, the 
MiniLab® procedures carried out by the technicians were not observed. Observation of the 
ADT procedure in exercise 1 found that only one technician failed to adhere correctly to the 
procedure and in that instance the test did not work. Technician’s also citied inter-operator 
variability as a risk factor for erroneous results with the MiniLab®. A kappa value for inter-
operator variability could not be calculated due to multiple operators. Even so, the data 
suggests that variability does exist in this sample of technicians although it is difficult to 
associate with the personal characteristics of the technician.  
However, the issues highlighted here concerning operator error may be because of a key 
limitation of both tests, the need for a subjective judgement; on the intensity of a colour 
reaction for the ADT and an assessment of the distance travelled by the spot on the TLC plate 
or the variation in its shape, size etc. for the MiniLab®.  Moreover, the vagueness of results as 
identified by the technicians from the ‘some API’ samples (substandard) in this study for both 
tests led to some of these samples being misclassified as acceptable quality. The findings from 
this study further demonstrate the need for caution when interpreting results from these two 
screening tests with any doubt about the quality of a medicine sample resulting in its referral 
for confirmatory testing. 
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My research also found that the MiniLab® and the ADT have similar attributes, yet they are 
quite different in terms of foreseeable roles within a MQSS. The former has been reported as a 
feasible technology for use outside of the laboratory [11] which is contrary to personal 
experience and to the findings from the FGDs in this study. The use of hazardous reagents, the 
need for essential but less portable equipment (with a total weight of 40 kg, bottles of 
reagents and storage jars), the requirement to undergo training as well as some prior 
experience of laboratory work suggest that this technology is best utilised in a laboratory 
environment. The MiniLab® also comes with a supply of solvents that need to be stored in a 
cool dry place. The ADT due to its ease of use, just two reagents and equipment (pipette and 
TLC sheet) has the potential to be formatted into an almost pocket-sized kit, which will enable 
its application in peripheral regional laboratories that lack technical equipment or regular 
power supply or for use by laboratory technicians in field surveys. They could also be used at 
the point of care in health care facilities and deployed when a treatment provider suspects a 
poor quality AD. At the point of entry (land borders or road checkpoints), the ADT could simply 
be utilised to implement spot checks of ADs for their quality. However, the MiniLab® is capable 
of screening the quality of around 85 essential medicines whereas the ADT specifically detects 
ADs only. 
An appraisal of the other currently available screening technologies is discussed in Section 2. It 
appears that the most of the new screening devices entering the market are quite similar to 
the ADT in their design principles; easy to use, handheld and in some cases inexpensive 
allowing the screening of a large volume of samples rapidly. They have also been designed to 
be used outside of laboratory settings with some such as the Counterfeit Detection Device 
(CD3+) being employed to check the quality of medicines at the point of entry into a 
country.[25] A key commonality amongst all new and existing screening devices is their 
capability in detecting very low SAPI or zero SAPI medicines (grossly substandard or falsified 
medicines), yet, their common weakness is the inability to detect ‘some SAPI’ (substandard) 
medicine. Moreover, there is a dearth of information on their accuracy in terms of their 
sensitivity and specificity [5] the former of which is crucial given their proposed use in non-
laboratory settings and especially where confirmatory testing maybe absent. 
5.3.1 Study limitations 
The ADT has been designed to be used in both laboratory and non-laboratory settings, yet, in 
this study only laboratory technicians performed the test in the context of an adequately 
equipped national reference laboratory. Prior to being deployed more widely, the ADT will 
need to be formatted into a kit and piloted with individuals who have minimal recent 
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laboratory experience. It would also need to be evaluated to determine its feasibility, 
practicality and accuracy when used by those working in different sectors such as medicines 
regulation (drug inspectors), healthcare (treatment providers) and customs (border officials). 
Nonetheless, the ADT has been piloted by individuals who had no prior knowledge of this test 
and in a different context in terms of environment, language and prior training. In further 
product testing at LSHTM it was found that increasing humidity and temperature (replicating 
environmental conditions such as those in the tropics) slightly accelerated the development of 
the pink and blue colours. This was not observed in the laboratory in Dakar despite the room 
temperature being warmer and the air more humid. The environment in the laboratory in 
Dakar more closely represents that of other malaria-endemic LMICs. Even so, at the time of 
the study it was winter in Dakar and so it would be expected that future use of the test would 
be in conditions with higher temperatures and humidity than those experienced during this 
study. 
The presence of the researcher (ML) at all times during the study may have skewed the 
perceptions of the technicians to a more favourable view of the ADT test and may account for 
a high level of confidence in interpretation of ADT test results. This is a form of social 
desirability bias [37] whereby an individual provides responses they perceive the researcher 
wants to hear or those that are socially and morally acceptable, although, for the second FGD 
(focus on perception of the ADT), the researcher (ML) was absent. 
Routine practice in Senegal when using the MiniLab® is to repeat the screening of samples that 
fail or are of dubious quality. On repeat testing, if the sample ‘fails’ or if it is still considered to 
be of dubious quality it would be retested with the MiniLab® by a different operator. In the 
evaluation of the performance of both screening tests, technicians did not repeat the 
screening of samples that they identified as poor quality nor were the results subjected to 
verification by a second operator. It is concevible that had the technicians repeated tests on 
the samples that they identified as poor quality they may have changed their decesion as to 
whether they send the sample for confirmatory testing or not, potentially increasing the 
proportion of correct results obtained from using both tests. 
An additional limitation in the evaluation of the two screening tests exercise, was that the 
techncians were provided with already solubilised samples. The process of crushing and 
dissolving a sample in an approriate solvent would normally be carried out by the technician. It 
is not known whether this may have affected the results. 
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5.4 Conclusion 
The ADT is a potentially useful screening test in detecting acceptable, very poor quality or zero 
SAPI ADs, but its ability to identify substandard (between 40% and 80% API) ADs is limited. The 
ADT could be used in a malaria endemic country for proactive point of care testing and at the 
point of entry into a country for specifically testing ACTs. Their ease of use, potential low cost 
and handheld design may appeal to MoHs. It must also be emphasised that as with all 
screening tests, identified suspect medicines should be subjected to confirmatory testing 
based on pharmacopeia methods to confirm actual SAPI. Screening followed by confirmatory 
testing is an integral part of a national MQSS, as is the case in Senegal where all medicines 
collected as part of routine medicine sampling surveys are first tested by the MiniLab® and any 
failing or doubtful quality samples are then analysed by HPLC. Technical capacity in LMICs to 
perform confirmatory testing must be also strengthened and screening technologies should 
work in tandem with well-equipped national and peripheral laboratories to ensure that poor 
quality medicines can be swiftly detected, and valid findings passed on to the appropriate 
national and international authorities to take regulatory action.  
 
5.5 Suggestions for formatting the artemisinin derivative test and the use of the 
GPHF MiniLab® 
In order for the ADT to be used in a malaria endemic country as part of a MQSS a few 
improvements are required. These are listed below along with broader suggestions for 
consideration by MQSS’ in all LMICs with regard to the MiniLab®. 
· A more extensive colour chart for the ADT needs to be created with focus upon how 
an acceptable pharmacopeial quality AD colour appears following testing, to help 
reduce misclassification. There is also a requirement to clarify the instructions on 
sending a sample for confirmatory testing in that any doubts about depth of colour 
should result in a sample being sent for HPLC analysis. The suggestion of adding 
resulting colours for 80% and 100% as a comparator may help in this regard. 
Furthermore, the colour chart should contain the resulting colours for all commercially 
available AD reference standards and be updated on a regular basis. To assist 
operators of the test in the interpretation of results, the colour chart could be further 
sophisticated by exploring colour pixel technology which can detect the depth of 
colour.  
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· The ADT should be piloted in non-laboratory settings with individuals with little or no 
laboratory experience in order to assess its suitability for use by boarder officials, 
treatment providers, etc. 
· The best use of the ADT maybe external to the traditional laboratory network of a 
MQSS and/or as part of the MiniLab® kit for the testing of ACTs only, for example 
when used for field surveys and post-marketing surveillance, for point-of-entry 
screening by land border customs officials, or to confirm medicine quality at point-of-
care by treatment providers prior to supplying or selling ADs to patients. 
· Although already widely used, the MiniLab® could also benefit from further evaluation 
alongside confirmatory testing using pharmacopeia methods to establish its true 
sensitivity and specificity and to determine how this varies between medicines, 
operators and contexts. 
· Where feasible, regular retraining on the MiniLab®, even on an informal basis must 
take place with an emphasis on results interpretation. This could be coupled with 
observation of operators to ensure the test procedure is correctly adhered to. 
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Chapter 6: Reflections, implications and conclusions  
Addressing the problem of poor quality medicines remains a challenge for many low-middle 
income countries (LMICs), compounded by limited regulatory and technical capacity at the 
national level. This thesis has examined the national surveillance system for assuring and 
monitoring the quality of medicines in Senegal, through a series of studies using differing 
methodological approaches to examine several facets of medicines quality surveillance 
systems (MQSS) with the aim to identify challenges to these component parts, how they could 
be addressed and thus how the system as a whole could be strengthened. The evidence 
presented also considers how the quality of information generated by future studies and 
surveys of medicine quality in LMICs could be improved. This final chapter reflects upon the 
implications of my findings for current and future medicines quality related research in LMICs. 
Suggestions are provided for certain components of surveillance systems that require specific 
focus to improve functionality and effectiveness as well as considering priority areas for 
medicines quality related policy.  
 
6.1 External risk factors for poor quality medicines  
Chapter 2 discussed the internal risk factors for poor quality medicines that can be acted upon 
by national governments using findings from interviews in Senegal with the MQSS 
stakeholders including representatives of the key authorities responsible for the system and 
treatment providers. Here I reflect on the external risk factors for poor quality medicines, 
which are beyond the sphere of influence of individual countries, their governments and 
National Medicines Regulatory Authorities (NMRAs). External factors include the high cost of 
medicine to the consumer, medicine shortages, substandard manufacturing practices and 
trade in fraudulent products as well as limited funding for medicines quality assurance at a 
global level and the role of multiple actors. 
Firstly, medicines are commodities, manufactured and marketed by pharmaceutical companies 
who have internal quality assurance and control processes, which provides them with 
confidence in the quality of the medicines they release onto the market. Nevertheless, there is 
variation in manufacturing competence and in quality assurance. Thus, schemes like WHO 
prequalification provide purchasers of medicines from accredited manufacturers (with Good 
Manufacturing Practice certification) with a degree of confidence that these medicines have 
met minimum standards for quality. Pharmaceutical companies and manufacturers are less 
involved in controlling medicines quality once medicines enter national distribution chains [1] 
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as these then become the responsibility of a NMRA. Even so, in resource constrained LMICs in 
particular, where regulatory and technical capacity is lacking, this raises questions regarding 
the corporate moral or social responsibility of pharmaceutical companies and manufacturers. 
Could manufacturers and pharmaceutical companies provide more assistance to support 
national surveillance systems? For example, based on findings in Senegal discussed in chapter 
2, a lack of drug reference standards was identified as a potential weakness of the MQSS by 
representatives of the national medicine quality control laboratory (MQCL). Drug reference 
standards are essential in confirming the quality of a medicine and are thus, integral to the 
medicine quality analysis process. Without them, results on the quality of a medicine are 
meaningless, yet, their procurement cost was often seen as prohibitive. Pharmaceutical 
companies could reduce the cost of drug reference standards when being purchased by LMICs 
either through differential pricing mechanisms or donation. Pharmaceutical companies could 
also offer consultation for the development of medicine quality control and assurance 
processes and training on the utilisation of pharmacopeia methods. 
Secondly, medicines quality assurance is underfunded at an international level which is 
perhaps best exemplified by the WHO prequalification scheme itself being unable to secure 
sustained funding, although there is an element of cost-recovery, by charging the 
manufacturer a fee when applying for pre-qualification status. [2] WHO prequalification has 
evolved over the last decade or so within the context of reports of the existence of poor 
quality medicines (especially in LMICs) and from recognition of the weaknesses of national 
systems for monitoring medicines quality. Assuring medicines quality at source is more cost-
effective than building capacity for medicines quality monitoring and control in resourced 
constrained countries as there are fewer locations in which medicines are manufactured or 
distributed (at the international/national level) compared to the vast numbers of 
outlets/facilities from which they are sold or supplied to the public.  Of further relevance, is 
the Affordable Medicine Facility for Malaria (AMFm) pilot initiative which along with the WHO 
prequalification scheme aimed to supply quality assured ACTs to the regulated sectors in 
LMICs. [3, 4] AMFm also successfully encouraged pharmaceutical companies to reduce the cost 
of ACTs, to make them affordable to consumers in malaria endemic countries, reducing the 
availability and market share of artemisinin based monotherapies and other less effective 
antimalarial medicines.  
Thirdly, my data presented in this thesis from interviews, especially with treatment providers 
highlighted a national problem of medicine shortages. This is a pervasive global challenge and 
not just an issue for Senegal or other LMICs. [5] Medicines shortage is a multifaceted issue 
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with numerous contributory causes, ranging from manufacturing problems (e.g. lack of raw 
material), acute demand (e.g. epidemics), external political and economic factors (poor 
financial incentives for manufacturers, changes in reimbursement and changes in regulatory 
requirements) or marketing, procurement, and supply chain management practices. [6] 
Medicine shortages are a risk factor for poor quality medicines as market gaps may be filled by 
opportune counterfeiters who sell counterfeit or substandard versions of the authentic 
medicines in short supply, at a lower price. [5] 
Finally, a variety of different actors are involved in assessing medicines quality including the 
WHO, pharmaceutical companies, academic institutions, international development agencies, 
and among these exist a range of professions and disciplines such as chemists, pharmacists, 
lawyers, politicians and academics. Whilst this heterogeneity possibly strengthens the pursuit 
of achieving minimum standards for medicines quality it may have also contributed to the 
protracted discussion that delayed agreement on definitions. [1] Furthermore, the inclusion of 
many interest groups with differing priorities leads to an increased risk of inconsistency in 
approaches to assessing medicines quality, as highlighted in chapter 4 whereby a lack of 
standardisation of study designs and reporting may render findings unreliable.  
These external factors demonstrate the need for international cooperation and a national 
system for assuring medicines quality to reduce the likelihood of poor quality medicines 
entering and circulating within a country. 
 
6.2 The gaps in knowledge on medicines quality at a national level 
6.2.1 Medicines quality and the informal health sector  
Findings presented in chapter 2 indicated that in Senegal, there was confidence among most 
stakeholders about the quality of medicines available in the public and regulated private 
sectors which was based on the perception of a robust regulatory system and adequate 
technical capacity to assure and control medicines quality nationally. Nonetheless, the ability 
of the MQAS to protect the public from the risk of poor quality medicines was perceived to be 
undermined by the presence of what was described as a large unregulated informal sector, 
and the absence of surveillance of medicines sold in this sector.  
Based on the interview findings and the evidence from the current literature presented in this 
thesis, the informal sector is possibly the single largest risk factor for poor quality medicines in 
Senegal (and LMICs in which there is a high proportion of unregulated medicine outlets and 
sellers) due to a lack of regulatory oversight and improper medicines storage. Yet, the extent 
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of this risk is unknown as there is little information in terms of the prevalence of poor quality 
medicines available in this sector. Estimates for the proportion of the population accessing the 
informal sector in Senegal are not available but a recent study undertaken in 3 districts in 
Ghana found that of 11,089 individuals surveyed, 31% chose to use informal health care 
services. [7] While this thesis advocates for the use of screening technologies in LMICs 
especially where technical capacity is limited, their impact would be minimal in countries 
where an extensive unregulated informal medicine sector accessed by a large proportion of 
the population exists. Nevertheless, the interview findings suggest that the doubts raised 
about the quality of medicines available through informal outlets, were perceptions based on 
anecdotal reports of poor quality medicines, not on empirical evidence. In the absence of 
empirical data, this widely accepted narrative can remain little more than an unproven belief.  
Private providers (non-governmental facilities) play a vital role in expanding access to 
treatment in settings with limited public health infrastructure as they are geographically 
convenient, have longer opening hours and are less frequently affected by medicine stock 
outs. Treatment seeking for medicines from the private sector is prominent in sub-Saharan 
Africa and Senegal is unlikely to be an exception. Indeed, a study mapping treatment-seeking 
rates in malaria endemic countries estimated that just under half of those seeking treatment 
would visit a government facility in the WHO West African region (48.91%). [8] There is a 
discernible difference between private sector providers, such as the private pharmacies in 
Senegal and informal medicine sellers, as the former are regulated by the NMRA and the latter 
are essentially unregulated. A key issue raised during interviews with stakeholders of the 
MQSS was the risk of legitimising informal sector trade if the quality of medicines from the 
sector was reported, although, this does not fully excuse the lack of surveillance. There also 
appeared to be socio-cultural and political reasons for not tackling the informal sector which 
could be unique to Senegal. Nevertheless, these findings serve to illustrate how moral and 
political considerations can play a key role in shaping surveillance systems, the research that is 
undertaken, and the resulting data available. 
Due to the location of informal medicines sellers in open markets in Senegal, it could be more 
challenging to implement regulatory and surveillance procedures when compared to the fixed 
locations of pharmacies and clinics. Even so, where fixed locations for informal medicine 
sellers exist, traders could be encouraged to consider formalising their business, through 
accreditation systems for drug shops such as those implemented in Uganda and Tanzania. [9, 
10] This would enable the NMRA to monitor some of these previously less regulated outlets 
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including monitoring their supply of medicines and even their participation in medicine quality 
surveys to provide a more representative picture of medicines quality. 
In light of this somewhat limited knowledge, there is a need to gain a better understanding of 
the informal medicines sector and the quality of medicines they sell both in Senegal and other 
LMICs. The assessment of medicines quality in the informal sector should be an urgent priority 
for research and should include periodic surveys for assessing medicines quality, as well as 
documenting the risk factors that are likely to affect quality, such as exposure to sunlight and 
high temperatures which are particular relevant to medicines sold via open market stalls. In 
addition, studies exploring the perceptions of informal sellers of the quality of the medicines 
they sell and their awareness and knowledge of the impact of poor quality medicines (and 
their general health knowledge) is required so that appropriate measures can be 
implemented. If there is evidence of the availability of poor quality or unregistered medicines 
in this sector punitive approaches such as legal action to shut down informal sector outlets or 
markets, financial penalties or even the conviction of individual traders could be taken. These 
measures may be challenging to implement in Senegal for political reasons and hence more 
pragmatic approaches are required. This may include education, training and communication 
campaigns targeting informal sector traders to raise awareness of the risks of obtaining 
medicines from unauthorised sources and storing medicines inappropriately as both increase 
the likelihood of poor quality medicines being available within this sector. Additionally, public 
health communication strategies that encompass information on medicines quality, should 
advocate for obtaining medicines from the regulated sectors whilst also warning of the 
potential risk of purchasing medicines from the informal sector (as their quality cannot be 
verified) which is a comparable approach to the previous ‘Street drugs kill’ campaign 
conducted in Senegal in 2009. [11] 
6.2.2 The effectiveness of medicines quality assurance in low-middle income countries 
At a national level, medicines quality assurance relies on adhering to the infrastructure for 
medicines regulation and medicines quality monitoring and control, set against the backdrop 
of an adequately functioning and operating health system. Regulation is recognised as the key 
component for an effective medicines quality assurance system (MQAS). [12, 13] Even with 
adequate technical capacity, including robust sampling strategies and a well-equipped MQCL, 
stringent medicines regulation is required to ensure that medicines that enter the distribution 
chain are of acceptable pharmacopeial quality and that tangible action can be taken when 
poor quality medicines are detected.  
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This thesis has outlined several core functions of medicines regulation in the context of the 
MQAS: 1) authorisation of manufacturers/wholesalers and the medicines they 
produce/distribute, 2) medicines quality sampling at the point of entry, 3) inspection of 
distributors (national wholesalers, health facilities, pharmacies and drug outlets) to assess 
their compliance with storage and national medicines policy guidelines, 4) implementation of 
robust sampling strategies as part of post-marketing surveillance activities, 5) information 
sharing with other relevant national and international agencies, 6) close coordination with 
MQCLs and 7) action based on findings from medicine quality surveys to include withdrawal of 
affected batches and enforcement of laws based on a legal medicines regulatory framework 
against producers and distributors of poor quality medicines.   
In Senegal, most of the key functions of medicines regulation relating to medicines quality 
were in place including authorisation, inspection, sampling through post-marketing 
surveillance, information sharing and action through the removal of affected medicines 
batches. Furthermore, working towards WHO prequalification accreditation was perceived to 
be a major step in enhancing national technical capacity, enabling the MQSS to broaden their 
control activities to include sampling at the point of entry. A sound regulatory system 
underpinned by a willingness amongst key actors to develop aspects relating to medicines 
quality control provides the basis for an effectively functioning national MQAS in Senegal, 
which is encouraging when compared to many LMICs in which regulatory and technical 
capacity is most often lacking. 
However, a key challenge in many LMICs is the ability of the MQAS (and regulatory system) to 
act on findings from surveys or ad hoc detection of poor quality medicines in terms of 
apprehending producers and distributors of such medicines and enacting judicial processes 
based on a legal framework, which may not exist. Recently standardised definitions for 
medicines quality [14] may provide Member States with the basis for creating a legal 
framework to prosecute those who produce and distribute poor quality medicines within a 
country. Indeed, in many countries, prosecution of those who violate medicines regulatory law 
is non-existent at present and would require cooperation and a shared mandate between 
several national agencies including health, customs, law enforcement and judiciary. [15] This is 
a key step in assuring medicines quality by deterring those who intend to produce and 
distribute poor quality medicines with penalties proportionate to the crime. 
Another gap in the knowledge of medicines quality assurance is a lack of information on the 
effectiveness of medicines regulation and medicines quality monitoring and control in LMICs. A 
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WHO report (2010) that presented an assessment of medicines regulation in 26 countries in 
sub-Saharan Africa reported that whilst 17 had a national MQCL, only 5/26 had the five key 
functions of medicine regulation. [16] Through the examination of the MQAS in Senegal which 
has been in place since around 2001, this thesis has sought to address this knowledge gap. 
When examined in relation to the health systems building blocks, [17] Senegal possesses all 
the basic components required to operate a system to control the quality of medicines 
circulating in the country. This includes a sound governance structure with engagement from 
several agencies including: the NMRA, organisations responsible for the supply of medicines 
and the control of medicines quality, as well as support from an external agency. Additionally, 
there is a functioning MQSS with adequate technical capacity that undertakes regular sampling 
of important medicines classes (primarily antimalarials, anti-tuberculosis medicines, 
antiretrovirals and oral contraceptives) and is committed to improving technical approaches 
for medicines quality assurance. There is also continued financial and technical support from 
United States Pharmacopeia (USP) who are responsible for enhancing technical and logistical 
capacity for medicines quality. 
Whilst the findings presented in this thesis have highlighted several key elements a country 
requires to effectively control the quality of medicines nationally, there are some limitations in 
the scope of the data presented associated with medicines regulation and quality assurance. 
This thesis has focussed on the surveillance aspects of a medicines quality control system not 
the MQAS as a whole. Hence, future research on MQAS could focus on providing an updated 
account of medicines regulation to enable appropriate external agencies (WHO and USP), 
academic institutions, international non-governmental organisations and even established and 
well performing NMRAs from neighbouring countries to support and develop regulation in 
countries where it is less effective or even absent. Additionally, research could explore a 
potential association between medicines regulation (including technical capacity) and 
medicines quality in a country to understand how effective regulation, assurance and control 
ought to be, to reduce the likelihood of poor quality medicines circulating.  
Support for building regulatory capacity is provided by USP in countries within which their Poor 
Quality Medicines programme operates. USP have successfully instituted an initiative in 
several countries that focuses on medicines registration with sampling at point of entry and 
routine sampling as part of post-marketing surveillance to identify unregistered medicines, for 
which there may be little data on their quality as they will not have been subjected to 
regulatory processes. [18] However, whilst USP state that they provide support for building 
regulatory capacity, their primary focus is on providing resources to build technical capacity 
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such as equipping laboratories to achieve WHO prequalification accreditation, as has been the 
case with their activities in Ethiopia, Ghana, Nigeria, and Kenya in recent years. [19] Technical 
capacity is paramount for the operation of an effective MQSS but must be underpinned by a 
robust medicines regulatory system which is integral to assuring medicine quality.  
6.2.3 Clinical and public health impact of substandard medicines 
To date, the agenda around medicines quality has been dominated by the legal and technical 
dimensions, and my research has identified the need for an in-depth understanding of the 
clinical impact of substandard medicines at the population level in LMICs, which remains 
largely unknown. In other words, what proportion of children treated for fever receive a 
substandard antimalarial? The answer to this question depends not only on the proportion of 
medicines that are substandard, but also the number of individuals who are at risk of being 
exposed to substandard medicines. What is the clinical implication on an individual of 
consuming a substandard (subtherapeutic) medicine? What are the public health implications 
of the widespread or repeated consumption of substandard medicines? A recent WHO study 
using impact modelling estimated that incremental deaths in sub-Saharan Africa due to 
substandard and falsified antimalarials may have comprised up to 5% of total malaria deaths 
between 2007-2016. [20] There is also a posited (but unproven) association between 
substandard antimalarials and drug resistance [2] which may have in part emerged from the 
literature on the development of artemisinin resistance in Southeast Asia from where the first 
reports of the problem with poor quality antimalarials were published. [21]  
From a technical perspective, substandard medicines are those that do not meet the criteria 
outlined in a drug monograph, either exceeding or not meeting tolerance limits for their SAPI. 
Medicines with SAPI below the tolerance limit are a concern for health because they will not 
result in an effective cure, hence, the problem of poor quality medicines goes beyond the need 
to detect just fakes. Furthermore, there is little understanding of the clinical impact on the 
individual or the implications for public health from consuming substandard (subtherapeutic) 
medicines that range from those that have some of the SAPI (e.g. 40%) to those that just fail to 
meet tolerance limits (e.g. < 80%). This group of substandard medicines will not be detected by 
the currently available screening technologies.  
6.2.4 The role of screening technologies  
Whether evidence on the quality of medicines is sufficiently reliable and robust to inform 
effective public health action, depends on (i) the robustness of the surveys used to collect 
samples for evaluation and whether they are representative of the medicines which are most 
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used by patients; as well as on (ii) the quality of the laboratory techniques employed to 
evaluate them. The second section of the thesis examined both of these parameters and both 
were found wanting. Both the artemisinin derivative test (ADT) and the MiniLab® were shown 
to be capable of detecting falsified and grossly substandard (10% API) artemisinin based 
medicines. The ADT has also previously shown capability in distinguishing between 10% 
(grossly substandard) and 50% (substandard) SAPI of the tested artemisinin based medicine 
(figure 5.2, chapter 5). However, in this study, both tests were shown to be less likely to detect 
substandard samples or differentiate between acceptable pharmacopeial quality and 
substandard samples (especially those of 40% API) which is a key limitation of screening tests 
for antimalarials and other medicine classes. [22] Furthermore, it was found that the 
competence of the operator in carrying out test procedures and interpreting the results 
affected the accuracy of the tests with Inter-operator variability having previously been cited 
as limiting the accuracy of screening tests. [23]  
The key attributes of a screening tests described in section 2 can be categorised as i) test 
performance versus the gold standard method of analysis and effective performance in field 
conditions, and ii) practical considerations (utility and cost). Further evaluations of test 
performance in comparison to the gold standard are required for all screening tests. In 
particular, essential information is required on the test parameters of sensitivity and specificity 
in the hands of different operators in the countries in which they are likely to be utilised. Aside 
from laboratory staff, this may also include groups such as customs officials and treatment 
providers. The results obtained will provide a clearer indication on the accuracy of these 
technologies in the hands of those most likely to use them, as well as in the situational context 
of field surveys in the tropics.  
Furthermore, policy makers deliberating on the potential role of screening tests may consider 
their individual practical attributes (portability, preferably handheld, ease of use and cost) 
before approving their use as part of a MQSS. Nonetheless, there is a limited understanding of 
the precise strategy in implementing screening technologies, in medicines quality analysis and 
more generally as part of a MQSS at scale. Hence, a series of pilot studies will be required to 
establish the effectiveness of the technologies in detecting poor quality medicines at country 
level as well as the ability to integrate them into a MQSS and the wider health system. A 
potential strategic approach to implementation using the devices mentioned in this thesis 
could be as follows; 1) employing screening tests such as paper test cards, ADT or CD3 at 
border points, health facilities and pharmacies to both assess quality at the point of entry and 
point of care as part of routine surveillance, 2) use of the MiniLab® in peripheral laboratories 
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specifically for medicines quality surveys and 3) final decisions for regulatory action made 
following confirmatory testing using pharmacopeia methods.  
Introducing screening tests at the service delivery level in a health system (at the point of care) 
or at the point of entry (outside of the current scope of a MQSS) will require additional 
research and evaluation centred on the accuracy of a test, in the hands of individuals with less 
laboratory experience such as treatment providers, pharmacists, medicine sellers and customs 
officials. Recent publications have discussed relevant examples of the barriers and facilitators 
to the roll out of rapid diagnostic tests for infectious diseases in sub-Saharan Africa such as end 
user beliefs, attitudes, perceptions, and satisfaction, as well as the competency of individuals 
in carrying out and interpreting results from a test. [24, 25] Similar considerations also apply 
when planning wider scale implementation of screening tests for assessing medicines quality 
and aspects such as the practical utility and usefulness of a test are likely to affect perceptions 
of its acceptability among users. 
6.2.5 The need for good evidence: systematic and rigorous medicines quality studies 
This thesis advocates for the use of more systematic and rigorous methods and standardised 
reporting of results in future medicine quality studies, following the reporting template that 
we produced and presented in chapter 4. This includes employing more representative 
approaches to sampling (including larger sample sizes), blinding of operators, verification of 
results (using a second operator, especially for screening tests), clarity in sample selection for 
confirmatory testing and the detailed reporting of other aspects within individual studies that 
may contribute to error and bias, and which need to be considered when interpreting the 
findings of a study.  
The introduction of reporting guidelines, such as CONSORT and STROBE, have assisted in 
standardising the reporting of clinical trials and epidemiological studies, increasing clarity and 
scientific rigour of study design as well as facilitating the interpretation of results and 
comparison between studies. In contrast, there is little guidance on the reporting of findings 
from medicine quality surveys with the sole exception of the MEDQUARG checklist. [26] In the 
absence of universally recommended guidelines, combining our published template with 
current guidelines for medicines quality studies such as those published by MEDQUARG and 
USP [27] will help academics, NMRAs and operators of a MQSS with guidance on the criteria 
that need to be satisfied when undertaking a medicines quality survey. Additionally, a 
standardised approach to survey design and reporting would enable the assessment of the 
reliability and generalisability of survey findings. The lack of standardisation limits comparisons 
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between studies. This casts doubt on the current empirical evidence for medicines quality 
including that of antimalarials and hence, the scale of the problem of poor quality antimalarials 
globally, nationally or regionally within countries is difficult to assess. 
Regardless of the quality of data on medicine quality, there remain significant geographical 
gaps in terms of the information available for certain countries and areas within countries. The 
WWARN antimalarial drug quality surveyor is a useful tool that has sought to pool existing 
antimalarial quality data from published sources and does, in part, address this gap. [28] 
However, national surveys conducted by NMRAs are seldom published and even data from 
countries in which the USP Poor Quality Medicines programme is active are not widely 
available. The sharing of national medicines quality survey data would be helpful to identify 
which countries (or areas within countries) are prone to the circulation of poor quality 
medicines, enabling further investigation by national agencies, USP, and WHO. Such data may 
also direct the efforts of academic institutions towards elucidating the most urgent gaps in 
understanding. Data from surveys can identify the sectors that are most at risk of poor quality 
medicines as well as the specific classes of medicines, origin and type of medicines which are 
compromised. Such surveys can also identify the places in which further assessment is most 
urgently needed to examine key internal factors that perpetuate poor medicines quality at a 
national level; weak medicines regulatory system, inadequate technical capacity, inability to 
apprehend and act against producers of poor quality medicines and inadequate medicines 
storage. 
In addition to improvements in survey methodology and reporting, there is a need to 
recognise that the picture of the risk presented by poor quality medicines would remain 
incomplete if surveys do not include all sources of treatment, i.e. all points of consumer access 
to medicines, in that country. As highlighted by MQSS stakeholders interviewed in Senegal, the 
sale of drugs in unregulated street markets present a particular set of challenges for medicines 
quality surveillance and regulatory action and can be overlooked in surveys.  Thus, in countries 
with a vibrant informal sector, these regulatory challenges to assuring medicine quality make it 
more imperative (not less) that medicine quality surveys include sampling from unregulated 
providers.  
 
6.3 Redefining medicine quality   
In order to compare data obtained from research undertaken in different settings, as well as 
consistency in the survey methodologies used, there is a need for medicine quality to be 
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defined in the same manner in every country. Moreover, universally accepted definitions are 
an important first step in creating a global legal framework for law enforcement and judicial 
processes against those that produce and distribute falsified medicines. For many years 
international agreement on the definitions for medicines quality has been lacking. It was not 
until 2017 that the World Health Assembly Member State mechanism reached consensus, 
classifying medicines quality into three categories; substandard, falsified and 
unregistered/unlicensed medicines. [29]  
Whilst substandard and falsified medicines fit a technical paradigm, whereby the former may 
contain too little or too much of the stated active pharmaceutical ingredient (SAPI) and the 
latter may contain zero SAPI, the wrong SAPI and incorrect labelling of the medicines 
packaging (deliberately misrepresenting the medicine), the terms ‘unregistered or unlicensed’ 
largely fit the legal paradigm. [30] Unregistered/unlicensed medicines are those that have 
bypassed the regulatory system within a country and hence do not meet the criteria for 
approval or licensing granted by a NMRA. [29] Therefore, the presence of 
unregistered/unlicensed medicines in a country may raise suspicion and prompt an NMRA to 
take action against distributors and sellers of such medicines although this does not 
necessarily mean that these medicines are of poor quality. The proportion of 
unregistered/unlicensed medicines in a country may also indicate the extent to which the 
NMRA is effectively enacting regulatory mechanisms by controlling medical products entering 
and being distributed in the country.  Overall, these recently agreed definitions appear to be 
intended to provide the impetus for action to be taken against producers, distributors and 
sellers of poor quality medicines. However, a legal framework that is universally agreed and 
accepted by member states, pharmaceutical companies and legal entities, obligating all parties 
to work together to apprehend and prosecute individuals who violate laws centred on the 
production and distribution of poor quality medicines does not exist, as yet. [1] This much 
needed universally agreed legal framework would provide a foundation upon which NMRAs, 
customs and law enforcement agencies could collaborate at inter and intra country level to 
take action against those who contravene medicine regulatory (and quality) laws 
strengthening the credibility of a MQAS.  
The recently agreed definitions whilst standardising the way in which medicines quality is 
framed, still require further adaptation to encompass the clinical and public health outcomes 
of consuming substandard as well as falsified medicines which would connect the technical 
and clinical paradigms, increasing their relevance to national NMRAs, policymakers and health 
professionals. My research findings showed that at a country level, health system stakeholders 
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described medicine quality in terms of a clinical paradigm centred on the health outcomes of 
consuming a poor quality medicine; the effectiveness of a medicine in treating physical 
symptoms. The terms falsified, counterfeit and substandard most commonly used to describe 
medicines that have failed quality assessment in the academic literature, were rarely 
mentioned by interviewees. The perceptions of medicines quality presented from findings in 
this thesis are therefore, in stark contrast to the technical and legal paradigms within which 
medicine quality is defined on a global level amongst academics, international policy-makers 
and pharmaceutical companies. Perceived factors that determined medicine quality also 
included its origin, type (generic or brand) and its cost. This is hardly surprisingly, since in the 
absence of screening tests at the point of care, a provider can only judge medical products on 
these parameters. 
The perceptions of health professionals and consumers are also important in terms of access 
to affordable essential medicines. The negative perceptions of generic medicines amongst 
medicine regulators and treatment providers presented in chapter 3, remain of some concern 
in light of the premise of global initiatives such as the existing WHO Essential Medicines list 
and recently concluded AMFm pilot which aimed to increase access to affordable and clinically 
useful medicines to LMICs. [3, 31] Generic medicines which are considerably cheaper than 
their brand name counterparts, comprise a significant proportion of the medicines available 
through these initiatives. Yet, they are perceived to be of inferior quality despite AMFm 
medicines being quality assured and the WHO prequalification status of several medicines on 
the WHO Essential Medicines list. The consumer’s preference for a brand name medicine, 
means that they are often willing to pay a higher cost. This is problematic in LMICs where large 
swathes of the population are impoverished, and the cost of medicine is often prohibitive and 
could expose the population to the risk of counterfeit brand name medicines infiltrating the 
market, which counterfeiters will supply for a lower price in comparison to the authentic 
product. 
Scepticism about the quality of generic medicines will exist until there is sound empirical 
evidence to suggest otherwise. Therefore, MQSS and other agencies that carry out medicine 
quality studies and surveys should specifically categorise results in order to differentiate 
between generic and brand medicines when reporting their findings on the quality of 
medicines in their sample. In light of the findings presented in chapter 3, it can be deduced 
that if a generic medicine is proven to be of acceptable pharmacopeial quality then such 
information should be disseminated to health professionals, treatment providers and 
consumers as they have all been shown to be dubious about the quality, efficacy and safety of 
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generics. [32-37] Ultimately, to achieve the specific component of Sustainable Development 
Goal 3 ‘access to affordable safe and quality assured medicines,’[38] there is a need for greater 
advocacy to address the negative and somewhat unfounded perceptions of generic medicines 
(based on a lack of empirical evidence) on behalf of the WHO, pharmaceutical companies, 
NMRAs and even health professionals to ensure affordable access to essential medicines.  
 
6.4 Focussing priorities  
The multifaceted and complex nature of medicines quality spanning several disciplines and 
actors has been presented in this thesis. It is recognised that medicines quality may not attract 
substantial funding in the near future if the current funding trajectory remains on course. 
Medicines quality is unlikely to become a national public health priority in LMICs as there are 
other more pressing issues such as the ongoing focus on treatment and prevention of 
communicable diseases as well as emerging concerns of the growing burden of non-
communicable diseases. [39] Hence, a pragmatic approach that focusses on ‘quick wins’ with 
minimal resources could be considered for countries in which a MQSS is in its infancy or lacking 
altogether. Some suggestions for evolving or developing medicines quality surveillance in 
resource constrained settings that may be relatively straightforward to implement are outlined 
below.  
1. Partnership building 
A key strength of the MQAS in Senegal was the presence of an established coordinating 
committee created by the MoH for monitoring the quality of antimalarial medicines nationally 
which comprised representatives of the NMRA, the national MQCL, the national malaria 
control programme, USP (as an implementing partner of USAID) and the central medical stores 
(the national distributor of medicines to public sector health facilities). An integral aspect that 
formed the basis of the confidence of medicines quality in Senegal amongst most of the 
interviewees, was a shared collaborative commitment to medicines quality assurance and a 
degree of pride in the manner in which the MQSS had developed in recent years. These 
findings underline the value of partnership building within nations. 
Moreover, where possible, national governments could allocate a capitated budget to a 
collaborative partnership between MQSS authorities, holding them accountable for medicines 
quality assurance nationally, although this assumes that governance arrangements are in place 
and funders such as USP are willing to support such an approach. This is a potentially 
important lesson for existing and nascent MQSS in other LMICs, whereby autonomy and 
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accountability may act as drivers for increasing engagement and empowerment of 
stakeholders in medicines quality activities. It also reflects some of the recommendations by 
the WHO following assessment of regulatory systems in sub-Saharan Africa, in which they 
state the importance of providing NMRAs autonomy, with a sufficient budget to allocate 
resources to conduct medicines regulation so as to improve regulatory capacity, system 
efficiency and effectiveness. [16] Expanding this partnership to include the private health 
sector in Senegal primarily represented by the pharmacist professional body would enable 
better engagement with a key health system stakeholder, strengthening the MQSS.  
Building regional, continental or even international partnerships should be considered. Given 
USP’s role in several sub-Saharan countries, the formation of a regional medicine quality forum 
may encourage data and knowledge sharing. Furthermore, resources could be shared or 
pooled by neighbouring countries. For example, attaining WHO prequalification status for the 
MQCL in Senegal could benefit the Western Sahel region with the quality control of medicines 
and other products undertaken in one country, minimising the need to build expensive 
technical capacity in every neighbouring country, where resources and health system 
infrastructure may be more limited. 
2. Strengthening post marketing surveillance 
If medicines regulation is robust and effective in limiting the import and distribution of poor 
quality medicines, post-marketing surveillance should amount to no more than addressing 
medicine quality issues as they arise and would involve; 1) responding to reports of the 
detection of a poor quality medicine, 2) taking action by withdrawing affected batches, 3) 
carrying out additional surveys to assess the extent of the problem for the medicine in 
question and 4) if appropriate, raising concerns with the manufacturer (if the medicine was 
substandard) or enacting legislative procedures (if the medicine was falsified), which may 
include apprehending and prosecuting sellers, distributors and producers. [39] Therefore, 
post-marketing surveillance could rely on passive reporting by treatment providers without the 
need for field surveys to sample and test medicines from points of sale. Nonetheless, there 
may be a few countries in sub-Saharan Africa that can employ a primarily active approach 
whereby there is no periodic sampling, reports of suspect quality medicines are pursued and 
investigated to locate the source and all affected batches are identified and withdrawn from 
circulation. This can be easier when medicines quality nationally is well controlled, and reports 
of medicines of suspect quality are rare. In countries employing an active approach, a virtuous 
cycle can develop in which instances of poor quality medicines entering circulation are 
infrequent and when they arise are removed from distribution chains swiftly whilst 
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maintaining a constant state of vigilance. This ‘end state’ for MQSS’ whereby treatment 
providers are fully engaged in the reporting of medicines of suspect quality is possibly a model 
that most MQSS’ should strive toward.  
Surveillance of medicines quality even on a limited scale is better than none and undertaking 
regular medicines quality surveys to build the knowledge base of medicine quality in a country 
would be an acceptable approach to surveillance as an initial step towards creating a 
functional and effective MQSS. A minimum requirement would be to collect medicine samples 
following representative sampling using a randomised approach and testing with a fully 
validated commercially available screening tests in sentinel sites, followed by confirmatory 
testing at a MQCL with appropriate gold standard (HPLC) equipment. These steps would 
ensure that, at the very least, the data produced on medicines quality is reliable and could be 
used to advocate to governments or external funders with evidence-based findings for further 
investment in technical and regulatory capacity.  
3. Utilising the existing health infrastructure 
The absence of a well-developed primary care structure in LMICs means that the public are 
particularly reliant on pharmacies and drug shops that are often geographically easier to 
access. Issues of medicine stock outs and long queues for treatment at government health 
centres also encourage patients to seek medicines from alternative providers. Drug shops and 
pharmacies are seen as offering a quicker and more convenient service. [40, 41] Therefore, 
pharmacists and drug shop operators are often the primary point of care and have an 
important, yet seemingly unrecognised role in the health system [42] despite a large 
proportion of the population in sub-Saharan Africa seeking treatment from the private sector – 
both regulated providers e.g. pharmacists and less regulated medicines sellers e.g. drug shop 
owners or market traders. [8] In light of their extensive knowledge on the safety, efficacy and 
quality of medicines, pharmacists are ideally placed to play an active role in the surveillance of 
medicines quality by identifying falsified products or those that may bypass usual supply chains 
(e.g. unregistered medicines) and documenting cases of treatment failure in patients. In 
Senegal there an abundance of regulated pharmacies with qualified and accredited 
pharmacists, [43] offering an existing infrastructure for the provision of medicines information, 
medicines quality surveillance and pharmacovigilance.  
However, in Senegal there was a noticeable disconnect between the strategic/operational 
levels in the health system and the provider level (both public and private, but especially with 
pharmacists). It is suggested that health systems in LMICs ought to engage better with 
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treatment providers and recognise the significance of their role at the point of care and in the 
specific context of medicines regulation and quality assurance, as the ‘frontline’ in a system for 
surveillance and monitoring. Indeed, pharmacists in some LMICs are already involved in 
pharmacovigilance systems (through reporting of adverse medicines reactions and issues of 
product safety). [44] Without the engagement of pharmacists and other treatment providers 
as active stakeholders in a MQSS, gaps in medicine quality data will continue to exist.  
Additional training of treatment providers on medicines quality and particularly the use of 
screening tests (implemented in health facilities and pharmacies) may provide a MQSS with a 
potentially significant resource in post marketing surveillance. Alternatively, where resources 
are limited, treatment providers could be educated in the visual identification of poor quality 
medicines (especially falsified versions) without the need for tests or devices. Visual inspection 
at the point of care could act as a first line in post-marketing surveillance in a MQSS. 
Moreover, establishing an effective feedback mechanism for treatment providers to report a 
medicine of suspect quality (with or without screening tests) would further develop the 
effectiveness of a MQSS. Information sharing between treatment providers and the MQSS 
could be enhanced using recent advances in mobile phone technology. Implementing a 
medicine quality alert system using mobile communication systems whereby a treatment 
provider can directly send details to the NMRA of the suspected quality of a medicine would 
result in a more efficient use of established resources. [45] Moreover, if such an alert system 
were to operate effectively it may limit the need for regular medicine quality surveys, whilst 
also strengthening post marketing surveillance. 
The selection of appropriate strategies for medicines quality assurance and control is 
dependent upon the specific country context. Contributory factors such as the resources 
available (especially financial investment), the effectiveness of the national medicines 
regulatory system, the robustness of the medicines supply chain and capability of the national 
MQCL, to produce valid and reliable results may determine selection of the best overall 
approach for medicines quality assurance and control at a given point in time. Strategies for 
assuring and controlling medicines quality must also consider the main sources of treatment 
and types of providers accessed by the patient population, especially the existence of an 
informal sector of uncertain scale, selling medicines of unknown quality which may potentially 
render a MQSS ineffective if not addressed. Further strategic considerations for medicines 
quality assurance and control may include investment in medicines regulation, passive and 
active approaches to detecting poor quality medicines and the most appropriate sampling 
technique and validated screening technology to employ (though these should always be used 
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alongside authorised pharmacopeia methods to provide robust evidence on medicines 
quality). Together these components form the basis of a MQSS strategy which has a specific 
role in a national health system; enabling the MQSS to fulfil its remit, namely to minimise the 
circulation of poor quality medicines and in instances where such medicines are detected, 
ensure that they are withdrawn from circulation promptly to limit their impact on public 
health. 
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Annex 3 - Interview Guide for MQSS authority representatives 
and other stakeholders (chapter 2/3) 
 
Topics of 
interest 
Questions Comments 
Background  
 
1. Key informant profile:  
 
What is your role within the organisation? 
 
How long have you been in this role? 
 
2. MQSS background and rationale 
 
Historical aspects: 
· Were you involved in any aspect of medicine quality 
monitoring before the MQSS was formally 
established? If yes, what did you do? 
 
· When did your organisation become involved in the 
MQSS? 
 
· In your opinion what were the reasons behind the 
creation of the MQSS and who were the main actors 
involved? 
 
How has the MQSS changed since its inception? 
Probe:  
· What are these changes?  
· Perceptions relating to whether these changes are 
thought of as good or bad?  
· What have been the main challenges for the MQSS 
in this time?  
· Which medicines does the MQSS focus upon for 
monitoring and why were these selected?  
Ease the 
interviewee into 
the discussion. 
 
Roles and 
responsibilities 
3. Perceived roles and responsibilities 
 
Have you as an individual had any previous roles with the 
MQSS?  
 
What are your specific responsibilities in relation to the 
MQSS? 
 
What is the role of your organisation within the MQSS? 
 
Please describe any challenges you have faced in fulfilling this 
role? 
Probe:  
· Have they had any guidance in this role? 
· If so, from whom? 
· Where or who would they go to for guidance? 
 
In your opinion, how central is your organisation in the 
functioning of the MQSS? 
 
Obtain written 
documentation 
where possible 
e.g. organogram 
of structure of 
MQSS and any 
documents 
stating roles and 
responsibilities 
of authorities 
with the MQSS. 
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Please briefly describe the roles and responsibilities you 
perceive of the other organisations central to the functioning 
of the MQSS. 
Probe:  
· How do these roles and responsibilities relate to 
your organisation? 
 
How do you communicate with the other MQSS authorities? 
Probe:  
· Regular communication?   
· Who with in terms of specific person(s)? Who is the 
main point of contact in each of the authorities? 
· How often?  
 
What challenges, if any, are faced when coordinating with 
these other authorities?  
General health 
system aspects 
4. Information Flow 
 
Please describe how information flows within the MQSS? 
Probe: 
· How does this information flow operate? 
· What are the different parts of it? (further probes on 
reporting, performance and data gathering) 
· Are there any problems relating to this? 
· If so how could they be overcome? 
 
 
5. Financing 
 
What is the main source of funding for your organisation for 
MQSS related activities? 
Probe: 
· Are there any additional sources of funding? 
· Is the total level of funding adequate for the efficient 
operation of the MQSS? 
· If extra funding were available what aspects of the 
MQSS could be improved? 
 
6. Human Resources 
 
In your opinion do you have an adequate number of staff 
with appropriate training or qualifications within the MQSS? 
 
Probe : 
· If not, where in the system are more qualified staff 
needed? 
· Who is involved in training them? 
 
Strengths and 
weaknesses  
 
7. Perceived strengths and weakness of MQSS? 
 
What do you see as the main strengths of the MQSS? 
 
What aspects do you believe the MQSS could improve upon? 
 
Of these aspects you have mentioned which are the most 
simple to change and which are the most difficult and why? 
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8. Perceived Strengths/Weaknesses of organisation 
 
In terms of medicine quality monitoring what are the main 
challenges for your organisation? 
 
In your opinion, how could your organisation play a greater 
or better role in the MQSS? 
 
QAMSA Study 9. Discussion on findings of QAMSA study: 
 
Are you aware of the QAMSA study? 
 
Please describe the reaction and any discussions that took 
place following the QAMSA report in 2010? 
 
To what extent were the findings from the QAMSA report a 
source of concern or not? 
Probe:  
· Did they have follow up meeting with WHO/USP 
regarding findings?  
· What was the response from the findings amongst 
various authorities in the MQSS? 
 
Do you feel that the QAMSA report led to any changes in the 
MQSS or in medicines regulation or not?  
Probe:  
· If so what specific aspects of the findings led to the 
changes?  
· What were these changes?  
Keep copy of 
report in French 
to show the 
interviewee if 
needed. 
Poor quality 
medicines  
10. Perceived situation of poor quality medicines 
 
Moving to the situation as it is currently in Senegal. 
 
How confident are you about the quality of medicines 
available currently in Senegal? 
 
To what extent do poor quality medicines pose a risk to 
public health in Senegal if at all? 
Probe: If interviewee acknowledges existence of poor quality 
medicines: 
· Which medicine have been found to be of poor 
quality? 
· Have the sampled poor quality medicines been fake 
(SFFC)(no API), substandard or degraded? 
· Where in Senegal have the poor quality medicines 
been found? Sector (public, private, informal), 
geographical location, urban/rural?  
 
Can you describe a previous example of what happened 
when a poor quality medicine was suspected in Senegal?   
Probe:  
· What are the procedures in place? 
· What action was taken and by whom? 
· Have poor quality ACTs been detected? 
· Do you consider these actions as adequate? 
· What else could have been done? 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
209 
 
11. Risk factors 
 
In your opinion what factors do you consider, increase the 
risk of poor quality medicins in Senegal? 
Probe:  
· Source of ACTs (country in manufacture, country of 
import)? 
· Impact of ACT stock outs in Senegal? 
· ACT costs? 
· Medicine regulation? 
· Sampling and detection? 
 
In your opinion how can the MQSS specifically work to assure 
the quality of all medicines in Senegal? 
 
To what extent does the current MQSS provide you with 
confidence with regard to the quality of medicines available 
in Senegal? 
 
 
 
 
 
 
Medicines 
supply and 
regulation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12. Supply Chain 
Apart from the CMS do public and private sector pharmacies 
purchase medicines (especially ACTs) from elsewhere? 
 
Supply chains: 
· What are the main levels of the supply chain in 
Senegal? 
 
· Who are the main actors at each level of the supply 
chain and what are their roles? 
 
In your opinion at which point(s) of the supply chain, if any, is 
there a risk of poor quality medicines appearing?  
Probe: 
· Which parts of the supply chain structure are most 
vulnerable? 
· How could they be improved? 
 
13. Medicines regulation 
 
What is the role of medicine regulation in Senegal? 
 
Does medicine regulation differ between the public, private 
and informal sectors? If so, how? 
 
How is medicine regulation linked to the MQSS? 
Probe:  
· Does interviewee see them as intrinsically connected 
or are they two separate ‘systems’ each regulator is 
involved with? 
 
Does the quality of medicines differ between sectors? If so 
why? 
Probe:  
· Specifically role of unregistered drug 
outlets/informal sector in Senegal on medicine 
quality and regulation? 
Obtain 
documentation 
relating to levels 
of supply chain 
in Senegal: 
wholesale, NGO 
etc 
 
 
 
 
 
 
 
 
 
 
 
Obtain 
documentation 
relating to levels 
of registration 
and/or 
classification of 
pharmacies in 
Senegal 
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· Where do informal sector buy their medicines from? 
(if known) 
 
What is the role of a drug inspector in Senegal? 
Probe:  
· How many inspectors are there? 
· How often do they inspect?  
· Do they inspect the informal sector?  
· Do drug inspectors have any linkages to the MQSS? 
 
If unanswered in previous questions: 
What are the most common challenges faced in terms of 
medicines regulation in Senegal? 
 
Medicine quality 
analysis and 
sampling 
 
 
14. Sampling 
 
Where do you collect/sample medicines from? 
Probe:  
· How do you collect medicines? (sampling strategies, 
samples sizes) 
· How often? (timings) 
· Where from? (sampling frame and locations) 
 
To what extent are you confident that the current sampling 
strategy provides the reassurance that any medicine supplied 
to a member of the public in Senegal is probably safe and of 
acceptable quality? 
Probe:  
· Do you have confidence in current strategy? 
· Does sampling strategy need improvement? Why? 
How could it be improved? 
 
Why were the sentinel sites where medicine quality 
laboratories are located, chosen? 
Probe:  
· Are the areas in nearest proximity to the sentinel 
sites only areas sampled or others as well? 
 
15. Medicine quality analysis  
 
What is the definition of a poor quality medicine in terms of  
results obtained from analysis? 
 
Please describe current techniques used in Senegal for 
medicine quality analysis and how they are used? 
Probe:  
· How various techniques fit into the current MQSS for 
detection of poor quality medicines? 
· Ask them to provide an example of what happens to 
a sampled medicines in terms of analysis? Why are 
these steps/procedures taken? 
 
For each technique: 
· What do you see as the main advantages of this 
technique? 
· Do you find any limitations with this technique? 
 
Obtain written 
documentation if 
possible for 
strategies; 
sampling sizes, 
frames locations 
and timing of 
collection etc.  
 
 
Obtain previous 
reports of 
sampling and 
collection 
activities. 
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To what extent do the current techniques provide you with 
the answers you need? 
 
Can you describe a previous example of what happened 
when a poor quality medicine was suspected in Senegal?   
Probe:  
· What are the procedures in place? 
· What action was taken and by whom? 
· Have poor quality ACTs been detected? 
· Do you consider these actions as adequate? 
· What else could have been done? 
 
What happens to the findings from medicine quality 
sampling and analysis collections? 
Probe: 
· Who do they report the findings to? 
· Why do they report them to that agency? 
· Do they publish the findings? 
· Do they investigate the sources of the poor quality 
medicine? 
 
In your opinion how can the MQSS specifically work to assure 
the quality of all medicines in Senegal? 
 
To what extent does the current MQSS provide you with 
confidence with regard to the quality of medicines available 
in Senegal? 
 
 Is there anything you would like to add? 
 
Have you any questions for me? 
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Annex 4 - Interview guide for treatment providers (chapter 2/3) 
 
Areas of 
interest 
Questions Comments 
Background 1. Key informant profile 
 
What is your role at this outlet/facility and what are you 
responsible for? 
 
How long have you worked here? 
 
What training have you or anyone else at this outlet 
received relating to malaria? 
 
Probe:  
· clinical diagnosis, RDTs 
· malaria drug treatment 
· ACTs  
 
2. Malaria situation 
 
I am interested in discussing malaria treatment with you. 
 
In your opinion what is the current situation with regard to 
drug treatment for malaria in Senegal? 
 
How and why has this situation changed in recent years? 
 
How do you diagnose patients that you suspect have 
malaria? 
 
What would you normally prescribe them for malaria 
infection? 
 
Probe: 
· What is the first line medicine normally prescribed 
or sold? 
· What is the second line medicine? 
· What is the brand of medicines supplied? 
· Why are these medicines prescribed or sold? 
· In what situation may you prescribe or sell another 
medicine? 
· What is the first line medicine recommended for 
treatment of malaria 
· If this is different to the one mentioned above as 
the one normally prescribed – then ask why the 
difference 
 
In your experience have any of the patients whom you have 
treated for malaria then returned here in subsequent days 
or weeks with malaria like symptoms?  
Probe: 
· How often does this occur? (if at all) 
· In your opinion what is the reason for this? 
Purpose of this 
section is to ease 
the interviewee 
into the interview. 
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Medicine 
procurement 
and quality 
 
 
 
 
 
 
 
 
 
 
3. Medicine (ACT) procurement  
 
Who decides which medicines to stock? (specifically ACTs) 
Probe :  
· Are there guidelines for this? 
· Where are these guidelines from? 
· Ask them to describe circumstances in which they 
have not adhered to guidelines In the past if 
applicable. 
 
Where are medicines bought from normally? 
 
Do you ever obtain medicines from other sources?  
Probe: 
· When was the last occasion they did this? 
· How often? 
· Why? 
 
What influences your decisions when buying medicines? 
Probe: 
· Cost 
· Availability 
· National policy 
· Quality 
 
If quality is mentioned why is it important to them? Would 
quality override any of the other influences on medicine 
procurement? 
 
 
4. Medicine quality perceptions 
 
How can you know a medicine is of acceptable quality? 
 
What can affect the quality of a medicine? 
 
How confident are you in the quality of medicines available 
here in this facility/outlet? 
 
Have you had any reason to doubt medicine quality in the 
past?  
Probe 
· If yes, what made you suspect the medicine?  
· If no, how would you recognise a poor quality 
medicine? 
 
What about the quality in Senegal generally? 
Probe: 
· If medicine quality is a concern, why is it a 
concern? 
· Is medicine quality a concern or consideration for 
patients? 
· Probe specifically on antimalarials or ACTs 
· What course of action would they/or did they take 
if they suspected a medicine was of poor quality? 
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5. Medicine Quality Surveillance 
 
Do you know if the government has a system in place to 
check on the quality of medicines?  
Probe: 
· If yes, what do they understand to be the main 
function of this system and does it fulfil its role? 
 
· Do they have any interaction with the system? 
 
How would it assist you in your role as a treatment provider 
to be able to test the quality of a medicine? 
 
How confident are you that the government is able to 
ensure that the medicines you supply to patients are of 
good quality? 
 Is there anything else you would like to add? 
 
Have you any questions for me? 
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Annex 5 - Sub-study 1: detailed results of ADT test procedure 
(chapter 5) 
 
Test 
procedure 
action 
Technician  Average 
score 
Description 
1 2 3 4 5 6 7 8 
1 10 10 10 10 10 10 10 10 10 Sample preparation (1); pulverise and 
dissolve in 10 ml of methanol 
2 10 0 0 10 10 10 10 10 7.5 Sample preparation (2): Sonicate for 
appropriate length of time (approx. 5 
mins) depending on pulverisation 
3 10 10 10 10 10 10 10 10 10 Sample preparation (3): Appropriate 
tablet breakdown/sedimentation and 
use of centrifuge if required 
4 0 10 10 10 0 10 0 0 5 Sample preparation (4): Appropriate 
labelling of sample (vial or Eppendorf 
tube) 
5 10 10 10 10 10 10 10 10 10 TLC preparation (1):  Draw square or 
circular shapes roughly 1cm2 or 1cm in 
diameter 
6 10 10 0 10 0 10 10 0 6.3 TLC preparation (2): Correct labelling of 
squares/circles 
7 10 10 10 10 10 10 10 10 10 Spotting (1): Drawing up of supernatant 
8 10 10 10 10 10 10 7 10 9.6 Spotting (2): Correct spotting of 
methanol within square/circle (2x5µl) 
(volume) 
9 10 10 10 10 10 10 10 10 10 Spotting (3): Correct spotting of tab 
within square/circle (2x5µl) (volume) 
10 10 0 10 10 10 10 10 10 8.8 Spotting (4): Correct spotting of DNP to 
within square/circle (1x5µl) (volume) 
11 10 0 9 9 10 9 7 10 8 Spotting (5): Correct spotting of FBS to 
within square/circle (1x5µl) (volume) 
12 10 10 10 10 10 10 10 10 10 Development (1): Correct storage of 
plate away from sunlight 
13 10 10 10 10 10 10 10 10 10 Development (2): Plate read after 40 
minutes 
14 10 0 9 9 8 9 10 10 8.1 Development (3): Appearance of plate 
after testing and development 
15 10 10 10 10 10 10 10 10 10 Additional steps (1): Pipette replaced 
after spotting of each methanol/sample 
16 10 10 10 10 10 10 10 10 10 Additional steps (2): Pipette replaced 
after spotting of DNP 
Total 
technician 
score 
150 120 138 158 138 158 144 140 143 
 
Time taken to 
complete test 
(mins) 
33 45 60 60 50 90 55 75 58.5 
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Annex 6 - Sub study 1: test procedure questionnaire (chapter 5) 
PARTICIPANT  DETAILS 
Participant name: Participant code:               |____|____| 
Date of interview:  Name of interviewer: 
ADT RATING:  1 = very difficult to use, 5 = very easy to use 
Training Manual                                                                                             1 2 3 4 5 
Test instructions (bench aid)                                                                      1 2 3 4 5 
Ease of preparing sample 1 2 3 4 5 
Ease of preparing TLC plate                                              1 2 3 4 5 
Ease of spotting test solution and reagents                                            1 2 3 4 5 
Number of steps to carry out ADT                                                    1 2 3 4 5 
Time to wait for results (1= too long, 5= appropriate 
length of time)    1 2 3 4 5 
Ease of interpreting test results                                                                  1 2 3 4 5 
FURTHER QUESTIONS 
How easy is this test to use? 
What specific difficulties did you encounter when using this test? 
What did you like most about this test? (What are its strengths?) 
What are the main challenges of this test? 
Will this test make your work easier? Give reasons for you answer. 
What challenges do you foresee in using this test in the field? 
Do you have any recommendations on how this test could be improved?   
Have you used a similar test in the past? (if so please state) 
Do you have any additional comments? 
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Annex 7 - Sub-study 2: results interpretation questionnaire 
(chapter 5) 
 
TECHNICAN DETAILS 
Participant name: Participant code:               |____|____| 
Date of interview:  Name of interviewer: 
ADT RATING: 1 = very difficult to use, 5 = very easy to use 
Colour chart and instructions for use                                                                                        1 2 3 4 5 
Instructions for results interpretation                                                                     1 2 3 4 5 
Clarity of pictures (not clear =1, very clear = 5)                                          1 2 3 4 5 
Influence of light in laboratory (great influence =1, no 
influence =5)    1 2 3 4 5 
Ease of results categorisation and interpretation                                    1 2 3 4 5 
Confidence in decision made (no confidence = 1 , very 
confident =5)     1 2 3 4 5 
FURTHER QUESTIONS 
How easy did you find test the results to interpret? 
How confident would you be in making a decision in sending for further testing or not? 
Which colour is easier to interpret and why? 
What difficulties did you encounter in interpreting the results? 
Which is easier to interpret results from the MiniLab® or this test? 
What are your thoughts on the difference between pictures for poor quality and acceptable pharmacopeial 
quality (good quality)? 
 
Do you have additional comments? 
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Annex 8 - Focus group guide 1; prior to laboratory exercises 
(chapter 5) 
 
Topics of 
interest 
Questions Comments 
Background Please discuss your role and your responsibilities as a 
technician in the context of the MQSS?  
Probe: 
· Why or how did you start working in medicine 
quality? 
· Do you all do the same work? 
· Do they enjoy their work in comparison to other 
lab work they have done? Why? 
· What is the range of experience of the technicians 
in terms of working within the MQSS? 
Purpose of this section 
is to ease the 
participants into 
discussion 
 
This section will 
provide some useful 
information relating to 
the background of the 
technicians – 
Education, training (self 
or taught), taught by 
whom, experience, 
satisfaction. 
Medicine 
quality 
analysis 
How do you assess the quality of a medicine? 
Probe: 
· Screening technique i.e. MiniLab® 
· What are the methods and procedures undertaken 
or followed? 
· How do they interpret the results from analysis? 
· How confident are they in their decision making? 
· Action taken if medicine fails 
 
What are the main challenges you face when deciding if a 
medicine is of acceptable pharmacopeial quality or not? 
 
Tell me more about the current techniques you use for 
medicine quality analysis? 
Probe:  
· Strengths? Challenges? 
· Ease of use? 
· Practicalities e.g. time of assay, use of hazardous 
substances/reagents 
· If not already covered above then ask about the 
reliability of the results 
 
If there was anything you could change about the MiniLab, 
what would it be and why? 
 
Tell me more about the laboratory here and others in 
Senegal you have worked in: (MQ specifically) 
Probe: 
· Equipment – functioning? Quality? Enough? 
Relates to what they 
actually do – will allow 
comparison about how 
closely their actual 
work practices align 
with guidelines. 
Quality of 
medicines 
 
What is an acceptable pharmacopeial quality medicine? 
Probe: 
· Who ultimately decides what an acceptable 
pharmacopeial quality medicine in the field is? 
 
The responses here 
ought to relate to what 
they perceive in 
relation to their work – 
what they are 
taught/have learnt. 
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· What are main risk factors for poor quality 
medicines? 
 
Describe your general findings in terms of the quality of 
medicines in Senegal? 
Probe: 
· How has medicine quality changed in their 
experience? 
· Ask for examples of when they have found poor 
quality medicines in Senegal. 
· Which medicines do they find fail the most and 
why? 
 
However, perhaps 
more personal 
perspectives on this 
definition can also be 
elicited. 
 
 
 
Additional 
questions 
 
 
 
Please tell me about any other aspects of your role as a 
technician, the medicine quality analysis technology or 
medicine quality in general. 
 
Is there anything else you would like to add? 
Have you any questions for me? 
In this section try and 
identify anything 
relevant that may have 
been missed 
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Annex 9 - Focus group guide 2; post laboratory exercises (chapter 
5) 
 
Topics of 
interest 
Questions Comments 
Acceptance of 
ADT test  
Tell me about your thoughts regarding the test? 
Probe: 
· What did you like about the test? 
o Manual/instructions 
o Preparation of sample/plates 
o Spotting  
o Reagents not being toxic 
o Rapid 
 
· What are the main challenges of the new test? 
o Time to wait for results 
o Confusion of FBS/DNP where to spot 
o Can it be used in the field – less laboratory 
equipment 
 
What do you see as the main advantages of the new test? 
o What did you like best? 
 
How confident are you in the results obtained and in 
interpretation? 
Probe:  
· How confident are they in the decision made? 
· Which colour did they prefer to interpret? 
· Which images were hard to interpret? 
 
If there was anything you could change about the ADT what 
would it be and why? 
Principal 
researcher not 
present. Please 
reassure staff that 
they should be 
open and candid 
about views and 
perceptions of the 
test. 
 
Use responses 
from 
questionnaires 
relating to ease of 
use and results 
interpretation. 
 
 
 
 
 
 
Perceived 
usefulness 
How well would this test fit into your everyday work of 
screening medicine quality? 
Probe: 
· Can this test be a viable alternative to the 
MiniLab® for ACT screening? Why? 
· How will the test be perceived among colleagues 
and their superiors? 
 
Do you find the test useful in terms of identifying medicines 
of good or poor quality? 
 
Do you think this is a useful screening test and why? 
 
ADT and 
Minilab 
comparison 
Which test did you find easier to use and interpret the 
results for ACT analysis and why? 
 
 
Additional 
questions 
 
 
 
 
What other aspects of the test (including the training 
manual) need to be considered prior to it being used by 
others for ACT screening in Senegal? 
 
Is there anything else you would like to add? 
 
Have you any questions for me? 
Try and raise any 
recurring points 
raised from 
questionnaires not 
captured in this 
guide. 
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Supplementary File 1: ADT manual, including colour chart and 
bench aid (chapter 5) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 The ADT  
(Artemisinin Derivative Test) 
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Introduction 
Numerous recent reports can be found of discoveries of poor quality medicines globally. 
Currently Artemisinin Combination Therapies (ACTs) are recommended treatment for 
uncomplicated P.falciparum malaria by the World Health Organisation. By 2008 77 out of 86 
malaria endemic countries had an active treatment policy stating that ACTs should be used to 
treat P.falciparum malaria. [1] The increase in demand for ACTs places them at the inevitable 
risk of being counterfeited or produced at lower cost using poor manufacturing practices. The 
first documented case of poor quality artemisinin was in 1999 in Cambodia where a nationwide 
survey found that 71% of 133 drug outlets stocked ‘fake’ artesunate. [2] Subsequently in recent 
years there has been a proliferation of poor quality antimalarials in Southeast Asia. [3-5] There 
have also been reports of the detection of poor quality artemisinin in sub-Saharan Africa and 
this appears to be a growing problem in some parts of West Africa in particular. [6-13] Based on 
this evidence, regular testing to ensure that ACTs are of acceptable pharmacopeial quality is vital 
in ensuring success of recent malaria control programmes to continue.   
Need for ADT test 
To assure quality of artemisinin derivative based medicines (ADs), medicine quality surveillance 
systems require appropriate laboratory facilities with, at the very least, adequate technical 
capacity. The gold standard for medicine quality content analysis is High Performance Liquid 
Chromatography (HPLC), which is an accurate, precise and specific analytical technique. [14] 
However, HPLC equipment has a relatively high capital and maintenance cost and reagents are 
also expensive. Furthermore, it requires a high level of technical expertise to operate. For these 
reasons it is only available at a limited number of reference laboratories and cannot be 
implemented for routine analysis in the field.  
The GPHF MiniLab® is a screening test that provides a rapid and simple assessment of medicine 
quality and therefore plays an important role in the monitoring of medicine quality in resource 
poor settings. [15] However, it has been reported that the MiniLab® can only detect grossly 
substandard and counterfeit medicines. [16] Therefore, the MiniLab® cannot be relied upon 
unequivocally for medicines quality monitoring systems and for definitive results precise 
analytical methods such as HPLC need to be utilised. 
To address the need for a reliable, affordable and accurate test that is readily portable and can 
be used at the point of screening, two simple colorimetric assays have been developed by Ioset 
and Kaur [17] that require minimal training and equipment and are specifically for the detection 
of the presence of ADs in ACTs and thus for determining the quality of ACTs. 
Application and content of test 
The ADT test includes two simple to use, rapid and reproducible assays that have been 
developed for the detection of ADs, not only in mono formulations but also in combination 
therapies (ACTs). These colorimetric assays utilise thin layer chromatography (TLC) silica gel 
sheets and either 2,4 dinitrophenylhydrazine (DNP) or 4-Benzoylamino-2, 5-
dimethoxybenzenediazonium-chloride hemi (zinc chloride) salt (Fast Blue Salt – FBS) as the 
reagents to detect the ADs. The principal of the test involves dissolving the pulverized tablet in 
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methanol and applying a very small amount of the resulting solution to a TLC sheet followed by 
either of the reagents and allowing the reaction to proceed at room temperature. If ADs are 
present in the sample the reaction(s) will produce a pink colour with the DNP or blue colour with 
FBS. Both colours will appear within 40 minutes.  
A complete validation of the two developed assays has been undertaken in the laboratory at the 
London School of Hygiene and Tropical Medicine following a systematic evaluation, including: 
1. The test has been evaluated for its specificity and validated against the other available 
field method the GPHF-MiniLab®. This includes testing of the following: 
a. All major antimalarials currently used on the market 
b. A wide selection of active principles from the WHO list of essential medicines  
c. A wide range of excipients used in the pharmaceutical formulation of tablets 
 
2. Application of the test to a representative range of samples (> 9000) from the field. 
 
3. Confirming the results against high performance liquid chromatography with photo-
diode array detection (HPLC-PDA) as the gold standard method. 
 
As a result of this validation it has been found that the ADT detects only artemisinin derivatives 
with the exception of artemisinin itself. 
 
ACTs (fixed dose combination) that can be tested 
Artemether/lumefantrine 
Artesunate/amodiaquine 
Artesunate/mefloquine 
Dihydroartemisinin-piperaquine 
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Procedure 
Principle 
The artemisinin derivatives are extracted with methanol and determined by the colour reaction 
test with reference to authentic standard (if available). 
List of equipment  
TLC aluminium sheets silica gel 60 F254  
Pestle (or other tool to pulverise tablet) 
Sonicate and/or centrifuge 
10ml vials 
Pipettes & pipette tips (measure 5 µl) 
Eppendorf tubes 
Pencil 
Ruler or Stencil to draw 1x1cm squares or 1cm diameter circles 
Reference standard (if available) 
List of reagents  
Methanol  
2M Sulphuric Acid2, 4 dinitrophenylhydrazine (DNP) 
4-Benzoylamino-2, 5-dimethoxybenzenediazonium chloride hemi (zinc chloride) salt (Fast Blue 
Salt – FBS).  
Test Procedure 
Both components of the ADT should be carried out on each sample i.e. testing with DNP and 
FBS. Results from each individual assay should corroborate the result of the other (see figure 
1). If either assay fails to produce the expected colour, the test would need to be repeated. A 
further discordant result would require the sample to be sent for definitive analysis by HPLC. 
Note: The procedures below assume that a reference standard is available. If this is not the 
case any steps referring to standards can be omitted. 
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Figure 1: ADT test developed at LSHTM to check the quality of artemisinin based medicines. The text in red shows 
the major steps for carrying out the test: steps 1 and 2 - preparation of the sample and TLC plate; step 3 – 
spotting of solution on matrix on TLC plate; step 4 – development of the results; step 5 - interpretation of resulting 
colours.  
Preparation of FBS 
To prepare the FBS dissolve 1mg of FBS powder in 950 µl of 2M Sulphuric acid and 50µl of 
methanol. Shake well to dissolve all the powder. The resulting solution can now be used as a 
reagent for testing the AD samples. DNP is commercially available in liquid form and is ready to 
use. 
Preparation of sample (step 1) 
If available an ultrasonic bath and/or centrifuge should be used. This section describes what to 
do with or without this equipment. Samples are pulverised with a pestle, emptied into a 10 ml 
vial, methanol (10 ml) added and solubilisation achieved by placing the mixture in an ultrasonic 
bath for 30s. Alternatively manual shaking can be used. If a tablet cannot be pulverised it will 
need to be left in the sonicate for up to 10 minutes.  If fragments still remain (and they cannot 
be broken down manually) the mixture should be centrifuged. If breaking down manually care 
should be taken not to break the glass vial. Draw up 1ml of the mixture and transfer to an 
Eppendorf tube for centrifugation. If centrifuge is not available the mixture is left on the bench 
until sedimentation occurs (a clear top layer is formed). The time taken for sedimentation to 
occur will be variable depending on the specific drug sample. Once centrifugation takes place 
the mixture is ready to test. 
Always label the sample (whether in original vial or Eppendorf tube) with a suitable code for the 
sample e.g. AL20 for artemether/lumefantrine 20mg/120mg.  
Once a sample has been prepared it must be tested on the same day. Leaving samples for 
extended periods of time can cause degradation and lead to erroneous results being obtained.   
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Figure 2: Matrix drawn on TLC plate 
To minimise the risk of contamination, clean out any remaining residue from the pestle using 
water and dry thoroughly (this is applicable to any other apparatus used) before preparing the 
next sample. 
Preparation of TLC plate (step 2) 
Prior to performing the test the TLC plate must be prepared as a matrix as in figure 1. This step 
can be undertaken at any time before or whilst preparing the sample.  Using a pencil (and if 
available a stencil) draw square or circular shapes roughly 1cm2 or 1cm in diameter. For each 
drug a minimum of 6 squares should be drawn, 3 in each row (or a total 4 squares with 2 squares 
in each row if no reference available).  
The first row is for DNP and the second for FBS, and should be labelled accordingly . The first 
column of squares or circles should be marked blank (BL). The second column should be marked 
as reference (Ref). The third column should be marked as ‘tablet’, however given that an 
individual plate will be used for several drugs it is advisable for the operator to use a familiar 
code for the drug as they would do when carrying out analysis with other similar tests and write 
this on the plate itself. The example in figure 2 is AL 20, AL 40 and AL 80, which represent 
artemether-lumefantrine 20mg/120mg, 40mg/240mg and 80mg/480mg respectively. 
 
 
Spotting (step 3) 
Regardless of the steps followed in preparing the sample once the supernatant has appeared 
and all insoluble fragments or particles have settled the sample is ready to test. Draw up the 
mixture using the pipette. Be careful to only draw up the supernatant (liquid at the top of the 
mixture). Make sure none of the sediment is drawn into the pipette. To minimise the risk of 
BL Ref Tab 
DNP 
FBS 
AL 40 
AL 20 
AL 20 
AL 40 
AL 80 
AL 80 
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contamination, use a different pipette tip once for each new sample (old pipette tips should be 
discarded). 
Previous experimentation with test parameters has suggested that the amount of mixture and 
reagent added can influence the depth of the colours produced. Therefore, to ensure 
standardised results it is recommended that the exact amount of sample mixture and reagent 
must be spotted and the sample mixture must be homogenous throughout. 
Step 1: Spotting of sample/reference mixture  
Note: In the steps below, It is recommended to spot 2 x 5µl as opposed to 1 x 10µl to ensure that 
the sample/reagents are enclosed within the square/circle. Spot 1 x 5µl to the square then spot 
another 1 x 5µl on top of it. 
Using the pipette: 
· To each blank square/circle; spot 2 x 5µl of methanol. Replace pipette tip 
· To each reference square/circle; 2 x 5µl of the reference mixture. Replace pipette tip 
· To each sample square/circle; 2 x 5µl of the sample mixture. Replace pipette tip. 
 
Step 2: Spotting of reagents 
It is not necessary to allow the sample/reference mixture spots to dry. Step 2 can commence 
immediately after Step 1. Using a different pipette for DNP and FBS reagents: 
· In the first row to each square/circle; spot 5µl of DNP. Replace pipette tip. 
· In the second row to each blank square/circle; spot 5µl of FBS.  
 
Repeat Steps 1 and 2 as necessary for each drug sample being analysed.  
Processing multiple samples (batch processing) 
Both the ‘preparation of the sample’ and ‘spotting’ steps can be conducted with multiple 
samples at the same time. 
When preparing samples, to save time it is advisable to produce a number of samples 
concurrently which can then be placed in the sonicate together. 
When spotting the samples, several mixtures can be spotted onto the same TLC plate. Ensure 
the steps in ‘Preparation of TLC plate’ have been followed and the matrix is large enough to 
accommodate multiple samples, and is clearly labelled with an appropriate code for each 
different drug sample. Spot each sample mixture onto the same TLC plate one after another; 
ensuring that pipette tips are changed and discarded after each different drug sample is 
spotted.  
Once spotting of all sample mixtures is complete the DNP and FBS can be spotted to all the 
squares/circles in the appropriately labelled rows as a single step. Ensure that after DNP has 
been spotted that the pipette tip is replaced prior to spotting with FBS.  In addition, if labelled 
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prior to use, the pipette tips used for spotting the methanol “blanks”, FBS and DNP can be 
reused. Discard these pipettes at the end of the day. 
Development (step 4) 
The TLC plate should be kept out of direct sunlight. The plate should not be read before 40 
minutes have elapsed. Although the minimum time taken for the colour with DNP to appear is 
20 minutes and the minimum time taken for the colour to appear with FBS is 40 minutes. The 
colours produced are stable for a maximum of 2 weeks. To appreciate the true depth of colour 
the plate can be re-read after 24 hours. 
Observation  
DNP will produce a pink colour and the FBS a blue colour if the active ingredient (AD) is present 
(see figure 1 above).  
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Results  
If both pink and blue colours appear with DNP and FBS respectively this indicates the ART is 
present in an ACT (see figure 3, showing colour reactions with different artemisinin-based 
drugs).  
 
         Figure 3: Colours produced following testing of artemisinin derivatives 
 
Results Interpretation and actions taken (step 5) 
The interpretation of test results is subjective. Figure 4 shows the range of colours produced by 
samples of artemether/lumafantrine (AL) 20mg/120mg. In this example the AL samples 
producing image C would be regarded as good quality. However the samples producing images 
A and B would be regarded as poor quality (A represents a sample that contains no active 
ingredient (ART) at all). 
 
 
Figure 4: A, B and C are samples of artemether in solution of artemether/lumefantrine 20mg/120mg 
 
DNP 
FBS 
A B C 
Poor Quality Good quality 
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Should the colour (blue or pink) not be observed with one reagent yet the other reagent did 
result in a colour reaction (i.e. the DNP and FBS results are inconsistent), then the test should 
be repeated. If when repeated, the results obtained remain inconsistent, the sample should be 
referred for definitive analysis by HPLC.  
 
Once results have been categorised and it has been determined whether the medicine is of good 
(acceptable) quality or poor quality, action must be taken. All poor quality samples need to be 
sent for further testing at a national medicine quality control laboratory for analysis by HPLC. 
Whilst it is not necessary to further samples deemed to be of good (acceptable) quality most 
medicine quality surveillance systems recommend that around 5% of these samples are tested 
further by laboratory methods. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
231 
 
Colour Chart 
The colour chart below represents images produced following testing of samples of various ADs. 
The chart should be used to cross check the identity of a sample. For example, if a sample 
according to labelling on packaging states it is artemether/lumefantrine 20mg/120mg the image 
produced by the sample using the ADT test should correspond in colour (including depth) to the 
image listed as good quality for artemether/lumefantrine 20mg/120mg on the colour chart. 
In terms of the quality of the medicine - any samples that produce images that are comparable 
to the poor quality images of ADs in the colour chart would need to be sent for further testing 
by HPLC. Samples that produce images that correspond to good (acceptable) quality images of 
ADs in the colour chart do not need to be sent for further testing. 
The images in the colour chart were produced using samples of medicines that are commonly 
available in sub-Saharan Africa. The interpretation of the colour chart maybe regarded as 
subjective. Colours obtained with samples may appear slightly different to the corresponding 
images on the colour chart. However, as a general rule if a deep pink or blue colour is observed 
an AD is present and the sample is of good (acceptable) quality. 
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Bench Aid 
ADT Testing Procedure (bench aid) 
Test preparation 
Note: The procedures below assume that a reference standard is available. If this is not the 
case any steps referring to standards can be omitted. 
 
Sample Preparation 
1. Pulverise samples with a pestle (if available), empty into a vial and dissolve resulting 
powder in 10 ml of methanol. Place mixture in ultrasonic bath for 30s. (If pestle is 
unavailable shake manually and place mixture in sonicate for up to 5 minutes). 
 
2. If fragments of tablet remain after step 1 attempt to break the tablet down manually, 
do this carefully so the vial does not break. Alternatively draw 1ml of the mixture, 
transfer to Eppendorf tube and centrifuge (If a centrifuge is not available the mixture is 
left on the bench until a clear top layer appears (sedimentation), the time taken for this 
is variable depending on the specific drug sample). 
 
3. Always label the sample (whether in original vial or Eppendorf tube) with a suitable code 
for the drug e.g AL 20  for artemether/lumefantrine 20mg/120mg 
 
4. The sample mixture is now ready to be tested. All prepared samples must be used on 
the same day. 
 
5. Clean out pestle using water and dry ensuring all residue is removed prior to 
pulverisation of next sample. This applies to any apparatus that may be reused. 
 
TLC plate preparation (see diagram below) 
This stage can be undertaken at any time before or during the sample preparation. 
 
6. Using a pencil and stencil draw square or circular shapes roughly 1cm2 or 1cm in 
diameter.  
 
7. For each drug 6 squares should be drawn, 3 in each row. The first row is for 2, 4 
dinitrophenylhydrazine (DNP) and the second row is for Fast Blue Salt (FBS). Label each 
row.  
 
8. Label the first column of squares/circles as blank (BL), the second column as reference 
(Ref) and the third column of squares/circles as ‘tablet.’  
 
9. Label each row of three squares with an appropriate code for the drug e.g AL 20 
(artemether/lumefantrine, 20mg/120mg) 
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Figure 1: Matrix drawn on TLC plate 
 
Testing steps 
Note: In all relevant steps below it is recommended to spot 2 x 5µl as opposed to 1x 10µl to 
ensure that the sample/reagents are enclosed within the square/circle. Spot 1 x 5µl to the square 
then spot another 1 x 5µl on top of it. 
1. Using a pipette, spot 2 x 5µl of methanol on the ‘blank’ (BL) square. Replace pipette tip. 
 
2. Spot exactly 2 x 5µl of reference mixtures to the (Ref) squares. Replace pipette tip. 
 
3. Spot exactly 2 x 5µl of sample mixture to the respective squares. Only draw up the 
supernatant (liquid at the top of the mixture), and make sure none of the sediment is 
drawn into the pipette. To minimise the risk of contamination, replace pipette tip before 
each new sample.  
  
4. In the first row to each square/circle spot 5µl of DNP. Replace pipette tip. 
 
5. In the second row to each blank square/circle spot 5µl of FBS. 
 
6. Repeat Steps 1-6 as necessary for each drug sample being analysed. 
 
Results Interpretation and actions taken (see diagram below)  
1. Keep the TLC plate out of direct sunlight.  
 
2. Read the plate after 40 minutes have elapsed.The colours produced are stable for a 
maximum of 2 weeks. To appreciate the true depth of colour the plate can be re-read 
after 24 hours. 
 
3. DNP will produce a pink colour and the FBS a blue colour if the active ingredient (AD) is 
present. The image below illustrates the type of colour reaction observed at differing 
levels of active pharmaceutical ingredient (API). 
BL Ref Tab 
DNP 
FBS 
AL 20 
AL 20 
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4. If a sample produces an image such as C then the sample is regarded as of acceptable 
pharmacopeial quality (good quality) and does not need further testing. 
 
5. If a sample produces an image such as those as A and B in the diagram below then the 
drug is regarded as poor quality. All samples regarded as poor quality should be sent for 
further testing by HPLC. 
 
6. If either of the pink or blue colours are not observed, the result is inconsistent and the 
ADT test should be repeated.  
 
7. If the results obtained on repeat testing are also inconsistent, the sample should be 
referred for analysis by HPLC. 
 
 
Figure 2: A, B and C are samples of artemether in solution of artemether/lumafantrine 20mg/120mg 
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